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Alzheimer’s disease is one of the greatest unmet medical needs in neurology. 
Despite numerous initiatives and extensive data, there is still a major deficiency in 
the disease progression characterization of Alzheimer’s disease. The objective of 
this thesis is to contribute to the disease progression characterization of 
Alzheimer’s disease through the development of a pathophysiologically 
meaningful model using commonly collected disease markers.  
In Chapter 2, data from the Alzheimer’s Disease Neuroimaging Initiative 
was evaluated to identify trends that might suggest a potential modeling approach. 
Comparing demographic-biomarker-clinical relationships between subjects from 
different symptomatic stages using descriptive statistics showed high variability 
within and between groups and nonlinear changes over the course of the disease. 
This reflected the importance of reducing the heterogeneity intrinsic to the study 
population and studying subjects of various stages together to understand the 
underlying disease progression. 
In order to position subjects from different symptomatic stages onto a 
single time scale, a pathological timeline was developed using an array of disease 
markers in Chapter 3. Overall, results aligned with prevailing theories in the 
literature. Results also suggested that disease progression in the test population 
might follow non-sigmoidal patterns and hippocampal atrophy might track more 
closely to changes in cerebrospinal fluid tau protein and less to brain glucose 
metabolism (as represented by fluorodeoxyglucose uptake) and cognitive 
changes. Comparison of subjects with and without beta-amyloid pathology 
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showed that changes in tau might be dependent on beta-amyloid changes and 
disease progression without cerebrospinal fluid biomarker abnormalities could 
occur at a slower rate. 
Using results from the disease time synchronization, longitudinal changes 
in Alzheimer’s Disease Assessment Scale-Cognitive Subscale was modeled with 
nonlinear mixed effect modeling. Disease progression was best described by a 
generalized logistic model which produced an asymmetrical nonlinear trajectory. 
Biomarkers that were critical but often overlooked or unavailable in previous 
models were included to test for sensitive covariates that could predict disease 
progression. Lower fluorodeoxyglucose uptake was associated with faster disease 
progression while covariates that were tested to have considerable influences in 
earlier Alzheimer’s disease models did not appear to be significant when the 
effect of fluorodeoxyglucose was taken into account. Additionally, a disease 
progression model based on fluorodeoxyglucose changes suggested that younger 
age is associated with faster decline in fluorodeoxyglucose uptake which could in 
turn exert an indirect effect on cognitive changes. Clinical trial simulations 
demonstrated that the use of fluorodeoxyglucose could potentially reduce the 
number of subjects needed or shorten the study duration for evaluating disease-
modifying therapies. 
This approach improved the quantitative characterization of Alzheimer’s 
disease by providing a platform to integrate data from subjects regardless of their 
symptomatic groups to allow a more complete presentation and interpretation of 
disease progression over time. The identification and understanding of how 
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covariates affect disease progression helped to elucidate the demographic-
biomarker-clinical relationships between subjects. Results provided important 
insights for clinical trial implementation such as endpoint selection, patient 
population and trial duration to study potential disease-modifying therapies. 
Future work may involve using more follow-up data and sensitive disease 
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Chapter 1 : Introduction 
1.1 Alzheimer’s disease 
1.1.1 Alzheimer’s disease and its socio-economic impact 
Alzheimer’s Disease (AD), the most common form of dementia, is a complex, 
progressive and irreversible brain disease. The disease is named after Dr. Alois 
Alzheimer who first published his findings on the pathology and clinical 
symptoms of AD in 1907. In the publication, he described the case of Mrs. 
Auguste D. who died of an unusual mental illness with symptoms such as 
memory loss, language problems and unpredictable behavior. Brain examination 
after death found numerous abnormal clumps and tangled bundles of fibers which 
are considered as the classical neuropathological signs of AD (1). 
AD is currently the fourth leading cause of death in developed countries 
and the prevalence of AD increases with age, from 2.5% in the 65-74 years to 
24% in the 85-93 years (2). Although it has been well established that age is the 
greatest risk factor and medications can provide short-term symptomatic relief, 
the cause and cure of AD remain elusive. In 2015, direct and indirect costs of 
caring for the 5.3 million AD patients in America is estimated to be $500 billion 
and these numbers are expected to grow, surpassing 13 million AD patients and 
$1 trillion per year by 2050, barring effective drug treatment (3). Treatments that 
can effectively delay the onset of AD by five years are expected to reduce the cost 
of care of AD patients by more than $400 billion in 2050 (4). In Singapore, the 
AD population is likely to affect 187,000 residents by 2050 from the current 
40,000 (5). AD is detrimental to the lives of caregivers too, with many of them 
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undergoing high emotional strain and it was estimated that 40% of them suffer 
from depression (3; 6). 
 
1.1.2 Clinical presentation 
For most AD patients, early disease stage is characterized by persistent episodic 
memory problems. As the disease progresses, memory loss becomes more 
pronounced and impairment to global cognitive abilities emerges, affecting 
thinking, reasoning, judgment and decision making (7). Changes in personality 
and behavioral problems, such as aggressiveness and delusions, can occur in some 
patients (8). Eventually, patients with advanced AD may lose the ability to 
perform basic tasks such as dressing and bathing, leaving them totally 
dysfunctional and dependent on custodial care (7). Although time from diagnosis 
to death varies between patients, the average lifespan of an AD patient after 
diagnosis is nine years, depending on age and comorbidities (7).  
 
1.1.3 Disease pathology 
The disease pathology of AD is observed as the abnormal formation and 
accumulation of insoluble, misfolded, neurotoxic proteins known as beta-amyloid 
(Aβ) plaques and neurofibrillary tangles (NFT), together with oxidative stress and 
inflammation in the brain (1). Brain images of AD patients displayed abnormal 
hippocampal and overall brain shrinkage (1). Various hypotheses, including the 
widely accepted amyloid cascade hypothesis, have been proposed but none 
proven with certainty for causing sporadic AD (9). 
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The amyloid cascade hypothesis states that the production and deposition 
of Aβ plaques are early and necessary events in the pathogenesis of AD. Aβ, 
believed to be crucial in synaptic potentiation, is formed from amyloid precursor 
protein (APP) after a series of cleavages by beta and gamma secretase (10). These 
cleavages result in a series of different Aβ isoforms varying in length at the C-
terminus, of which Aβ1-42 is thought to be the most clinically important as it 
represents the majority of the eventual deposited parenchymal Aβ plaques in 
brains of AD patients (9). Clinical support for the amyloid cascade hypothesis 
comes from the work of Naslund et al. demonstrating that parenchymal Aβ 
concentration was elevated early in the disease stage and correlated with cognitive 
decline in a cohort of mildly impaired individuals (11). In addition, genetics 
studies reported deterministic genes causing autosomal dominant AD (also known 
as familial AD) such as APP, presenilin-1 and presenilin-2 are all linked to the 
production of Aβ. Furthermore, Apolipoprotein E-e4 (APOE-e4), a specific 
genotype of the APOE allele believed to be involved in trafficking of Aβ, is 
associated with increased risk of sporadic AD (12). In contrast, researchers 
discovered that a coding mutation (A673T) in the APP gene slows the activity of 
the enzyme beta secretase and hence the production of Aβ. Icelanders with this 
beneficial mutation were found to be over five times more likely than those 
without it to reach the age of 85 without an AD diagnosis (13). All these, together 




Abnormalities in tau deposition lead to an alternative hypothesis for the 
cause of AD. Tau, predominantly found in axons, is required for stabilizing 
microtubules and regulation of motor-driven axonal transport (10). Under normal 
conditions, the soluble tau protein undergoes phosphorylation and 
dephosphorylation, a process which exists in equilibrium. It is postulated that 
certain pathological conditions can imbalance the dynamics, resulting in an 
increased amount of abnormally hyperphoshorylated tau (14). This can lead to the 
reduction in binding and increase in detachment of tau from the microtubules and 
subsequently the disassembly of microtubules. Hyperphosphorylated tau then 
accumulates in the cell body, aggregates into abnormal filaments and eventually 
forms NFT during the course of AD (14).   
By direct examination of postmortem human brains, Braak et al. showed 
that tau deposition and distribution followed systematic stages that map out 
neurodegeneration, beginning in the transentorhinal region preceding the 
development of Aβ deposits while Aβ plaques formation exhibited considerable 
variability in shape, size and quantity in early AD (15). A study of over 3000 
brain autopsies published in early 2015 concluded that tau, but not Aβ, was able 
to predict age at onset, disease duration and final cognitive score (16). In addition, 
tau pathology without the overt Aβ pathology is a recognized characteristic of 
other forms of dementia. Together, these data support the hypothesis that tau 
might actually be the main driver of AD. 
Studies of autosomal dominant mutation carriers revealed abnormal Aβ 
and tau changes 15–25 years before expected symptom onset, suggesting an 
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interaction of the two entities leading to AD (17). A combination of Aβ and tau 
was able to better predict AD, even at the prodromal stage, and differentiate AD 
from other neurodegenerative dementias compared to the use of individual 
biomarkers (18; 19). Ittner et al. took a step further and put forward three possible 
modes of interaction between Aβ and tau – 1)Aβ mediates tau pathology, 2)tau 
drives Aβ toxicity and 3)synergistic harmful effects between Aβ and tau (10). 
None of these have been proven, thus the molecular nature of their interplay 
remains uncertain. Numerous theories had been formulated from in-vitro or 
animal studies but were unable to translate into clinical relevance because of the 
inherent differences and complexities of the human brain.  
 
1.1.4 Diagnostic criteria 
AD diagnostic criteria have been constantly refined throughout the years. The first 
set of diagnostics for the disease was published by the National Institute of 
Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and 
Related Disorders Association (NINCDS–ADRDA) in 1984. As per guidelines 
from NINCDS–ADRDA, AD was considered as a form of dementia and clinical 
diagnosis could only be defined as “probable” at best until histological 
examinations for Aβ plaques and NFT had been confirmed by post mortem 
examinations (20). Moreover, clinical assessment for AD could occur only when 
the disease had manifested to the point of causing significant functional disability 
and fulfiling the threshold criterion of dementia (20). Clinical misdiagnosis based 
on the NINCDS–ADRDA guidelines published in 1984 is common as reported 
6 
 
recently in a study of close to 1000 autopsies of dementia patients from 2005-
2010 (21). It was revealed that up to 30% of those diagnosed with AD had been 
misdiagnosed while close to 40% of the non-AD patients had evidence of AD 
pathology when autopsied (21). Thus, despite extensive evaluation, diagnosis 
could never be fully accurate without post-mortem results and misclassifications 
with other forms of dementia could arise, especially at old age. 
 Current clinical diagnosis of AD includes the use of patients’ history, 
information from caregivers/relatives, clinical examinations or tests based on the 
presence of characteristic neurological and neuropsychological features, together 
with the absence of alternative conditions. Classification of subjects for research 
purposes is more challenging due to the high heterogeneity of AD symptoms but 
most studies typically employed neuropsychological tests to define disease 
severity and clinical examination to exclude other forms of neuropsychological 
disorders (22). For instance, the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI), which was launched in 2003 as a collaboration between academics, 
pharmaceutical industry, regulatory bodies and nonprofit organizations to study 
the natural disease progression of AD, enrolled and classified subjects into five 
symptomatic stages of disease severity: cognitively normal (NL), significant 
memory concern (SMC), early mild cognitive impairment (EMCI), late mild 
cognitive impairment (LMCI) and AD (23). Briefly, NL subjects had Mini-Mental 
State Examination (MMSE) between 24-30 (inclusive), Clinical Dementia Rating 
Scale (CDR) of 0, education-adjusted memory scores on Wechsler Memory Scale 
Logical Memory II (WMS-II) within the normal range and non-depressed. SMC 
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subjects were similar to NL subjects, but with significant subjective memory 
concerns and cognitive change index of 16 or more. EMCI subjects had objective 
memory loss as measured by WMS-II, CDR of 0.5, absence of significant levels 
of impairment in other cognitive domains and essentially preserved activities of 
daily living. LMCI subjects had more serious objective memory loss as measured 
by WMS-II compared to the EMCI subjects. Lastly, mild AD patients, the most 
severe group, had MMSE between 20-26 (inclusive), CDR of 0.5 or 1.0, and meet 
NINCDS–ADRDA criteria for probable AD. Detailed description of each class of 
subjects can be found in the ADNI1, ADNI-Grand Opportunities and ADNI2 
procedures manuals (24; 25; 26). 
 Recent acquired clinical knowledge and emergence of reliable biomarker 
testing have caused a major shift in research diagnostic criteria for AD, moving 
from a “clinicopathological” entity of post-mortem autopsies to a 
“clinicobiological” entity by biomarker testing (18; 27; 28). Both the International 
Working Group (IWG) for New Research Criteria for the Diagnosis of AD and 
the National Institute on Aging–Alzheimer’s Association published on the use of 
different biomarkers in AD diagnosis in 2007 and 2011 respectively (27; 28). 
Most recently, IWG published a new framework (IWG-2) that categorized 
biomarkers into two major groups, diagnostic and progression, each with different 
roles in the AD pathology (18). Specifically, the presence of diagnostic 
biomarkers – either as an abnormal increase in ligand retention from Aβ imaging 
or an AD molecular signature of decreased cerebrospinal fluid (CSF) Aβ and 
increased CSF tau – was sufficient for an AD diagnosis, replacing the previous 
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post-mortem confirmation necessary for a definitive AD diagnosis as per the 
NINCDS–ADRDA guidelines (18). With that, there is a need to develop better 
assessment and standardization of biomarkers and further understand the natural 
history of disease progression through temporal changes in biomarkers. 
 Despite the advances in diagnostic capabilities, biomarker testing is not 
commonly done in the clinic. Without an effective cure or prevention method, 
many healthcare providers felt that biomarker assessments are unlikely to affect 
relevant clinical outcomes such as treatment options or patients’ quality of life 
and as a consequence, biomarker testing is not routinely carried out by physicians 
and their reimbursement by insurance companies remain limited (29). Unlike 
diseases such as diabetes and hypertension, none of the existing biomarkers are 
valid surrogate outcomes of AD. For example, some subjects had considerable 
amount of Aβ plaques discovered upon autopsy but remained cognitively normal 
(14). In addition, high variability and lack of standardization posed barriers to 
data interpretation as many NL individuals could have abnormal biomarker 
concentrations (30). Other considerations that made biomarker measurements 
unappealing are the complexities and complications involved. For instance, 
lumbar puncture for collecting CSF samples could be challenging and is known to 
cause a list of post-procedure effects including headache that might develop in up 
to a quarter of the subjects (31). Imaging technology require strict structural 
systems for regulatory compliant operation, costly tools and skilled labor, which 
could be a huge economic burden (32). Digital imaging data collected with 
increasing sophisticated acquisition methods require strong computing 
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capabilities, networking, and storage solutions (33). Lastly, specialized positron-
emission tomography (PET) imaging require costly radioligands and some 
patients could remain uncomfortable on possible radiation exposure even when 
on-site expertise was present to ensure effectiveness and safety (33).  
 
1.1.5 Current treatment 
Currently, there is no known cure or prevention for AD, even though research and 
money are not lacking as displayed by the vast amount of drug development and 
clinical trials initiated by the pharmaceutical industry (34; 35). Only 
cholinesterase inhibitors (Aricept, Exelon and Razadyne), a N-methyl-D-aspartate 
receptor antagonist (Namenda) and a combination of Aricept and Namenda 
(Namzaric) have been approved by the Food and Drug Administration (FDA) to 
provide symptomatic relief for AD. However, results from randomized controlled 
trials and several meta-analyses on the approved medications showed modest 
improvements on several clinical measures of AD (36). It had been suggested that 
the apparent small mean improvement on clinical scales might be contributed by a 
subpopulation of subjects achieving substantial benefit while the majority did not 
benefit from the treatment at all (37). Furthermore, adding Namenda to patients 
whose conditions were stabilized with cholinesterase inhibitors resulted in 
conflicting responses in clinical benefits (37). Despite their highly controversial 
usage, the combined sales of Aricept, Exelon and Namenda were estimated to 
exceed $4 billion in 2013 (38; 39; 40). 
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1.1.6 Treatment research 
Many epidemiologic, preclinical and pathologic studies have linked AD to 
various comorbidities and medical conditions, often with inconclusive results. 
Two of the most common hypotheses put forward by multiple research groups 
were that hypercholesterolemia and inflammation due to Aβ aggregation in the 
brain contributed to the cause of AD. Regrettably, the most up-to-date published 
Cochrane reviews reported that statins, aspirin, steroids, traditional non-steroidal 
anti-inflammatory drugs and cyclooxygenase-2 inhibitors showed no significant 
benefits on the treatment of AD (41; 42). Research also suggested that AD and 
type II diabetes mellitus share common cellular and molecular mechanisms but 
results from clinical trials of rosiglitazone, an oral diabetes drug, did not 
demonstrate any significant improvement in cognitive function by controlling 
peripheral glucose levels of AD patients (43; 44). Pilot trials using intranasal 
insulin, interestingly, displayed promising effects and the findings led to a series 
of larger studies that focused on targeting insulin levels in the brain (45; 46). One 
of them is the Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) 
trial which is a multi-center, double-blind, placebo-controlled Phase II/III study to 
evaluate the impact of inhaled insulin in MCI and AD participants (47). 
Recognizing the fast changing science and the challenges in conducting 
clinical trials that target AD, the FDA published a set of guidance in early 2013 to 
assist pharmaceutical industry on clinical trial designs and executions by 
suggesting possible patient populations, enrichment methods and different 
endpoints (48; 49). The guidance supported the use of biomarkers in AD research 
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as proposed by IWG-2 and described approaches of demonstrating disease 
modification by biomarkers either as the primary or supportive secondary 
endpoint (49). However, the guidance also noted the lack of widespread evidence-
based agreement on appropriate biomarkers that can predict clinical outcomes. 
Again, it demonstrated the need for more research to understand AD and the roles 
of biomarkers in the underlying disease progression in order to come up with 
meaningful targets, facilitate clinical studies and foster development of 
efficacious and innovative drugs in this therapeutic area. 
 
1.2 Disease markers of AD 
1.2.1 Biomarkers 
Biomarkers are objective measures of biological or pathogenic events that serve 
various purposes in clinical trials and drug discovery processes such as screening 
and diagnostic tools, monitor disease progression and drug interaction, act as 
surrogate endpoints for clinical outcomes, and evaluate patient safety or drug risk 
profiles.  
In AD, the longstanding biomarkers can be classified into diagnostic and 
progression biomarkers as mentioned in the IWG-2 research criteria. The most 
commonly mentioned diagnostic biomarkers are Aβ and tau, which are also 
identified as CSF markers of AD. The most commonly mentioned progression 
biomarkers are results from PET imaging of radiotracer 18F-fluorodeoxyglucose 
(FDG) and volumetric magnetic resonance imaging (MRI), also known as 
imaging markers of AD (18). CSF markers are indicators of AD pathology in the 
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brain and abnormal concentrations should be present at any stage, thus useful for 
diagnosis. However, their concentrations can remain static especially at the late 
stages of the disease and therefore do not provide good clinical severity relevance 
(18). On the other hand, imaging markers have a more dynamic range that can 
change over the course of disease which makes them useful for measuring and 
monitoring neurodegeneration but they lack the pathological specificity for AD 
(18). Aβ and tau PET tracers are associated with the amount of Aβ and tau in the 
brain and thus can be labeled as diagnostic biomarkers in the same context (50; 
51).  
 
1.2.2 Diagnostic biomarkers 
1.2.2.1 CSF biomarkers 
CSF Aβ and tau, both endogenous proteins, had long been discovered as the 
building blocks for Aβ plaques and NFT respectively. Studies observed that 
concentrations of CSF Aβ from lumbar puncture correlated inversely with total 
Aβ plaques in the brain at autopsy (52; 53). This is likely due to the increased 
formation of Aβ plaques in the brain that act as “Aβ sinks”, resulting in the 
reduced concentration of soluble Aβ present in the CSF (54). Unlike CSF Aβ, 
CSF tau is shown to correlate positively with postmortem NFT (52; 55). It is 
believed that tau disassociates from microtubules upon hyperphosphorylation, 
possibly due to downstream effects of Aβ toxicity, and the magnitude is 
correlated with the extent of neuronal damage and clinical prognosis (52; 55; 56). 
Strong correlations were observed between concentrations of CSF tau and 
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phosphorylated tau (p-tau) in both AD and non-AD elderly individuals while 
recent studies suggested that p-tau might help in discriminating AD from other 
types of dementia (57; 58; 59; 60).  
 In 2009, Shaw et al. dichotomized subjects using cutpoints of CSF Aβ ≤ 
192 pg/mL and CSF tau ≥ 93 pg/mL based on the ADNI database and these 
thresholds have since been widely used by those working on the ADNI database 
(61). Despite the recognition and advancement in the field of AD biomarkers, 
CSF biomarkers are still seldom used in clinic due to reasons such as the side 
effects of lumbar puncture and the high variability between studies, leading to the 
lack of unified cutpoints. To minimize the variation in CSF biomarker 
measurements, several studies and initiatives were launched to develop certified 
reference materials and methods that serve as “gold standards” (62; 63; 64). 
 
1.2.2.2 Imaging biomarkers 
Much attention and resources has been invested into AD diagnostic marker 
imaging, resulting in rapid development. Since the early 21st century, 
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Pittsburgh compound B (PIB) has been widely studied as an Aβ tracer and proven 
to accurately detect and quantify Aβ plaques in the brain (65). More recently, 18F-
florbetapir (florbetapir), also known as Amyvid, was approved by FDA and 
European Medicines Agency for detection of Aβ deposits in the brain as part of 
the battery of tests for clinical assessment of memory disorders (66; 67). 
Comparatively, florbetapir has a half-life more than five times higher than PIB 
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and requires a much shorter scanning time of 10 minutes versus 90 minutes, 
giving it more convenience and wider clinical applications (68).  
Similarly to CSF biomarkers, research papers have published cutpoints to 
differentiate healthy subjects from AD patients using imaging biomarkers at 
florbetapir ≥ 1.1 Standard Uptake Value Ratio (SUVr) and PIB ≥ 1.5 SUVr (69; 
70). SUVr represents an automated quantitative ratio that measures regional 
ligand retention in predefined areas to a reference region. These cutpoints are 
increasingly part of the inclusion criteria in clinical trials trying to prove the 
amyloid cascade hypothesis and investigate the possibility of slowing the 
progression of memory decline associated with brain Aβ (49; 50). The success of 
Aβ imaging tools has also spurred the development of tau tracers with AV1451 
being one of the most widely studied tau PET tracer to date (71). It is expected to 
permit non-invasive and early Braak staging, inform the degree of tau deposition, 
assist in the differentiation of AD and non-AD disease tauopathies and hopefully 
elucidate the underlying disease pathology (72).  
 
1.2.2.3 Plasma biomarkers 
There has been a constant search for reliable biomarkers in plasma to characterize 
AD as a convenient sampling alternative to lumbar puncture. However, this task 
contains several challenges. Concentrations detected in the plasma may not be 
reflective of concentration in the brain due to the low permeability of the blood-
brain-barrier. Detection of analytes in plasma and inferring them to changes in the 
brain is complicated by the high dilution effect of plasma, plasma protein binding, 
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peripheral production of the same analytes and confounding systemic changes. 
For instance, results from the Australian Imaging Biomarkers and Lifestyle study 
of aging described significant influence on plasma biomarkers by peripheral 
inflammation and renal function (73). Furthermore, in contrast to CSF Aβ, most 
studies on plasma Aβ concentration found no significant differences between 
healthy control and AD patients and no correlation with brain amyloid burden 
(74; 75).  
 
1.2.3 Progression biomarkers 
1.2.3.1 Imaging biomarkers 
FDG-PET had been employed extensively to study loss of brain matter in AD as 
signals correlated strongly with synaptic density and activity (76). A number of 
studies utilizing FDG–PET demonstrated that AD patients had lower brain 
glucose metabolism, measured by a composite value calculated from multi-
regional uptake of FDG, compared with healthy, age-matched elderly (77; 78). 
Decreased FDG uptake correlated with cognitive decline, lowered Aβ and 
increased tau, suggesting that it is a viable marker of synaptic dysfunction that 
accompanied neurodegeneration in human brain (79).  
Progressive brain atrophy, monitored using volumetric MRI, is a well-
studied characteristic of AD and the cause of atrophy in AD is likely due to 
dendritic pruning and loss of synapses and neurons (80). Atrophy occurred at 
specific regions with varying speed during different stages of the disease and 
findings correlated with rates of neuropsychological deficits and Braak’s staging 
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at autopsy (81; 82). Of all types of MRI-related biomarkers, hippocampal atrophy 
is well established and documented for assessing disease stage and progression in 
AD (83; 84).  
Notably, both FDG and hippocampal changes are associated with non-AD 
conditions which decrease their utility to monitor AD. For instance, cerebral 
hypometabolism is a common symptom of brain injury due to ischemia and 
hemorrhage (85). Hippocampal atrophy can occur due to old age, neurotoxicity 
and other forms of dementia and even in AD patients, early age of onset and non-
amnestic clinical presentations were reported to be more hippocampal sparring 
than others (18; 86).  
 
1.2.4 Neuropsychological endpoints 
Early AD pathology usually affects episodic memory before debilitating 
temperament, executive function and visuospatial abilities. Although the recent 
advancement and development of fluid and neuroimaging biomarkers have 
improved diagnosis and progression measurement, neuropsychological 
characterization remains an essential component of AD diagnosis (18; 87). 
Application of these tests gives instantaneous results that reflect preserved 
abilities, allows separation of AD from cognitive changes due to old age and 
distinguishes the symptoms from dementia associated with other types of 
neuropathology (88). Because of the relative ease of implementation and multiple 
options catering to different domains of interest, these assessments are helpful in 
staging and tracking of the disease. Although there is no single 
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neuropsychological assessment that cover the entire spectrum of changes 
throughout the disease duration or standardization between tests for comparison, 
mapping out the neuropsychological profiles is still crucial in understanding 
individual deficits so that help to the patient and caregivers could be disseminated 
appropriately. Four neuropsychological tests that are commonly used in clinical 




Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog): The 
ADAS-cog is considered the gold-standard outcome measurement for AD 
registration trials since it is the primary cognitive endpoint for most of the FDA 
approved medication intended for the treatment of mild and moderate AD (89; 
90). It is a structured scale modified from the original ADAS by Mohs et al. to 
evaluate memory, reasoning, language, orientation, ideational praxis and 
constructional praxis (91; 92). Ratings of spoken language, language 
comprehension, word finding difficulty, and ability to remember test instructions 
are also obtained and scores can range from 0 (best) to 70 (worst) (92). 
 
1.2.4.2 MMSE 
The MMSE from Folstein et al. is a brief instrument used to assess cognitive 
function in elderly subjects. The instrument is divided into two sections. The first 
section measures orientation, memory and attention with a maximum score of 21. 
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The second section tests the ability of the subject to name objects, follow verbal 
and written commands, write a sentence and copy figures with a maximum score 
of 9. The range for the total MMSE score is 0 to 30 with lower scores indicative 
of poorer performance and greater cognitive impairment (93). Traditionally, 
scores of 27 or higher are considered NL while scores between 21 to 26, 10 to 20 
and below 10 are considered mild, moderate and severe AD cases respectively 
(94). It takes about 5 – 10 minutes to administer and therefore practical to use 
repeatedly and routinely. 
 
1.2.4.3 CDR-SB 
The CDR – Sum of Boxes (CDR-SB) by Berg et al. is a semistructured interview 
performed with the subject and caregiver (informant) that provides an index of 
global functioning. The informant is queried about the subject’s memory, 
orientation, judgment and problem solving, community affairs, home and hobbies, 
and personal care. 0, 0.5, 1,2 and 3 stand for the various degrees of impairment 
beginning with none, questionable, mild, moderate and lastly severe (95). By 
assigning a severity score for each of the six domains, a total score known as sum 
of boxes is obtained - hence the abbreviation CDR-SB (96). The ability to assess 
both cognitive and functional disability in subjects makes it an attractive primary 
outcome measure for clinical status. CDR-SB is increasingly incorporated into 
clinical trials after being listed as one of the suggested outcome measures in the 





Functional Assessment Questionnaire (FAQ) designed by Pfeffer et al. is based on 
an interview with a caregiver or qualified partner to rate a subject on their ability 
to perform 10 complex activities of daily living - manage finances, complete 
forms, shop, perform games of skill, prepare hot beverages and a balanced meal, 
follow current events, attend to television programs, books or magazines, 
remember appointments, and travel out of the neighborhood. Each activity is 
categorized as 0 (does without difficulty), 1 (needs frequent advice or assistance), 
or 2 (someone has taken over the activity). Scores are summed across items to 
provide a total disability score, with higher scores signify greater impairment. If 
an activity is never or very rarely carried out, a pro-rated proportional score can 
be derived. No memory or mental status component is evaluated (97). 
 
1.3 Models of AD 
1.3.1 Disease progression modeling  
Disease progression refers to the change of a disease over time which can be 
assessed by observing a clinically relevant endpoint that reflects the clinical status 
of a patient or measures the severity of a disease. Disease progression modeling, 
the modeling of the target disease progression using mathematical expressions to 
characterize the entire disease progression trajectory, is not new with history 
dating back to the 1970s where longitudinal trials to study disease time course 
were conducted (98). Today, it is an important aspect of pharmacology as it helps 
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with early detection and management of chronic diseases and facilitates clinical 
trial design for drug development. 
One of the earliest disease progression models of AD was developed by 
Holford and Peace using a simple linear model to describe changes in disease 
severity, represented by ADAS-cog (99). The typical disease progression model 
consists of a base structure that describes the change in endpoint over time, 
covariates that affect key structural parameters and certain random effect 
component/s to account for the intrinsic variability of the model. Most models 
utilized mixed effect modeling to describe fixed effects at the group level and 
random effects to account for inter-individual variability to analyze longitudinal 
data. General estimating equations, latent growth models/growth mixture models 
and Bayesian models were also used in tracking disease progression but less 
frequently. General estimating equations, an extension of generalized linear 
models, is commonly used for longitudinal data analysis when the population-
average effect is of primary interest (100). Latent growth models and growth 
mixture models are useful for identifying subpopulations which share similar 
growth trajectories within in a large heterogeneous longitudinal dataset (101). 
Bayesian models pool information from different sources in a coherent manner to 
give an appropriate weightage to the information contributed by each subject, i.e. 
subjects with limited data will have lesser impact on the model (102). Table 1.1 
presents a list of recent AD progression models, sorted by their unique PubMed 
ID (PMID), and the following paragraphs will give a more detailed review of 
some AD progression models most relevant to the thesis. 
  
 
Table 1.1 List of disease progression models of AD. 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Ito et al. (103) 2010 
Study level data from 




age and year of 
publication  19592311 





Center AD MMSE Mixed effect models 
MMSE, psychosis 
status, age, APOE 
genotype, education 
and sex 19781112 
Li et al. (105) 2010 
Seven randomly 
selected communities 
in the city of 
Chongqing AD 
MMSE and Activity of 
Daily Living (ADL) Mixed effect models 
Comorbidities, 
medication usage, 
APOE genotype and 
drinking/smoking 
habits 20164563 
Doody et al. 
(106) 2010 
Baylor Alzheimer’s 
Disease and Memory 
Disorders Center AD 
Multiple 
neuropsychological 
tests   








age, APOE genotype, 
education and sex 20178566 
Wilson et al. 
(107) 2010 
Chicago Health and 
Aging Project All 
Global cognition 
(composite score from 
4 tests) Mixed effect models 
Disease stage, age, 
race and sex 20308679 








multiple tests)  
Linear regression 
models  Disease stage 20374677 
        
  
 
Table 1.1         Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Buracchio et al. 
(109) 2010 
Oregon Brain Aging 
Study 
Normal at 
baseline Gait and tapping speed  Mixed effect models Sex 20697049 














estimating equations  Physical activity 20808142 





age, APOE genotype, 
education, family 
history of AD and sex 20810324 
Chiang et al. 




paragraph recall scores 
and ADAS-cog 
Linear mixed effect 
models APOE genotype 20980669 





middle temporal gyrus 
measurements 
Linear mixed effect 
models Disease stage 21113707 
Skup et al. 
(114) 2011 ADNI All Gray matter regions 
Generalized 
estimating equations  Disease stage and sex 21356315 
        
        
        
        
  
 
        
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 




Progression Study  AD MMSE and CDR-SB  
Linear mixed effect 
models 
Level of physical and 
cognitive activities 
(time varying), 
general health  rating 
(time varying), 
duration of dementia, 
age, APOE genotype, 
education, estimated 
premorbid IQ, 
occupation and sex 21441386 










tests   
Linear mixed effect 
models Disease stage 21498903 
Leoutsakos et 
al. (117) 2012 
Alzheimer’s Disease 
Anti-inflammatory 





age and APOE 
genotype  21560159 
Samtani et al. 
(118) 2012 ADNI MCI ADAS-cog 
Nonlinear mixed 
effect models  






genetic factors 21659625 
        
        
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Gomeni et al. 
(119) 2012 Clinical trials AD ADAS-cog 
Nonlinear mixed 
effect models 
MMSE, age, APOE 
genotype, education 
and sex 21782528 
Kavanagh et al. 
(120) 2011 Clinical trials AD MMSE Mixed effect models 
MMSE, medication 
usage and drug 
switch 21891871 
Zhang et al. 
(121) 2011 ADNI All ADAS-cog and MMSE 
Linear regression 
models 
Brain atrophy and 
lesion index score 
(baseline and time 
varying) 21971475 
Bernick et al. 
(122) 2012 Clinical trials AD 
Multiple 
neuropsychological and 
neuropsychiatric tests  Mixed effect models Age 22431834 
Samtani et al. 
(123) 2013 ADNI MCI ADAS-cog 
Nonlinear mixed 
effect models 







genetic factors 22534009 
Johnson et al. 
(124) 2012 ADNI MCI/NL 
Multiple 
neuropsychological 
tests Latent growth models Disease stage 22562439 
        
        
        
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Han et al. (125) 2012 ADNI All 
Rey Audio Verbal 
Learning Test and 
executive (composite 
score from 4 tests) 
evaluation 
Linear mixed effect 
models  
CSF biomarkers and 
neuroimaging 
variables (baseline 
and time varying) 22648764 





baseline AD lesions counts Latent growth models 
Cognitive evaluation 
(baseline and time 
varying) 22695618 
Yu et al. (127) 2012 
Religious Orders 
Studies and the 





score from 17 tests) 
evaluation Mixed effect models 
Age, APOE 
genotype, education 
and sex 22814083 
Rogers et al. 
(128) 2012 
CAMD/ADNI/Study 
level data from 




usage, age, APOE 
genotype  and sex 22821139 
Silbert et al. 
(129) 2012 






ventricular CSF and 
hippocampal volume  Mixed effect models 
No covariate tested in 
mixed effect 
modeling 22843262 
Holland et al. 
(130) 2012 ADNI All 
Multiple 
neuropsychological and 
intracranial regions of 
interest evaluation 
Linear mixed effect 
models Disease stage and age 22876315 
Pillai et al. 
(131) 2013 ADNI MCI/NL 
Multiple intracranial 
region of interest 
Multivariate linear 
regression models 
Disease stage and 
education 22905705 







Modified MMSE and 
Digit Symbol 
Substitution Test  
Nonlinear mixed 
effect models 
Psychosis status and 
genetic factors 22952074 
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 




disease stage, MRI 
measures, age, APOE 
genotype and sex  22990808 
Ruiz et al. 
(133) 2013 
The Memory Clinic 
of Fundació ACE AD 
MMSE and Global 
Deterioration Score  
Linear mixed effect 
models Genetic factors 23036585 
Velayudhan et 




thickness and whole 
brain volume 23047370 
William-
Faltaos et al. 
(135) 2013 CAMD AD ADAS-cog Mixed effect models 
ADAS-cog, MMSE, 
age, BMI, race, 
weight and sex 23211395 
Trzepacz et al. 





subscale Mixed effect models  
MMSE, multiple 
regions of interest in 
the brain, age, APOE 
genotype, education 
and sex 23253778 
Zahodne et al. 
(137) 2013 
Multicenter Study of 
Predictors of Disease 
Course in 
Alzheimer's Disease AD 
Blessed Dementia 
Rating Scale and 







recruitment sites, age, 
education and sex 23302654 
        
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 




Tomography study AD/NL 
Multiple 
neuropsychological and 
intracranial regions of 
interest evaluation 
Linear mixed effect 
models Types of AD 23391426 
Fung et al. 
(139) 2013 
Religious Orders 
Studies and the 






neuropsychiatric tests  
Linear mixed effect 
models  APOE genotype 23650207 
Steinberg et al. 
(140) 2014 
Cache County Study 





Linear mixed effect 
models  
Vascular factors and 
medication usage 23681754 







University AD CDR-SB 
Linear mixed effect 
models 
Family, genetic 
factors and sex 23727081 
Mez et al. (142) 2013 
National Alzheimer's 
Coordinating Center AD 
MMSE, CDR-SB and 
FAQ 
Generalized 
estimating equations  AD subgroups 23755200 
Toledo et al. 
(143) 2013 ADNI All 
CSF biomarkers and 
ADAS-cog Mixed effect models 
Disease stage, CSF 
biomarkers and 
APOE genotype 23812320 
Handels et al. 
(144) 2013 Kungsholmen project 
Normal at 
baseline MMSE and ADL Mixed effect models 
MMSE (time 
varying), age(time 
varying),  time after 
diagnosis (time-
varying), education 
and sex 23948894 
        
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Mattsson et al. 
(145) 2013 ADNI NL CSF biomarkers 
Linear mixed effect 
models CSF proteins 23962923 
Soto et al. 
(146) 2013 
Sixteen university 
hospitals in France AD MMSE 
Linear mixed effect 
models Medication usage 24000874 
Delor et al. 
(147) 2013 ADNI AD/MCI CDR-SB 
Nonlinear mixed 
effect models 
A list of covariates 
including cognitive 






genetic factors. 24088949 
Besser et al. 
(148) 2014 
National Alzheimer's 
Coordinating Center AD/MCI CDR-SB Mixed effect models  
Age, APOE 
genotype, BMI, 
education, sex and 
weight change 24126214 
Beason-Held et 
al. (149)  2013 
Baltimore 




Regional cerebral blood 
flow Mixed effect models Disease stage 24227712 





total cholesterol, age, 
APOE genotype, 
education and sex 24531162 
Amieva et al. 






Linear mixed effect 
models 




Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Ueckert et al. 
(152) 2012 CAMD AD Cognitive  disability 
Linear mixed effect 
models No covariates tested 24595495 
Samtani et al. 
(153) 2014 ADNI AD/MCI CDR-SB 
Nonlinear mixed 
effect models 









genetic factors 24926196 
Gifford et al. 
(154) 2015 
National Alzheimer's 




Linear mixed effect 
models 
Disease stage and 
types of complaints 25061054 
Qiu et al. (155) 2014 ADNI All 
ADAS-cog, 
hippocampal volume 




Disease stage, age, 
APOE genotype and 
sex 25088003 
Conrado et al. 





genotyping and sex 25168488 
Dowling et al. 
(157) 2015 ADNI All ADAS-cog Latent growth models 
FDG-PET uptake 
(time varying) and 
CSF biomarkers 25450107 
        
        
        
  
 
Table 1.1          Continued 
Author Year Data source Population Endpoint Type of model Covariates tested PMID 
Berres et al. 
(158) 2014 ADNI  MCI 
Neuropsychological 
test battery (composite 




test battery, APOE 
genotype, FAQ, BMI, 
education and sex 25530953 
Ascher-
Svanum et al. 




Mixed effect models 
repeated measures Diabetes status 25676448 
Huijbers et al. 




volume, MMSE and 
CDR-SB 




CSF amyloid-β, age 
and sex 25678559 
Hallikainen et 
al. (161) 2014 
Kuopio ALSOVA 
Study AD CDR-SB 
Generalized 
estimating equations  
Multiple 
neuropsychological 
tests (time varying), 
age, education and 
sex 25685140 
Droogsma et al. 
(162) 2015 
Frisian Alzheimer's 
disease cohort study  AD 
Medial temporal lobe 
atrophy  




Spalletta et al. 
(163) 2015 
Outpatients memory 




Linear mixed effect 
models 
No covariate tested in 
linear mixed effect 
modeling 26402103 




In 2010, a meta-analysis consisting of study-level data from literature was 
conducted by Ito et al. to model disease progression using longitudinal response 
of ADAS-cog in mild and moderate AD patients. The rate of change in ADAS-
cog for the untreated disease (placebo) group was described by a simple linear 
model containing a slope and an intercept while drug effects were incorporated 
using sigmoidal functions. The model estimated disease progression in AD 
patients to be 5.5 ADAS-cog points per year with ADAS-cog at study entry as the 
only significant covariate affecting rate of cognitive decline (103). Similar results 
were obtained by Ito et al. when modeling individual AD patients with a linear 
base model but incorporating power functions to describe the curvilinear 
relationship between ADAS-cog and significant covariates (111). In addition to 
ADAS-cog at study entry, age, APOE genotype and gender were found to 
influence the rate of disease progression (111). These relationships were also 
observed in an ADAS-cog beta regression meta-analysis model using both 
summary-level and patient-level data conducted by Rogers et al. in 2012. (128). 
In comparison, Gomeni et al. developed a more complex indirect response model 
to describe ADAS-cog changes over time using data from two randomized 
clinical trials conducted in AD patients (119). Results from Gomeni’s model 
showed that MMSE score at study entry, education, age and APOE genotype were 
significant covariates on the rate of ADAS-cog change. The predicted yearly 
progression of ADAS-cog ranged from 2.3-4.5 points which was fairly consistent 
with other publications (119). In 2013, William-Faltaos et al. from the FDA 




trials conducted in mild to moderate AD patients (135). The result was a log-
linear model which predicted an increase of three points per year, with ADAS-cog 
and MMSE score at study entry being significant covariates of progression rate 
(135). Using ADAS-cog as the endpoint but in a different population, Samtani et 
al. developed a semi-mechanistic logistic mixture model describing the disease 
progression in MCI subjects (123). The model predicted an inflection point at 
ADAS-cog of 42 and the rate of progression was influenced by Trail Making Test 
part B score at study entry and CSF biomarker pathology (123). One of the most 
recent longitudinal ADAS-cog model published used an asymmetrical logistic 
model with beta-distributed residuals, incorporating between-study, between-
subject, and residual variability (156). Results from the model estimated an 
inflection point at ADAS-cog of 52 and an initial progression rate of 3.4 ADAS-
cog points per year for a typical AD patient in the trial. Younger age, APOE 
genotype and, surprisingly, stable usage of AD medications were significant 
covariates predicting faster AD progression, after accounting for disease severity 
at study entry (156).  
Several groups also modeled CDR-SB as an endpoint, especially after the 
mention of it being a potential outcome measure in the FDA guidance for 
pharmaceutical industry published in 2013 (49). Delor et al. combined data from 
MCI subjects and AD patients to develop a CDR-SB longitudinal logistic mixture 
model and as expected, cognition and functional performance at study entry 
turned out to be significant covariates of disease progression rate (147). Samtani 




and AD patients respectively using a semi-mechanistic logistic mixture model 
(153). Disease progression rate was influenced by CSF biomarker pathology, 
Trail Making Test part A score at study entry, delayed logical memory test score 
at study entry and current level of impairment as measured by CDR–SB (153). 
Lastly, Ito et al. developed a longitudinal model to predict CDR-SB time-profile 
in MCI subjects which estimated an annual increase of 0.5 points (150). Higher 
disease severity at study entry measured by MMSE and FAQ, lower hippocampal 
volume at study entry and APOE-e4 carrier status were expected to speed up the 
rate of disease progression (150). 
These models provided a better understanding of disease progression 
through the decline of cognition and function in subjects from various stages of 
AD and at the same time, described the relationships between risk factors (as 
covariates) and clinical outcomes. Furthermore, with integrated clinical 
information, these models acted as a quantitative platform for hypotheses testing 
and drug development through simulations and trial design optimization. As 
clinical knowledge of AD advanced with technology and time, modifications, 
such as selecting a more pathophysiological model and testing new covariates 
believed to influence AD progression, were incorporated to ensure the models 
remained pharmacologically sound and plausible rather than one which purely 





1.3.2 Pathological models 
One approach towards a greater understanding of the events that occur in a 
disease is to combine various pieces of relevant information to map out a disease 
model. In 2010, Jack et al. presented a landmark paper on a hypothetical model of 
biomarker dynamics in the AD pathological cascade in which he argued that 
biomarkers could be used to stage AD because they change in a temporally 
ordered manner; beginning with CSF biomarker abnormalities, followed by 
imaging biomarker abnormalities before the appearance of any clinical symptoms 
(164). The hypothesis was used to explain why certain neurodegenerative 
biomarkers, such as brain atrophy, which was postulated to be the last biomarker 
to become abnormal, correlated better with clinical severity than other 
biomarkers. The paper also suggested that the rate of change in biomarker vary 
over time and was likely to adopt a sigmoidal shape, thus holistic biomarker-
based staging of the disease at any time should take into account the magnitude 
and slope of several different biomarkers rather than focus on a single endpoint. 
Lastly, it was hypothesized that a variable lag phase of unknown duration exist 
between Aβ plaque formation and the neurodegenerative cascade such that Aβ 
changes would have reached a plateau by the time clinical symptoms started to 
appear (164). The series of temporal events proposed by Jack et al. that lead to 






Figure 1.1 Hypothetical model of dynamic biomarkers of the Alzheimer’s 
pathological cascade from Jack et al. (164). 
 
Despite its shortcomings and caveats, the novel model proposed by Jack et 
al. received great attention by many because of the congruent arguments 
supported by various studies and previous hypotheses. It was brought up that the 
model did not align with the Braak’s model of tau formation preceding Aβ 
changes and there was evidence showing brain atrophy occurring before alteration 
of tau (165). Other studies found that Aβ and tau affect MRI results independently 
and FDG-PET changes preceded tau abnormalities and was likely to decline 
linearly (125; 166). Nevertheless, the publication was a major research milestone 
which linked temporal evolution of biomarkers with disease progression and has 
since been the interest of many research groups. 
In 2013, Jack et al. published an updated version of the model with 
accumulated findings and changes that addressed the shortcomings in the previous 





              Time 
Figure 1.2 Revised hypothetical model of dynamic biomarkers of the 
Alzheimer’s pathological cascade adapted from Jack et al. (167). 
 
replaced by time and it was recognized that time taken to transverse the disease 
pathway from left to right could vary between individuals. A segment was added 
in the model to account for genetic factors, lifestyle risks, comorbidities and 
cognitive reserve (brain resiliency) of the individual that would account for 
different likelihood of cognitive impairment. Shape of the curves became less 
identical as biomarkers were separated into diagnostic and progression markers 
and gaps between curves varied to reflect different degrees of overlap between 
temporal changes. In other words, the revised hypothetical model incorporated 
multiple sources of variability, suggesting that the complexity of AD was 
underrated previously as new information unfolds (167). The revised model is 
illustrated by Figure 1.2 (167). 
With the introduction of the hypothetical pathological model by Jack et al. 




as ADNI, some groups attempted to model the natural progression of AD by 
including subjects from different symptomatic stages of the disease and 
positioning them onto a single time scale (168; 169; 170). In 2011, Yang et al. 
noted that the high inter-individual variability within disease stages and short 
follow-up period of clinical trials affected the ability to capture significant 
changes in biomarkers (168). A synchronization method that de-convolved 
disease progression in subjects from different disease stages was applied to fit the 
data to a theoretical curve of disease progression. An exponential equation was 
chosen to describe changes in ADAS-cog and a pathological time based on 
ADAS-cog progression was estimated for each subject. The estimated 
pathological time was then applied to the rest of the biomarkers to characterize 
the evolution of pathological changes and understand progression patterns during 
the course of disease. Results were in general agreement with prevailing theories 
of the AD cascade and subsequently used to establish the timeline for a series of 
disease marker changes (168). A similar synchronization method was taken by 
Delor et al. to develop a longitudinal logistic mixture model for CDR-SB (147). 
Schiratti et al. constructed a disease progression model by using subject-specific 
time reparamertization estimated from cortical thickness measurements to account 
for the individual differences in age at disease onset and speed of disease 
progression (169). 
Rather than using a specific endpoint such as ADAS-cog or MRI 
measurements, Donohue et al. attempted to synchronize the temporal ordering of 




(SEMOR) of several disease markers (170). In short, the algorithm utilized simple 
linear regression for short-term subject-level effects and nonparametric monotone 
smoothing for long-term features simultaneously to predict the pathological time 
of each individual. A time shift component was introduced in the model to allow 
subjects, with maximum follow-up period of six years, to be moved forward or 
backward along the x-axis in order to achieve optimal fitting and the resultant 
estimated long-term growth curves were aligned with the hypothetical model 
proposed by Jack et al. (170).  
 
1.3.3 Other models 
Alternative forms of disease progression models not included in Table 1.1 include 
event-based models that predicted the ordering of categorical variables but did not 
provide information on the time between events and the rate of change in disease 
severity. Nevertheless they are commonly employed to study patterns of change, 
predict risks of mortality or AD conversion and classify a set of predictors that 
would form the “AD signature” (171; 172; 173; 174). Several groups also worked 
on modeling a variable that could act as a time proxy (175; 176). Although they 
might provide a more standardized and sensitive comparison between subjects 
across studies, such models required more assumptions and increased the 
complexity of result interpretation. Lastly, it was not the aim of the thesis to 
develop a system biology model that described the timeline of events at a 
molecular level such as one that was proposed by Anatasio et al., therefore such 




1.3.4 Limitations of models 
Despite all the listed advantages, there are limitations to current models of disease 
progression. Although the general model building strategies and structures were 
similar across studies, the data used for model building differed across studies. A 
diverse range of endpoints was selected to measure disease progression with 
neuropsychological tests listed in the previous section (Section 1.2.4) being the 
most commonly used. However, some groups (Scarmeas et al, Wilson et 
al.,Ueckert et al., Yu et al.) chose relatively obscure composite endpoints which 
were reported to provide improved sensitivity of clinical outcomes compared to 
existing scales (107; 110; 127; 152). In contrast to existing scales, new scales 
might be study specific and thus require additional validation using broader 
populations before applying them across studies to look for trends of disease 
progression. Furthermore, a recent study of several new composite scores 
revealed that none of them outperformed existing scales when applied to the test 
populations and concluded that additional validation and improvements were 
needed (178).  
Covariates collected and tested also varied between studies and models. 
To date, there are few studies that attempted to examine the demographic-
biomarker-clinical-relationships between subjects simultaneously. This is likely 
linked to the difficulty and cost necessary to obtain large amount of data and it 
has not been until fairly recent that the significance of early biomarker changes in 
disease progression is recognized or technology to collect them becomes 




Honolulu Asia Aging Study, PAQUID Cohort Study and Religious Orders Study 
provided extensive longitudinal information, they did not collect CSF and PET 
biomarker data that might be crucial in detecting the change in biomarkers 
throughout the course of disease progression (179; 180; 181).  
Most modeling efforts investigated covariate effects as part of the model 
building process but covariates included in published model might not always be 
physiologically meaningful. For instance, APOE genotype was reported to be a 
significant covariate in models that described the longitudinal changes in clinical 
endpoints (Conrado et al., Fung et al, Ito et al.) but its functional role lies 
primarily in Aβ trafficking and might not have any direct effect on cognition 
(111; 139; 156). It should also be apparent that neuropsychological scores at study 
entry could not directly influence disease progression rate but only acted as a 
function of disease severity. Including CSF and imaging biomarkers in model 
development could give a more pathophysiologically meaningful model, 
especially if the data is available and the underlying process is known. In the few 
models that included CSF and imaging biomarkers as covariates (Delor et al, 
Samtani et al.), most of them tested data collected at study entry but discarded the 
time-varying longitudinal data which might be more informative for disease 
progression modeling (118; 147; 182).  
 AD is a long-term progressive disease whereas clinical trials data had 
relatively short follow-up period, typically less than two years, compared to the 
total disease duration (183). The entire disease evolution over time might not be 




markers of AD pathology appear to change over significantly different time scales 
and behave nonlinearly with respect to disease stage/time (167). Moreover, 
modeling a subset of subjects specific to a symptomatic stage limits the temporal 
resolution and power to discriminate disease changes between groups (168). This 
might explain why certain covariates, such as CSF biomarkers, did not show any 
significant relationships with cognitive decline in AD subjects as the rate of 
change in CSF biomarkers might have plateaued much earlier before any 
significant change in cognition could take place (184; 185). Hence, disease 
progression might be better understood and quantified by the inclusion of subjects 
from different disease stages.  
Lastly, one of the most important limitations of typical AD progression 
models is the use of symptomatic staging such as “NL”, “MCI” and “mild AD”, 
for classifying subjects and developing a time-course model. Although 
symptomatic staging is an invaluable classification tool, it relies heavily on 
imprecise clinical data and assessments that allow subjective interpretation. This 
can lead to inter-observer variation and impact diagnostic accuracy. Furthermore, 
the use of symptomatic staging would have to assume every subject in the same 
group started off at the same “reference” point which is conceptually not possible. 
As Jack et al. pointed out in the revised hypothetical model, there is a significant 
degree of overlap between symptomatic groups and high inter-individual 
variability within each group (167). Even with well-structured studies, the 
characteristic temporal changes of specific markers might still be obscured due to 




pathophysiological staging framework across broad clinical stages. Nevertheless, 
disease progression models often assumed time of study entry as the “reference” 
point and segregated subjects by baseline disease stage or disease severity. To 
overcome this problem, time shifts models could be leveraged to provide a 
pathological timeline that enabled more accurate and precise disease progression 
tracking. In particular, results from Donohue et al. were obtained by taking into 
account a diverse list of outcome measures and therefore expected to be more 
accurate compared to those estimated from a single measure (170). However, 
relationships between disease markers were not extensively explored and 
quantified in a statistical framework beyond disease time synchronization. 
 
1.4 Hypotheses, objectives and specific aims 
As mentioned, most current models focused on subjects from a single disease 
stage, used a trial and error approach rather than knowledge of the underlying 
mechanisms for model development and neglected the high variability in the rate 
of disease progression among individuals. Therefore, they might not be suitable 
for predicting beyond the observed conditions and results might be difficult to 
interpret and unconvincing. Although they could be initially useful to correlate 
disease markers for further research, characteristic temporal changes of each 
marker have to be mapped out in order to link the components together and 
understand the disease better. 
It was hypothesized that disease markers collected in clinical studies could 




characteristic changes at different stages of the disease according to the 
pathological cascade model proposed by Jack et al. (167). Together, the 
relationships between the disease markers could be used to build a model that 
described the pathophysiology of AD.  
 The aim of this research project is to combine commonly collected disease 
markers to develop a pathophysiologically meaningful model of AD with the 
following specific objectives: 
1) Investigate differences in demographic-biomarker-clinical 
relationships in subjects of different disease severity, from NL to AD, 
and subgroups of interest, defined by study, conversion and Aβ 
burden, to assess the data and look for trends of disease progression 
to support subsequent disease progression modeling. 
2) Position each subject on a pathological timeline by applying the 
synchronization method from Donohue et al. for mapping of temporal 
changes in disease markers and calibrating subject-specific time 
component to facilitate model development. 
3) Develop a pathophysiological AD progression model to describe 
longitudinal change in ADAS-cog. Investigate the influence of key 
CSF and imaging biomarkers, as well as relevant demographic factors 
on the rate of disease progression by means of covariate testing.    
In order to test the hypotheses and achieve the objectives of the thesis, 
analyses were conducted to investigate the behavior of biomarkers and their 




applied to characterize the differences between the various groups of subjects to 
acquire fundamental understanding of the underlying trends of disease 
progression. The temporal order of events in the AD pathology was reconstructed 
and mapped out through the time synchronization method proposed by Donohue 
et al. (170). In the original work by Donohue et al., subjects were segregated 
based on their disease markers status and neuropsychological endpoints were 
applied to transform the model-estimated pathological timeline (170). In contrast, 
this thesis focused on a larger dataset and studied the general trends of disease 
progression without any post-modeling transformation. Finally, disease 
progression models of AD were constructed and longitudinal relationships 
between disease markers were explored and quantified via covariate testing.  
The completed models were pathophysiologically meaningful yet simple 
to comprehend, inclusive of different disease populations and could be easily 
computed to aid decision making. It could be considered as an improved disease 
progression model of AD that shed some light on the underlying mechanisms of 
AD. For clinical researchers, it could be used to test new hypotheses, confirm or 
rebut old ones and act as a starting point for modeling other neurodegenerative 
disorders such as Parkinson’s or frontotemporal dementia. This model could 
theoretically be valuable for simulation of responses at different 
exposures/disease stages and optimization of clinical trial design for 
investigational new drugs. Physicians could potentially use this model for 




clinical outcomes more accurately, thus deciding the most appropriate actions to 





Chapter 2 : Quantifying the characteristics of ADNI subjects 
2.1 Introduction 
Previous research has documented positive association of AD progression with 
CSF tau concentration and negative associations with CSF Aβ concentration, 
FDG uptake and brain volume (61; 76; 77). While increased CSF tau 
concentration and reduced CSF Aβ concentration translate into higher 
neurofibrillary tangle and amyloid burden in the brain, lower FDG uptake 
correspond to lower brain glucose metabolism. More recently, radioactive agents 
such as florbetapir and PIB have been used for PET imaging of the brain to 
estimate amyloid plaque density in subjects who were being evaluated for AD 
(186). In contrast to CSF Aβ, lower florbetapir and PIB SUVr represent lower 
amyloid burden in the brain. 
Based on the growing body of research that supports the use of biomarkers 
in AD, the recent International Working Group (IWG)-2 AD diagnostic 
framework for research published in 2014 recommended the utility of 
pathophysiological markers (CSF proteins and amyloid PET) as diagnostic 
biomarkers and topographic markers (FDG and MRI measurements) as 
progression biomarkers of AD (18). Nevertheless, there is currently no validated 
biomarker of AD and the authors of the IWG-2 acknowledged that the new 
framework required additional validation to determine its application within 
clinical practice (18). 
Similarly, demographic factors such as increasing age and the presence of 




disproportionally affected with AD. Higher education is thought to offer a 
protective effect against AD by providing higher resilience against the deleterious 
effect of the disease. In addition, all of these demographic factors have been 
reported to exhibit significant influence on rate of disease progression in AD 
subjects (119; 128; 150). A number of them have demonstrated significant 
associations with biomarker values as well. For instance, it has been reported that 
APOE-e4 allele carriers have significant lower CSF Aβ concentrations compared 
to non-carriers and the existence of sex-related structural differences in the 
hippocampus (187; 188; 189). Also, aging is generally thought to cause an 
increase in amyloid and neurofibrillary tangle burden in the brain, worsen brain 
atrophy and decrease in glucose metabolism (190; 191; 192). 
However, assessment of the impact of demographic factors on AD can be 
complicated by the presence of other physiological processes. For example, aging 
leads to an increase in age-related comorbidities, particularly neurodegenerative 
non-AD type proteinopathies, cardiovascular and cerebrovascular diseases which 
can affect imaging biomarkers and cognition, thus increasing confounding cases 
of mixed pathologies (193). It should also be noted that APOE genes are also 
involved in cholesterol transport, immunological processes and inflammation 
modulation, though statins and NSAIDs demonstrated no clear benefits on 
cognition based on randomized controlled clinical trials (41; 42). 
Symptoms of AD can be divided into several areas such as cognitive 
impairment, daily function, global impression, behavior, quality of life as well as 




scales available for assessment of AD, MMSE, ADAS-cog, CDR-SB and FAQ 
are some of the most commonly used. Most of these assessments target a single 
domain of the disease, usually cognition or function. Although MMSE is the most 
often used scale for clinical assessment of cognition due to its fast and simple 
administration, ADAS-cog remains as the gold-standard outcome measurement of 
cognition for AD registration clinical trials (90; 194). While CDR-SB provides a 
multidimensional evaluation of cognitive and functional symptoms using a 
semistructured interview performed with the patient and caregiver, FAQ rates the 
subject’s degree of dysfunction or the need for assistance based on information 
obtained from the caregiver. Increasing ADAS-cog, CDR-SB and FAQ scores and 
decreasing MMSE scores indicate disease worsening. 
Most existing longitudinal analyses evaluated the effects of a limited 
number of disease markers on selected populations without exploring the relative 
contributions of each of these factors at different stages of the disease. This could 
lead to omission of important trends as the disease progresses and introduction of 
confounding factors that could mislead the results. It was hypothesized that 
disease markers collected in clinical studies such as ADNI could be used to 
differentiate the healthy from the diseased population and exhibited characteristic 
changes at different stages of the disease according to the pathological cascade 
model proposed by Jack et al. (167). The primary analytical objective of this 
chapter is to investigate the demographic-biomarker-clinical relationships in 
ADNI subjects of different disease severity, from NL to AD, and subgroups of 




for trends of disease progression. This investigation would provide multiple levels 
of insights into the potential demographic-biomarker-clinical relationships that 
would support subsequent disease progression modeling. 
 
2.2 Material and Methods 
2.2.1 Study design and participants 
Data used in the preparation of this thesis were obtained from the ADNI database 
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private 
partnership, led by Principal Investigator Michael W. Weiner, MD. It is an 
ongoing, longitudinal, multicenter, non-interventional study to test whether MRI, 
PET, other biological markers, and clinical and neuropsychological assessment 
can be combined to measure the progression of MCI and early AD. For up-to-date 
information, see www.adni-info.org.  
The initial goal of ADNI was to recruit 200 NL, 400 LMCI and 200 AD 
subjects, but with the availability of more funds, ADNI1 was followed by ADNI-
Grand Opportunities (ADNIGO) and ADNI2. Subjects in ADNI1 were given the 
option to be followed-up as new ADNI studies commenced. EMCI and SMC 
enrollment began in ADNIGO and ADNI2 respectively, and additional NL, LMCI 
and AD subjects were recruited in ADNI2. Together, these five groups of subjects 
were believed to represent different spectrum of the disease, from normal subjects 
(NL) to those in varying degrees of preclinical and symptomatic stages (SMC, 
EMCI and LMCI) and finally to subjects that fits the clinical diagnosis of AD. 




neuropsychological assessments and MRI measurements were taken. In addition, 
a subset of subjects underwent procedures to collect information on brain glucose 
metabolism using FDG-PET and CSF biomarkers concentrations. Multiple 
amendments were made during the course of ADNI and links to study details of 
ADNI1, ADNIGO and ADNI2 can be found in the ADNI homepage (www.adni-
info.org) (195). Overall, ADNI provided a rich, multidimensional data to test 
existing hypotheses of AD with longitudinal data on multiple disease markers of 
interest collected from ADNI1, ADNIGO and ADNI2. 
 
2.2.2 Disease marker measures 
2.2.2.1 Neuropsychological endpoints 
Collection of clinical assessments was managed by the ADNI Clinical Core (196). 
ADAS-cog, MMSE and FAQ were obtained directly from the ADNI database and 
included in the dataset as measurements of clinical endpoints. In additional, CDR-
SB was derived by summing CDR severity scores from six different domains - 
memory, orientation, judgment and problem solving, community affairs, home 
and hobbies, and personal care – and included in the dataset as well.  
 
2.2.2.2 Biomarkers 
CSF samples were batch-processed using a standardized protocol, under the 
direction of the ADNI Biomarker Core (62; 197). CSF measures of Aβ and tau 
were obtained directly from the ADNI database and used in the construction of 




Brain glucose metabolism was assessed using FDG-PET scans and the 
acquisition, quality control and analysis of longitudinal FDG-PET scans was 
carried out under the supervision of the ADNI PET core (198). FDG uptake 
results from prespecified regions of interest (ROIs) were used to construct the 
dataset (199). The values of five predefined, previously validated and highly 
correlated ROIs from the ADNI database - the left and right angular, left and right 
temporal and posterior cingulate regions – were averaged to generate a composite 
value that was labelled as FDG in the subsequent sections of this thesis (199; 78).  
Both PIB and florbetapir, processed under the guidance from the ADNI 
PET core, were measures of Aβ deposits in the brain in ADNI1 and ADNIGO/2 
respectively (198). For quantification of florbetapir, mean tracer retention from 
gray matter for four predefined cortical ROIs – frontal cortex, anterior/posterior 
cingulate cortex, lateral temporal cortex and lateral parietal cortex – were 
normalized to the uptake in the whole cerebellum to give a composite florbetapir 
SUVr (200; 201). An automated ROIs template method was used in the 
assessment of PIB similar to that of florbetapir (199). Florbetapir SUVr was 
directly obtained from the ADNI database while PIB SUVr was a calculated 
average ratio of the four brain ROIs, used for florbetapir SUVr calculation, to the 
cerebellum.  
Analysis of MRI was conducted under the guidance of the ADNI MRI 
core and hippocampal volumes measured using FreeSurfer were utilized to 
construct the dataset (202; 203). Individual left and right hippocampal volumes at 




hippocampal volume measure. Notably, different field strengths and versions of 
FreeSurfer were used in the studies: cross-sectional images from ADNI1 used a 
1.5T MR scanner and FreeSurfer version 4.3 whereas ADNIGO/2 utilized a 3T 
MR scanner and FreeSurfer version 5.1. 
 
2.2.2.3 Adjusted hippocampal volume 
Individual hippocampal volume was further adjusted by intracranial volume 
(ICV), gender and different field strengths/FreeSurfer versions using least square 
linear regression modeling. A linear regression was developed using hippocampal 
volume measures from NL subjects as: 
HVNL = α1.ICVNL + α2.FSV + α0    (Eq. 2.1) 
where HVNL is the raw hippocampal volume, ICVNL is the raw intracranial 
volume, FSV is the field strength/FreeSurfer version used (coded as 0 for the 
combination of field strength of 1.5T and FreeSurfer version 4.3 and 1 for the 
combination of field strength of 3T and FreeSurfer version 5.1), αi (i = 1,2) are the 
regression coefficients to be computed from the data and α0 represents y-axis 
intercept of the model. The coefficients and y-axis intercept from the regression 
model were applied to compute adjusted hippocampal volume (AHV) as a 
residual for each individual as: 
AHV = (HV – α1.ICV – α2.FSV - α0)/1000   (Eq. 2.2) 
where HV and ICV are the raw hippocampal volume and intracranial volume at 




representation of hippocampal atrophy with more negative values corresponding 
to increasing loss of hippocampal volume. 
 
2.2.3 Dataset creation 
Dataset creation utilized data files downloaded from the ADNI database up to 
March 2014 (204). Neuropsychological endpoints, CSF biomarkers, imagining 
biomarkers and demographic information were obtained from respective files 
containing the relevant data of interest and loaded into TIBCO Spotfire S+® 8.2 
for Windows (TIBCO, Boston, MA) for additional modifications and merging by 
unique subject identifier and visit (205).  
During the data collection process, unscheduled and follow-up visits were 
not included as there was no quantifiable time attached to the values from these 
visits. Data that fell outside the predefined range of each assessment, for example 
negative CDR-SB and MMSE, were not included as well. As CSF data was 
analyzed by batches, the most up-to-date values were selected to be included in 
the dataset in the case where two or more values for the same timepoint were 
available. Missing values were left as missing without any imputations. A 
minimum of two samples were required to study disease progression, thus 
participants with only baseline observations were left out from the dataset. Lastly, 
subjects who had their diagnostic categories modified at baseline were manually 





 Due to the length of the study and high subjectivity of clinical diagnosis, 
subjects’ medical condition could remain stable, worsen or improve over time or 
both. To reduce variability from misclassification, only subjects with stable 
medical condition over the course of the study (non-converters) or progressed to a 
more serious disease stage (converters) were included in the analysis dataset. 
Thus, subjects whose conditions improved or were unstable, defined by diagnoses 
of both improvement and worsening in disease stage during the course of the 
study, were excluded. The final categories of non-converters included in the 
dataset were NL, SMC, EMCI, LMCI and AD non-converters. The final 
categories of converters included in the dataset were NL to MCI/AD and MCI to 
AD converters. 
 
2.2.4 Statistical and graphical analyses 
Baseline values and 12-month change from baseline values were employed for 
comparison between different groups of interest in this chapter. 12-month change 
of continuous disease markers was calculated by subtracting baseline value from 
the value at 12-month for each subject. Summary statistics, medians (ranges) for 
continuous measures and counts (%) for categorical measures, for each group of 
interest was calculated using individual baseline or 12-month change values. 
Subjects with missing variable information were not included in the summary 
statistics calculation for the particular variable. Differences in continuous and 
categorical variables between two groups were analyzed using Wilcoxon rank-




All statistical and graphical analyses were conducted using TIBCO 
Spotfire S+® 8.2 for Windows (TIBCO, Boston, MA) and the criterion for 
statistical significance was set at p < 0.05, unless stated otherwise (205). 
 
2.2.4.1 ADNI1 vs ADNI2  
The entire ADNI study spanned across a period of more than a decade during 
which there had been protocol amendments, data collection changes and 
technological replacements. ADNI1 started in 2004 and lasted for five years while 
ADNI2 only started in 2011 and is currently ongoing (23). In order to check the 
comparability of subjects and the presence of systemic difference between ADNI1 
and ADNI2, summary statistics of baseline characteristics and 12-month change 
in disease markers were tabulated for NL, LMCI and AD non-converters from 
each study. Comparisons of baseline and 12-month change in disease markers 
between symptomatic groups from ADNI1 and ADNI2 were carried out. EMCI 
and SMC subjects were left out from the comparison between ADNI1 and ADNI2 
as enrollment of these cohorts only began in ADNI2 and annual change was not 
calculated for FDG, CSF biomarkers and florbetapir due to the lack of 12-month 
data in ADNI2.  
 
2.2.4.2 Non-converters 
Summary statistics of baseline characteristics and 12-month change in disease 
markers were tabulated for NL, SMC, EMCI, LMCI and AD non-converters to 




month change in disease markers between the healthy and diseased population, 
taken to be NL and AD subjects respectively, were performed to assess the utility 
of outcome measures to detect AD. 
The demographic-biomarker-clinical relationships in each symptomatic 
group were assessed using linear mixed effect models. Firstly, correlations 
between continuous psychometric scores and biomarker values, as well as age and 
education, were assessed using Spearman's rank correlation coefficient analysis. 
Based on the calculated Spearman’s rank correlation coefficients, only pairs with 
an absolute correlation coefficient > 0.1 and p < 0.1 were input into the 
subsequent association analyses to ensure pairs with considerable amount of 
trends were captured and at the same time, delimit those whose true correlation 
coefficients should be of much lower values. Linear mixed effect modeling with 
subject as random effect was selected to investigate the associations between 
measures of interest and factors selected from the previous correlation analysis in 
each symptomatic group. Univariate models, with criterion set at p < 0.1, were 
tested, followed by a joint model assessment that included all significant factors 
from the univariate analyses to build a multivariate linear mixed effect model for 
each measure of interest. Gender and APOE-e4 genotype, both binary data, were 
included during the univariate analyses. Finally, fixed effect parameters with 
coefficients that were statistically significant in the multivariate analyses were 





2.2.4.3 Non-converters vs converters 
During the course of the study, subjects might deteriorate to a more serious 
clinical stage and this group of subjects, labelled as converters in the study, made 
up a considerable proportion of the ADNI population. To investigate trends that 
might predict the risk of conversion to AD, LMCI non-converters and LMCI 
converters were studied. Descriptive statistics of baseline characteristics were 
tabulated and differences between the two groups were examined. As time of 
conversion varied for each individual, 12-month change, Spearman's rank 
correlation coefficient analysis and linear mixed effect modeling were not used to 
evaluate the converters. 
In addition, a logistic regression analysis was conducted to evaluate the 
predictive power of baseline demographic factors and biomarkers that have shown 
significant differences between LMCI non-converters and LMCI converters in the 
descriptive analysis. The model was implemented in R Version 3.2.2 (R Core 
Team, Vienna, Austria) using RStudio Version 0.98.507 (RStudio, Boston, MA) 
and the criterion for statistical significance was set at p < 0.05 (206; 207). 
 
2.2.4.4 Aβ pathology and cognitive reserve 
It was hypothesized that cognitive reserve might shield subjects from AD and 
provide an explanation why some individuals with high amyloid burden retained 
normal cognition (208). Aβ pathology was used to dichotomize non-converters to 
study possible signs of cognitive reserve. Aβ pathology (Aβ+) was defined as at 




1.5 SUVr while the absence of Aβ pathology (Aβ-) was defined as having Aβ 
measures within the cutpoints for all samples collected from an individual. 
Subjects without any Aβ measures were excluded from this analysis. 
Demographic factors (APOE-e4 genotype, gender, age and education) and 
baseline biomarkers (AHV, FDG and CSF tau) belonging to the two most extreme 
groups of subjects – NL subjects with Aβ pathology and AD subjects lacking the 
Aβ pathology - were summarized and examined for trends suggesting protective 






2.3 Results  
2.3.1 ADNI subjects and observations 
 
Table 2.1 Counts of subjects and observations by baseline diagnosis. 
Outcome 
NL SMC EMCI LMCI AD Total 
Subject/Observation count (n/N) 
ADAS-cog 404/2101 77/153 274/985 511/2764 312/1028 1578/7031 
MMSE 404/2109 77/153 274/988 511/2776 312/1033 1578/7059 
CDR-SB 404/2093 77/153 274/980 511/2796 312/1036 1578/7058 
FAQ 404/2106 77/151 274/982 511/2804 311/1038 1577/7081 
AHV 404/1904 66/100 274/1112 511/2500 307/970 1562/6586 
FDG 336/802 76/76 273/363 374/1172 223/452 1282/2865 
CSF Aβ pg/mL 169/368 3/3 99/121 271/518 176/266 718/1276 
Florbetapir SUVr 270/404 59/59 274/404 241/323 127/139 971/1329 
PIB SUVr 18/46 NA NA 57/121 17/31 92/198 
CSF tau pg/mL 167/359 3/3 88/108 267/511 171/261 696/1242 
Note: PIB was not collected for SMC and EMCI subjects. 
 
Table 2.1 provides counts of subjects and observations by baseline diagnosis. In 
total, 1578 subjects met the inclusion criteria for the analysis. The number of 
subjects and observations available in the dataset vary by symptomatic groups and 
outcomes. More observations were available for NL, LMCI and AD as they were 
enrolled in both ADNI1 and ADNI2 whereas EMCI and SMC enrollment only 
occurred during ADNIGO and ADNI2 respectively. Fewer observations were 
available for CSF samples and PET scans relative to neuropsychological 
assessments and MRI scans. Out of all the ADNI participants, 20.0% (n = 316) 
progressed to a more serious medical stage during the course of the study and 





2.3.2 ADNI1 vs ADNI2 
 






 Age (years) 
Education 
(years) 
  Count (%) Median (range) 
NL 
     ADNI1 169 39(23.1%) 85(50.3%) 76.0(56.0,89.0) 16.0(6.00,20.0) 







- - * - 
      LMCI 
     ADNI1 165 74(44.8%) 56.0(33.9%) 75.0(56.0,89.0) 16.0(4.00,20.0) 







- * * * 
      AD 
     ADNI1 178 120(67.4%) 85(48.7%) 76.0(55.0,90.0) 15.5(4.00,20.0) 







- - - * 
Abbreviations: APOE+ = subjects with at least one APOE-e4 allele 
a
 Results were presented in counts (%). 
b 
* = significant differences at p-value set at 0.05; - = no significant differences at p-value set at 
0.05. 
 
Table 2.2-2.4 summarizes the baseline sociodemographic characteristics, 
neuropsychological assessments and biomarkers of NL, LMCI and AD non-
converters from ADNI1 and ADNI2. Distribution of subjects’ age and education 
were significantly different between ADNI1 and ADNI2. ADNI2 also had 




Table 2.3 Comparison of ADNI1 and ADNI2 - Baseline neuropsychological 
assessments. 
Groups n ADAS-cog  MMSE  CDR-SB  FAQ  
  
Median (range) 
























- - - - 
      LMCI 
























- * - - 
      AD 
























* - - - 
a 




Conversely, relatively fewer statistically significant pairs were found in 
the comparison of baseline neuropsychological assessments and biomarkers. 
Subjects from ADNI1 generally had similar baseline neuropsychological 
assessments values compared to ADNI2. Baseline MMSE distribution was 
significantly different in the LMCI pair, however the median and range of the two 
groups were the same. ADAS-cog distribution was also tested to be significantly 





Table 2.4 Comparison of ADNI1 and ADNI2 - Baseline biomarkers. 
 







  Median (range) 
NL 
























- - - - 
      LMCI 
























- - - - 
      AD 
























- - * - 
a
 * = significant differences at p-value set at 0.05; - = no significant differences at p-value set at 
0.05. 
 
ADNI1 and ADNI2 had comparable biomarker levels except for CSF Aβ 
concentration in the AD pair. Although a higher than expected difference was 
observed when comparing median AHV between NL subjects from ADNI1 with 
ADNI2, no significance difference was observed. Graphical analyses of 







Table 2.5 Comparison of ADNI1 and ADNI2 – 12-month change in 
continuous measures. 
Outcomes n ADAS-cog  MMSE  CDR-SB  FAQ  AHV (units) 
  Median (range) 
NL 




























- * * - - 
       LMCI 




























- * - - - 
       AD 




























- - - - - 
a
 * = significant differences at p-value set at 0.05; - = no significant differences at p-value set at 
0.05. 
 
Summary statistics of 12-month change in neuropsychological 
assessments and AHV between symptomatic groups of ADNI1 and ADNI2 are 
presented in Table 2.5. Evaluation of the 12-month change in neuropsychological 
assessments between ADNI1 and ADNI2 showed no significant differences 
between most groups. Of those with significance differences, MMSE and CDR-
SB in the NL pair and MMSE in the LMCI pair, all had median 12-month change 
value of zero. Graphical analyses of statistically significant pairs are presented in 






Table 2.6 Baseline sociodemographic characteristics of non-converters by 
diagnosis. 







 Median (range)  





















































Abbreviations: APOE+ = subjects with at least one APOE-e4 allele 
a
 Results were presented in counts (%). 
b
 Not calculated due to lack of data  
c
 Comparison of healthy (NL) and diseased (AD) population. * = significant differences at p-value 
set at 0.05; - = no significant differences at p-value set at 0.05. 
 
Table 2.7 Baseline neuropsychological assessments of non-converters by 
diagnosis. 





 Median (range) 















































 Comparison of healthy (NL) and diseased (AD) population. * = significant differences at p-value 






Table 2.8 Baseline biomarkers of non-converters by diagnosis. 





 Median (range)  






























































 Not calculated due to insufficient data.  
b
 Comparison of healthy (NL) and diseased (AD) population. * = significant differences at p-value 
set at 0.05. 
 
Summary statistics of baseline sociodemographic characteristics, 
neuropsychological assessments and biomarkers of NL, SMC, EMCI, LMCI and 
AD non-converters from a combined dataset of ADNI1, ADNIGO and ADNI2 
subjects are tabulated in Table 2.6-2.8. Graphical analyses are presented in the 
appendices (Figure A2.1). Comparing median baseline neuropsychological 
assessments and biomarkers across symptomatic stages, SMC subjects had values 
closer to those of NL, EMCI subjects had values positioned between NL and 
LMCI, and AD subjects had the worst neuropsychological performances and 
biomarker values, fulfilling the goals of ADNI to recruit subjects of different 
severity to bridge the spectrum of the disease. As expected, disease severity 
followed the general trend: NL/SMC>EMCI>LMCI>AD and ADAS-cog, CDR-
SB, FAQ, AHV, FDG and CSF Aβ decreased while MMSE, florbetapir and CSF 





Table 2.9 12-month change in neuropsychological assessments of non-
converters by diagnosis. 















































 Comparison of healthy (NL) and diseased (AD) population. * = significant differences at p-value 
set at 0.05. 
 
Table 2.10 12-month change in biomarkers of non-converters by diagnosis. 






















































 Calculated using change from baseline at 24-month divided by 2 due to the lack of 12-month 
data. 
b 
Comparison of healthy (NL) and diseased (AD) population. * = significant differences at p-value 
set at 0.05; - = no significant differences at p-value set at 0.05. 
 
Comparison of NL and AD subjects showed significant differences in all 
baseline characteristics except for age and gender of participants. Percentage of 
APOE-e4 allele carriers increased with disease severity as seen from left to right 
in Table 2.6. Boundary effect of neuropsychological assessments was evident in 
early stages of the disease as shown in Table 2.7, with NL and SMC subjects 
having a median score of zero in baseline CDR-SB and FAQ. Surprisingly, SMC 




AHV, FDG and florbetapir. Lastly, the range of variables in each group was wide, 
such that the median value of the AD group fit into the range of the NL group and 
vice versa for all disease markers examined.  
Table 2.9-2.10 reports the median and range of 12-month change in 
neuropsychological assessments and biomarkers in each symptomatic group. 
Values were not calculated for SMC subjects due to the insufficient follow-up 
period. Graphical depictions of longitudinal data are located in the appendices 
(Figure A2.5-A2.13). In general, 12-month change in neuropsychological 
assessments and biomarkers exhibited a trend of nonlinear worsening from 
NL>EMCI>LCMI>AD, with a wide variability observed in the ranges. Largest 
absolute 12-month change occurred in the AD group in all variables except for 
CSF Aβ. 
 Although significant differences were observed between NL and AD in all 
neuropsychological assessments tested, most groups had no observable decline in 
cognition and function over a period of 12 months, denoted by a median value of 
zero in MMSE, CDR-SB and FAQ. Interestingly, NL and EMCI subjects 
exhibited improvement in cognition after one year into the trial, as shown by the 
decrease in the annual change of ADAS-cog. 12-month change in AHV and FDG 
were also significantly different between NL and AD, with approximately four 
and eight fold deterioration in AHV and FDG respectively. In contrast, there were 
no significant differences in 12-month change of CSF biomarkers between NL 
and AD. Furthermore, the 12-month change in CSF biomarkers did not conform 




AD, instead LMCI subjects had the highest decline and smallest increase in CSF 
Aβ and CSF tau concentrations respectively. Additional analyses on 12-month 
change in CSF biomarkers using Kruskal-Wallis test did not demonstrate 
significant differences between NL, LMCI and AD groups.  
Table 2.11 marks the Spearman correlations tabulations, with pairs of 
variables that had absolute correlation coefficient more than 0.1 and p < 0.1 
bolded with asterisk (*). The table shows that age had significant correlations on 
most neuropsychological assessments up to the onset of clinical AD while 
significant correlations between neuropsychological assessments and progression 
biomarkers - brain glucose metabolism represented by FDG and brain atrophy 
represented by AHV - gradually surfaced and strengthened with increasing 
disease severity from NL to AD. Notably, FDG had stronger relationships with 
cognition and function than AHV as the disease progressed as measured by the 
increasing correlation coefficient magnitudes at each stage.  
 Three other significant trends were observed across all groups, 1) age was 
correlated with AHV and FDG, 2) CSF Aβ was positively correlated with FDG 
and 3) a negative relationship was observed between CSF tau and CSF Aβ. CSF 
biomarkers were also observed to correlate weakly with ADAS-cog and MMSE 
in most groups. In non-AD subjects, years of education was directly linked to 
cognition (ADAS-cog and MMSE) and positive correlations were found between 
FDG and AHV. Interestingly, the direction of correlation between age and FDG 






Table 2.11 Results from inter-variables Spearman's rank correlation coefficient analysis. Pairs with absolute correlation 
coefficients > 0.1 and p < 0.1 were bolded with asterisk (*). 
 Neuropsychological assessments Progression biomarkers Diagnostic biomarkers 
NL (n=340) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -0.0962 0.0254 -0.00400 -0.0485 NC NC NC NC 
FDG -0.162 * 0.0700 -0.0550 -0.126 * 0.238 * NC NC NC 
CSF Aβ -0.132 * -0.0121 0.00916 -0.0793 0.0473 0.194 * NC NC 
CSF tau 0.0475 -0.0922 0.0230 0.0350 -0.0680 0.00572 -0.274 * NC 
Age 0.154 * -0.102 * 0.0399 0.0458 -0.392 * -0.198 * -0.0296 0.190 * 
Education -0.0572 0.139 * -0.0296 0.00163 -0.11 * 0.0467 -0.0125 -0.00123 
         EMCI (n=260) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -0.297 * 0.23 * -0.144 * -0.210 * NC NC NC NC 
FDG -0.287 * 0.148 * -0.255 * -0.212 * 0.306 * NC NC NC 
CSF Aβ -0.124 0.158 * -0.0927 -0.158 * 0.162 * 0.201 * NC NC 
CSF tau 0.174 * -0.187 * 0.0573 0.0199 -0.120 -0.123 -0.622 * NC 
Age 0.332 * -0.258 * 0.116 * 0.178 * -0.487 * -0.381 * -0.198 * 0.240 * 
Education -0.210 * 0.243 * -0.138 * -0.0969 -0.0217 0.0995 5.33e-005 -0.0362 
Abbreviations: NC = not calculated. 
 
         
         
         
         
         






Table 2.11      Continued 
 Neuropsychological assessments Progression biomarkers Diagnostic biomarkers 
LMCI (n=277) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -0.410 * 0.369 * -0.285 * -0.226 * NC NC NC NC 
FDG -0.337 * 0.337 * -0.313 * -0.259 * 0.426 * NC NC NC 
CSF Aβ -0.147 * 0.162 * -0.0944 -0.0882 0.167 * 0.177 * NC NC 
CSF tau 0.177 * -0.0888 0.0748 -0.00824 -0.176 * 0.0947 -0.390 * NC 
Age 0.168 * -0.122 * 0.134 * 0.0675 -0.412 * -0.192 * 0.0513 0.0234 
Education -0.124 * 0.127 * -0.0535 -0.0352 0.0786 0.0368 0.0456 -0.0487 
 
AD (n=312) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -0.228 * 0.244 * -0.240 * -0.241 * NC NC NC NC 
FDG -0.466 * 0.391 * -0.370 * -0.395 * 0.0856 NC NC NC 
CSF Aβ -0.120 * 0.0619 -0.0690 -0.0335 -0.00431 0.285 * NC NC 
CSF tau 0.136 * -0.132 * 0.0282 -0.0285 -0.0108 -0.0698 -0.126 * NC 
Age 0.00462 -0.0108 0.0930 0.0491 -0.330 * 0.345 * 0.251 * -0.0939 
Education -0.00664 0.0380 -0.0230 -0.0170 0.0954 -0.0915 -0.0101 -0.163 * 








Table 2.12 Results from multivariate association analyses using linear mixed effect modeling. Row names represent independent 
variables and column headers represent dependent variables. Association coefficients with p < 0.05 were bolded with asterisk (*). 
 Neuropsychological assessments Progression biomarkers Diagnostic biomarkers 
NL (n=340) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV NC NC NC NC NC 0.0663* NC NC 
FDG -0.832 NC NC -0.861 0.381 * NC 107 * NC 
CSF Aβ -0.00578 NC NC NC NC 0.000537 * NC -0.0928 * 
CSF tau NC NC NC NC NC NC -0.270 * NC 
Age 0.0764 -0.0254 * NC NC -0.0292 * -0.000937 NC 0.986 * 
Education NC 0.113 * NC NC -0.0144 NC NC NC 
APOE+ NC NC NC NC NC 0.00483 -22.3 * NC 
Female -0.946 0.293 * NC -0.0440 NC NC NC NC 
         EMCI (n=260) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -1.51 * -0.250 -0.102 
-
0.00284 NC 0.0278 NC NC 
FDG -4.84 * 1.69 -1.39 * -3.93 0.709 * NC 36.0 NC 
CSF Aβ NC NC NC 
-
0.00885 NC 0.000250 NC -0.254 * 
CSF tau NC -0.00815 NC NC NC NC -0.456 * NC 
Age 0.0576 -0.0500 -0.00760 0.0223 -0.0294 * -0.00446 * -1.55 * NC 
Education -0.172 0.0311 -0.0338 * NC NC NC NC NC 
APOE+ NC -0.229 NC NC NC -0.0262 -25.1 * 11.0 
Female -1.15 * NC -0.209 * -0.457 NC 0.0531 * NC NC 







Table 2.12      Continued 
 Neuropsychological assessments Progression biomarkers Diagnostic biomarkers 
LMCI (n=277) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -1.37 0.598 -0.303 * -0.910 * NC 0.114 * 17.8 * -21.5 * 
FDG -7.71 * 3.65 * -1.21 * -5.59 * 1.27 * NC -24.0 NC 
CSF Aβ 0.00186 0.0347 NC NC 0.00191 * 0.000180 NC -0.200 * 
CSF tau 0.00134 NC NC NC -0.00165 * NC -0.128 * NC 
Age -0.0456 0.00132 0.000412 NC -0.0310 * 0.00242 NC NC 
Education -0.130 0.0180 NC NC NC NC NC NC 
APOE+ 0.946 -0.415 NC NC NC NC -42.6 * 29.3 * 
Female NC NC NC NC NC NC NC NC 
         
AD (n=312) ADAS-cog MMSE CDR-SB FAQ AHV FDG CSF Aβ CSF tau 
AHV -4.82 * 1.63 * -1.53 * -4.66 * NC NC NC NC 
FDG -22.6 * 8.80 * -6.33 * -22.0 * NC NC 25.0 NC 
CSF Aβ -0.0176 NC NC NC NC 0.00116 * NC NC 
CSF tau NC NC NC NC NC NC NC NC 
Age NC NC NC NC -0.0216 * 0.00384 * 0.973 * NC 
Education NC NC NC NC NC NC NC -1.19 
APOE+ NC NC NC NC NC NC -14.2 NC 
Female NC NC NC NC NC NC NC 33.3 * 




phenomenon was observed between age and CSF biomarkers. In addition, several 
pairs of measures with significant correlations were observed but were less 
consistent and hence not reported. Only those bolded with asterisk were included 
in the linear mixed effect modeling analyses. 
Table 2.12 contains the coefficients from multivariate association analyses 
using linear mixed effect modeling between dependent variables (column 
headers) and independent variables (row names). Significant associations were 
found between sociodemographic factors, such as age, education and gender, and 
neuropsychological assessments in the NL and EMCI groups. However, as the 
disease progressed to LMCI and AD, these relationships were not significant, 
with AHV and FDG being the only two measures that had significant associations 
with cognition and function assessments. APOE genotype, CSF Aβ and CSF tau 
did not exhibit any significant relationships with neuropsychological assessments 
in any groups. 
Among the biomarkers, significant relationships were noted between FDG 
and AHV as well as between CSF Aβ and CSF tau in the non-AD subjects, with 
the largest absolute association coefficients in the LMCI and EMCI groups 
respectively. A positive relationship was found between CSF Aβ and FDG, 
although it was significant only in the NL and AD groups. Between biomarkers 
and sociodemographic factors, age was the only factor that had a significant and 
consistent association with AHV. In addition, presence of APOE-e4 genotype was 
associated with lower CSF Aβ concentrations prior to the onset of clinical 
symptoms of AD. Similar to what was observed in the correlation analyses, 
 74 
 
increasing age was significantly associated with a decrease in CSF Aβ and FDG 
in the EMCI group, while AD subjects had positive associations between the 
same factors.  
 
2.3.4 Non-converters vs converters 
Table 2.13-2.15 compares summary statistics of baseline sociodemographic 
characteristics, neuropsychological assessments and biomarkers between LMCI 
non-converters and converters who progressed to AD during the course of the 
study. Percentage of female subjects, median age and years of education between 
the two groups were similar. However, LMCI subjects with APOE-e4 genotype 
and poorer prognostic values, based on baseline biomarkers, were more likely to 
progress to AD. As expected, converters had median neuropsychological 
assessments and biomarker values between those of non-converters and AD 
subjects (Table 2.7 and Table 2.8).  Even though differences between non-
converters and converters were statistically significant in multiple outcomes, the 
range of disease marker values for the two comparison groups overlapped each 
other to a great extent. 
Baseline FDG value was the only significant disease marker in the 
multivariate logistic regression model that predicted conversion to AD (Table 
2.16). The model predicted that for every 0.1 unit increase in baseline FDG, the 
odds of a LMCI subject converting to AD during the course of the study decrease 




Table 2.13 Comparison of LMCI non-converters and converters - Baseline 
sociodemographic characteristics. 





 Median(range)  
n 277 234  
APOE+(%)
a
 129(46.6%) 155(66.5%) * 
Female(%)
a
 108(39.0%) 92(40.2%) - 
Age (years) 74.0(48.0,91.0) 74.0(55.0,89.0) - 
Education 
(years) 16.0(4.00,20.0) 16.0(6.00,20.0) - 
Abbreviations: APOE+ = subjects with at least one APOE-e4 allele. 
a
 Results were presented in counts (%). 
b 
* = significant differences at p-value set at 0.05; - = no significant differences at p-value set at 
0.05. 
 
Table 2.14 Comparison of LMCI non-converters and converters – Baseline 
neuropsychological assessments. 
Outcomes LMCI LMCI → AD Wilcoxon RS testa 
 Median(range)  
n 277 234  
ADAS 10.0(1.00,27.0) 13.0(2.00,27.7) * 
MMSE 28.0(24.0,30.0) 27.0(23.0,30.0) * 
CDR-SB 1.50(0.500,5.50) 2.00(0.500,5.00) * 
FAQ 1.00(0.00,21.0) 4.00(0.00,21.0) * 
a 
* = significant differences at p-value set at 0.05. 
 
Table 2.15 Comparison of LMCI non-converters and converters – Baseline 
biomarkers. 
Outcomes LMCI LMCI → AD Wilcoxon RS testa 
 Median(range)  
n 277 234  
AHV (units) -0.329(-1.71,1.16) -0.601(-2.01,0.803) * 
FDG (units) 1.23(0.767,1.71) 1.16(0.782,1.55) * 
CSF Aβ (pg/mL) 155(40.5,304) 143(60.7,288) * 
Florbetapir (SUVr) 1.20(0.836,1.86) 1.41(0.981,1.93) * 
CSF tau (pg/mL) 79.2(23.9,309) 108(28.5,354) * 
a 





Table 2.16 Logistic regression model of LMCI conversion. 
Disease markers Odds Ratio(95% CI) P-value 
APOE+ 1.99 (0.910,4.39) 0.0880 
AHV
a
 (units) 0.938 (0.875,1.00) 0.0631 
FDG
a
 (units) 0.734 (0.557,0.946) <0.05 
CSF Aβ (pg/mL) 1.00 (0.994,1.01) 0.634 
CSF tau (pg/mL) 1.00 (0.997,1.01) 0.288 
Abbreviations: APOE+ = subjects with at least one APOE-e4 allele, CI = confidence interval 
a 
Results reported as per 0.1 unit change. 
 
2.3.5 Aβ pathology and cognitive reserve 
 
Table 2.17 Comparison of NL subjects with Aβ pathology and AD subjects 
without Aβ pathology - Baseline sociodemographic characteristics. 





 Median(range)  
n 99 18  
APOE+(%)
a
 39(39.4%) 1(7.69%) * 
Female(%)
a
 56(56.6%) 5(27.8%) * 
Age (years) 74.0(60.0,87.0) 79.5(61.0,90.0) * 
Education 
(years) 16.0(6.00,20.0) 16.0(8.00,20.0) - 
Abbreviations: APOE+ = subjects with at least one APOE-e4 allele.
 
a
 Results were presented in counts (%). 
b 
* = significant differences at p-value set at 0.05; - = no significant differences at p-value set at 
0.05. 
 
Table 2.18 Comparison of NL subjects with Aβ pathology and AD subjects 
without Aβ pathology – Baseline biomarkers. 
Outcomes NL, Aβ+ AD, Aβ- Wilcoxon RS testa 
 Median(range)  
n 99 18  
AHV (units) 0.0235(-0.964,0.897) -1.05(-1.84,0.317) * 
FDG (units) 1.31(0.991,1.62) 1.16(0.997,1.35) * 
CSF tau (pg/mL) 67.1(29.3,211) 79.9(40.7,245) - 
a 





Summary statistics of baseline sociodemographic characteristics and biomarkers 
of NL subjects with Aβ pathology and AD subjects without Aβ pathology are 
tabulated in Table 2.17 and Table 2.18. Graphical analyses are presented in the 
appendices (Figure A2.14). In total, only 18 subjects in the AD group (7.76%) did 
not have signs of Aβ pathology while 99 of the NL subjects (39.6%) exhibited 
signs of Aβ pathology. NL subjects in this comparison had higher percentage of 
APOE-e4 carriers and women, and were significantly younger than the AD 
subjects. Lower AHV and FDG values, which were less favorable, were observed 
and anticipated in the AD subjects when compared to the NL subjects. However, 
both groups had comparable years of education and CSF tau concentration. 
 
2.4 Discussion 
The purpose of this work was to characterize the clinical, biomarker and 
demographic data from ADNI subjects at various stages of AD and to investigate 
potential relationships in subject characteristics. The main findings were that 
disease progression followed a general trend of NL/SMC>EMCI>LMCI>LMCI 
converters>AD, where NL subjects had the best and AD subjects had the worst 
neuropsychological and biomarker values. Baseline and 12-month change in all 
measures of interest exhibited significant differences between NL and AD, except 
for 12-month change in CSF biomarkers. Nevertheless, having a single disease 
marker as diagnostic or predictive tool remained implausible at this point due to 
the large variability within each group. Types and degrees of association were 
found to vary between symptomatic stages. For example, cognitive and functional 
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changes in NL and EMCI groups were associated with sociodemographic factors 
but as the disease progressed to LMCI and AD, AHV and FDG were the only two 
measures that had significant associations with neuropsychological assessments. 
Systemic differences between the studies and signs of cognitive reserve were not 
apparent from the analyses conducted. 
It was hypothesized that disease markers change in a temporal sequence 
according to the pathological cascade model described in Figure 1.1-1.2. Based on 
results from the baseline and 12-month change analyses, a reasonable postulation 
would be that CSF biomarkers were among the first to change as baseline 
concentrations were significantly different between NL and AD while no 
significant differences were detected in the 12-month change between groups. 
This implied that there might be a steep change in CSF biomarkers prior to study 
enrollment and a plateau in CSF biomarker change would have been achieved 
when subjects were diagnosed. This was followed by change in FDG and AHV 
which were significantly different between NL and AD in both baseline levels and 
12-month change. Although significant differences were also observed for 
baseline and 12-month change in neuropsychological assessments between NL 
and AD, no observable decline was noted after 12 months in all groups except for 
AD, suggesting that changes in neuropsychological assessments occurred after 
biomarker changes. Hence, the postulated trend from the results is in agreement 




2.4.1 Adjusted hippocampal volume 
Intracranial volume (ICV) is often used as proxy variable for premorbid brain 
volume in neurodegeneration research, thus normalizing by ICV is a common 
approach to better estimate the extent of atrophy that is caused by the disease and 
to remove intrinsic variability in brain volume (187; 209). Gender difference in 
brain volume is also a well-established phenomenon, with males having larger 
brain volumes than females in general (187). Analysis of MRI data from ADNI 
studies was further complicated by the evolution of imaging acquisition and 
processing standards over the duration of the trial. Cross-sectional images from 
ADNI1 were analyzed using a 1.5T MR scanner and FreeSurfer version 4.3 while 
ADNIGO/2 utilized a 3T MR scanner and FreeSurfer version 5.1. Therefore, raw 
hippocampal volume measurements were adjusted by the subject’s ICV, gender 
and data acquisition method. 
 
2.4.2 ADNI1 vs ADNI2 
Prior to the start of the analyses, subjects from ADNI1 and ADNI2 were 
compared for possible sources of systemic differences. Significant differences in 
distribution of baseline and 12-month change in neuropsychological assessments 
between NL and LMCI subjects from ADNI1 and ADNI2 were observed. This 
was an unexpected result, as minimum cognitive changes were expected in these 
subjects. Furthermore, for MMSE and CDR-SB, NL and LMCI subjects from 
ADNI1 and ADNI2 had identical median baseline values and median 12-month 
change values of zero, suggesting no clinical significant differences between the 
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groups. Notably, age, gender and education are some of the demographic factors 
that have been reported to affect MMSE and found to be significantly different 
between subjects from ADNI1 and ADNI2 (210; 211). No differences were found 
when comparing baseline and 12-month change results between the AD groups, 
except for distribution of baseline ADAS-cog and CSF Aβ. For ADAS-cog, a 
three to four points change was taken to be clinically significant whereas ADNI1 
and ADNI2 AD subjects only had a two points median difference (212). 
Moreover, for the AD subjects with CSF biomarker data reported, more than 90% 
in both groups had CSF Aβ concentrations below the generally accepted cutoff 
value of 192 pg/mL, confirming that subjects in both groups appeared to have 
been appropriately diagnosed and any differences present would have little 
clinical significance (61). No significant differences were observed when 
comparing baseline and 12-month change in AHV between the groups, suggesting 
that the adjustment method employed managed to account for the data acquisition 
and gender differences. In general, results suggested no critical systemic 
differences between the various ADNI studies and justified the combination of 
data from ADNI1 and ADNIGO/2 for further analyses. 
 
2.4.3 Neuropsychological assessments 
Of the four clinical endpoints studied, ADAS-cog had the widest range and hence 
most likely to be able to track changes in cognition of the various symptomatic 
groups tested. Although the ADAS-cog, like other cognitive scales, has limited 
sensitivity in assessing change in non-AD and severe AD subjects due to floor 
 81 
 
and ceiling effects, these limitations are expected to be more conspicuous in the 
other neuropsychological assessments. It is recognized that both CDR-SB and 
FAQ incorporate functional components that are only anticipated to be impacted 
at the later stages of the disease. This is displayed in Table 2.7 where ADAS-cog 
was able to discern the cognitive differences between EMCI and LMCI but 
median FAQ was identical for both groups. Furthermore, 12-month change in 
cognition and function could not be identified using MMSE, CDR-SB or FAQ in 
the non-AD subjects as shown in Table 2.9. Therefore, it would require larger 
sample sizes or more sensitive tests to separate out effects of different risk factors 
in non-AD subjects. Remarkably, NL and EMCI subjects shown improvement in 
ADAS-cog after one year into the trial, possibly due to “practice effects”. 
“Practice effects” could be introduced by increasing subjects’ familiarity and 
exposure to test instruments, paradigms, and items, leading to improved cognitive 
performances across testing sessions (213). 
 
2.4.4 Progressive biomarkers 
FDG and AHV are believed to be progressive markers that indicate disease 
severity. Both FDG and AHV exhibited significant differences between the 
healthy and diseased population in their baseline and 12-month change. In 
addition, both biomarkers were significantly associated with neuropsychological 
assessments, as well as each other, as shown in the multivariate analyses, 
suggesting that they might be part of a common pathway that could be directly or 
indirectly linked to neurobiological damage. This is supported by reports of 
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metabolic changes corresponding well with structural changes in the brain (214; 
215). Although results showed FDG to have stronger correlations with 
neuropsychological assessments in AD subjects (Table 2.11) and could better 
predict LMCI conversion (Table 2.16) compared to AHV, contradictory results 
were presented in the literature on which is a better tool for disease progression 
monitoring (215; 216; 217). However, the low availability and high financial cost 
of FDG-PET might outweigh any sensitivity and specificity advantage it had 
against MRI, making MRI the likely method of choice in clinical AD (215). 
Similar to ADAS-cog, some subjects had an increase in brain glucose metabolism 
and hippocampal volume after enrolling into the trial (Table 2.10) and these 
observations could be attributed to assay variability and measurement error. Also, 
it should be noted that imaging biomarkers collected were not AD-specific, and 
could thus respond to lifestyle or environmental changes. For example, research 
had shown that aerobic exercises is associated with hippocampal volume in the 
elderly and this might be one of the reasons why unexpected imaging biomarker 
changes were observed over the course of this non-interventional study (218; 219; 
220).  
 
2.4.5 Diagnostic biomarkers 
Baseline CSF biomarker concentrations were significantly different between NL 
and AD groups but no significant differences were observed in the 12-month 
change between groups (Table 2.8 and Table 2.10). This implied that there might 
be a steep change in CSF biomarkers prior to study enrollment and supported 
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their use as AD diagnostic markers rather than disease progression markers. 
Linear mixed effect modeling found significant associations between CSF tau and 
CSF Aβ in the non-AD populations but neither biomarker exhibited any 
significant associations with neuropsychological assessments at any stage. The 
models reinforced the roles of CSF Aβ and CSF tau as “early stage” biomarkers 
and the hypothesis that their alternations happened early in the disease pathway, 
leading to changes in downstream mechanisms that were more likely to be 
responsible for driving cognitive and functional decline. Undeniably, what was 
observed could be due to the disproportionately small sample size with CSF 
biomarker results that has insufficient power to show any statistical difference in 
12-month change. Also, the conflicting trend of LMCI group having the lowest 
increment in CSF tau seemed counterintuitive which could be due to outliers that 
skewed the data or explained by a lack of information to detect a true change in 
the midst of high variability commonly seen in physiological compounds. 
Significant differences were found in almost all neuropsychological tests 
and biomarkers when comparing baseline and 12-month change between NL and 
AD. Similarly, significant differences were observed in all baseline psychometric 
assessments and biomarkers tested between LMCI non-converters and converters. 
However, results displayed a high degree of variability and overlap between the 
groups, limiting the use of any single measure as a diagnostic tool. Despite the 
stringent inclusion and exclusion criteria, subjects in ADNI were selected and 
categorized based on a series of general clinical observations without taking 
biomarkers into account. It should be noted that AD is a complex progressive 
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disease where overlapping results between symptomatic stages could be linked to 
the progressive nature of the disease. Diagnosis of the various AD stages is 
subjective and can never be fully accurate, not to mention the number of sites and 
physicians involved in the ADNI study. On top of that, the presence of different 
types of neuropathology among participants who exhibited the same clinical 
symptoms could lead to misleading biomarker results and increasing variability. 
For example, subjects might be suffering from non-AD tauopathies but 
experiencing AD-like symptoms. No standardization between the 
neuropsychological assessments exists as each test is unique and often measures a 
different domain of the disease. In addition, cardiovascular and cerebrovascular 
diseases could affect imaging results and populations exhibiting different 
progression trends might exist. Lastly, it has been widely acknowledged that 
possible sources of biomarker variability could arise from different sample 
handling techniques, analytical procedures and analytical kits/reagents along with 
measurement errors, even for well-designed studies such as ADNI (18; 62; 221).  
 
2.4.6 Demographic factors 
Results from baseline analyses shown no apparent variations in age between the 
groups and a plausible explanation would be that the effect of age was masked by 
the inclusion/exclusion criteria of ADNI which selected subjects between 55 to 90 
years old. In addition, no significant associations were found between age and 
neuropsychological assessments in the presence of other factors in the 
multivariate association analyses except for an effect on MMSE in NL subjects, 
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suggesting that age might exert its effect, if any, indirectly on cognition and 
function via other biological pathways. Examining the effects of age on 
biomarkers show that increasing age was significantly associated with a decrease 
in CSF Aβ and FDG in EMCI and yet having positive associations with the same 
factors in AD. This seemingly contradictory protective effect of increasing age in 
AD calls for further investigation and research. Age was the only factor that had a 
significant and consistent association with AHV as shown in the multivariate 
association analyses, suggesting that hippocampal atrophy was partially due to the 
natural process of aging, regardless of disease stage.  
APOE-e4 genotype, a well-known risk factor of AD, is often linked to Aβ 
trafficking which makes it a strong advocate of the Aβ cascade hypothesis (50). 
Distribution of APOE-e4 allele varies among different human populations, 
ranging from 7.10% in Chinese to 40.7% in African Pygmies (222). 26.4% of the 
NL non-converters subjects in the ADNI dataset were carriers of APOE-e4 allele, 
matching what was reported for US population in the literature (223). On the 
other hand, 69.2% of the AD subjects were APOE-e4 carriers which was 
comparable to the estimated prevalence of 62.1% reported in a recent meta-
analysis conducted on patients diagnosed with AD (224). Groups with higher 
prevalence rates of APOE-e4 genotype had lower concentrations of CSF Aβ 
(Table 2.6 and Table 2.8) and LMCI converters had similar APOE-e4 prevalence 
rates (66.5%, Table 2.13) compared to AD subjects. Multivariate analyses 
concluded the presence of an association between APOE-e4 genotype and lower 
CSF Aβ concentration prior to the onset of AD symptoms while no other 
 86 
 
significant associations were observed between APOE-e4 genotype and other 
biomarkers or neuropsychological assessments. Together, these observations 
reinforced that the risk of APOE-e4 genotype on AD is likely to be mediated by 
its relationship with CSF Aβ.  
Pertaining to gender, it was reported that while men might have a higher 
risk of getting MCI, women were disproportionally affected with AD and this 
remained a widely debated topic with theories ranging from longevity to lifestyle 
to gender-specific pathological differences (225; 226). Results from baseline 
comparison found no significant differences between percentage of female NL 
non-converters and AD subjects as well as female LMCI non-converters and 
converters in the ADNI population (Table 2.6 and Table 2.13). Nevertheless, it is 
possible that factors excluding potential subjects from ADNI studies could create 
sampling bias, for instances, unavailability of study partners, residents of nursing 
facilities and major neurological disorders such as depression, were more likely to 
affect women than men (227; 228). Although female NL and EMCI subjects 
performed better cognitively as indicated in the multivariate association analyses, 
female AD subjects had higher CSF tau concentration, which could predispose 
them to brain insults, leading to AD. Therefore, like age, gender might play a duo 
role in AD – protector in the preclinical states and aggressor in the late stages. 
Gender is also a well-known covariate of hippocampal volume and no significant 
association between gender and AHV was observed in all symptomatic groups, 




Education is often reported to be a significant covariate in models 
describing longitudinal cognitive changes and epidemiological studies of AD 
(119; 226; 229; 230). Education is believed to provide cognitive resilience where 
subjects with higher education were able to cope better with the disease through 
compensatory neural reserve buildup from years of schooling (208). Although 
years of education between NL and AD were tested to be significantly different, 
the median value was identical. Moreover, education was not observed to be 
significant when tested for trends of AD conversion or cognitive reserve (Table 
2.13 and Table 2.17). As expected, other than associations with MMSE and CDR-
SB in NL and EMCI subjects respectively, no significant associations were found 
between education and all other disease markers in the linear mixed effect 
modeling analyses. 
 
2.4.7 Aβ pathology and cognitive reserve 
Lastly, NL subjects with Aβ pathology was compared with AD subjects without 
Aβ pathology to investigate trends of cognitive reserve that might protect 
individuals from the insults of AD. Results reinforced previous findings that Aβ 
concentration is modulated by APOE-e4 genotype as shown in the percentage of 
APOE-e4 carriers in the NL group (39.4%) which was higher than the AD group 
(7.69%) (Table 2.17) and the general NL population (26.4%) (Table 2.6). 
Surprisingly, both groups had similar concentrations of baseline CSF tau (Table 
2.18), indicating that Aβ might be an important driver of CSF tau increase and the 
presence of an alternative form of AD mediated by factors other than CSF 
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biomarkers in a small proportion of subjects. Of note, the number of AD subjects 
without Aβ pathology was exceptionally small, making it a less than ideal 
representation of this particular population. Furthermore, AD subjects without Aβ 
pathology were significantly older (Table 2.17), introducing an important source 
of bias as age is both a risk factor of AD and affects biomarker concentrations and 
psychological performance (130; 191). Unfortunately, analysis by age categories 
was limited by the small sample size. As for the NL subjects with Aβ pathology 
who were thought to be at “high-risk” of AD, a “lag time” could exist between Aβ 
plaques formation and downstream physiological changes. However, the follow-
up period is insufficient to determine if these “high-risk” NL subjects would 
convert to a more serious disease stage during their lifetime. A bigger group of 
subjects with a longer follow-up period is necessary to study the effect of 
cognitive reserve with regards to Aβ pathology. 
 
2.4.8 Limitations 
Although ADNI enrolled a fairly large number of participants and collected a rich 
array of biomarker data, making it ideal for longitudinal analyses to uncover 
potential relationships between disease markers, it is not without its limitations. 
“Structured missingness” was introduced deliberately by the study design, 
resulting in partial data availability for some measures such as CSF biomarkers 
and PET imaging results, which could limit the power of longitudinal analyses. 
With a predefined sample size and sequential visits as far as two years apart, 
small apparent magnitude of changes, significant relationships with fairly variable 
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endpoints and changes that occurred between visits could go undetected. The 
nature of the study could also lead to biasness as subjects were recruited 
according to a list of criteria that might not be a good representation of the general 
AD population. Furthermore, as all the sites were in North America, subjects were 
overall better educated and less ethnically diverse, making results from ADNI less 
applicable for generalization. Finally, considering AD being a disease that lasted 
for decades, data was collected over a relatively short period of time. With a 
median follow-up period of two years, results could only provide “snapshots” of 
events over the study period at best, while pathological changes could be missed. 
Even though resources were limited, the ADNI team managed to enroll subjects 
over a wide spectrum of disease severity based on symptomatic staging and 
followed them in parallel as an attempt to mitigate the issue of long disease 
duration. Nonetheless, extrapolation of the disease time course using the data 
should be done with caution.  
Additionally, there were several notable limitations in the current 
analyses. Differences in disease severity beyond broad symptomatic classification 
were not considered as it was assumed all subjects belonging to the same 
symptomatic stage were comparable at all levels, even though intra-group 
variations might impede the accurate capturing of pathological changes. For 
example, the LMCI group contained non-converters and potential converters who 
would progress to AD if tracked long enough. Results demonstrated that LMCI 
non-converters and converters were fundamentally different in baseline disease 
markers (Table 2.14 -2.15) even though they belonged to the same enrollment 
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category. It is likely that disease progression in LMCI converters occurred earlier 
and faster compared to the non-converters. If grouped as one, it would introduce 
an unaccounted disease-duration factor which greatly increases the variability and 
possibly lead to erroneous results. A common way to address this issue is to use 
cognitive performance at baseline as a covariate which was adopted by many 
modeling groups, though it might be an over-simplistic solution to the problem, 
especially when attempting to understand the long-term changes and underlying 
mechanisms of disease pathology (111; 123; 135). Thus, the current staging 
methods created high inter-individual variability within each symptomatic group, 
especially when there was inadequate longitudinal data to map out the entire 
disease trajectory.  
The analyses were performed with selected, key objectives in mind, 
mainly to compare the different symptomatic groups using baseline, 12-month 
and longitudinal results. With the amount of data, variables, groups and models, it 
was a challenge to integrate all the results to give an appropriate conclusion and at 
the same time, might have led to an oversight of other important trends along the 
way. Although a stepwise approach was taken to reduce the number of factors 
tested in linear mixed effect modeling, multiple testing could still inflate Type 1 
error. On top of that, the statistical analysis methods chosen assumed the 
relationships between variables to be linear and this is unlikely the case. It has 
been recognized that the rate of change in endogenous biological compounds does 
not extend indefinitely but begin to plateau or saturate at some point. On the other 
hand, more than two samples would be needed to detect nonlinearity and some 
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subjects in the study did not have sufficient data to support these analyses. A 
further complication is the fact that various measures of interest appeared to 
progress on significantly different time scales as seen in the baseline and 12-
month change results, making it difficult to draw direct relationships between 
them using current methods.    
  Lastly, key variables examined in this study represented a small selection 
of the data collected and selection was based on literature review which might be 
biased and limited. Most of the chosen disease markers were composite scores or 
values made up of results from several sections and it is possible that individual or 
a subset of constituents had better sensitivity and selectivity than the overall 
outcome (152). Out of the numerous FDG-PET and MRI processing approaches 
taken by various laboratories, only one of each was used in the analyses. Other 
common biomarkers and neuropsychological assessments such as CSF 
phosphorylated tau (p-tau), isoprostanes, Rey Auditory Verbal Learning Test and 
Trail Making Tests were left out due to overlapping information or assessments 
being less commonly used as clinical endpoints for model development.  
 
2.5 Conclusion 
In the current analysis, effects and dynamics of twelve of the most widely studied 
neuropsychological assessments (ADAS-cog, MMSE, CDR-SB and FAQ), 
biomarkers (AHV, FDG, CSF Aβ and CSF tau) and demographics descriptors 
(Age, APOE genotype, education and gender) were investigated using data from 
ADNI. Descriptive baseline and 12-month change in disease markers were 
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employed to better understand the general trends, trajectories and temporal 
changes of disease markers while longitudinal models helped to elucidate and 
quantify the complicated relationships between psychometric tests, biomarkers 
and demographics in different groups of subjects.   
In conclusion, the analyses confirmed significant differences in key 
biomarkers between the healthy and diseased groups. CSF Aβ concentrations 
plateaued early in the course of the disease as anticipated whereas CSF tau 
appeared to behave discordantly except for an inverse relationship with CSF Aβ. 
As expected, abnormal hippocampal atrophy and glucose metabolism occurred 
prior to cognitive changes and had the strongest correlations with 
neuropsychological worsening as the disease progressed. The findings on 
temporal sequencing of biomarkers generally aligned with what Jack et al. 
proposed in the hypothetical model but without long term data, these hypotheses 
could not be confirmed (167). Demographic factors such as age and education 
might have direct influences on neuropsychological outcomes in NL and EMCI 
subjects and indirect effects in AD subjects through their associations with “late 
stage” biomarkers such as FDG and AHV. These relationships reflected the 
nonlinear changes throughout the course of the disease and the importance of 
studying subjects of various stages together to understand the underlying disease 
progression. 
 However, high variability was observed for each of the measure and none 
had the dynamic range to cover the full spectrum of the disease. Also, the use of 
broad symptomatic staging could lead to high intra-group heterogeneity and 
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failing to account for it in group-wise comparisons by treating every individual 
within a given group as relatively homogenous might vex attempts to map out 
important trends of disease progression. In the Dominantly Inherited Alzheimer’s 
Network, a landmark study of familial AD, Bateman et al. was able to deploy the 
onset age of subjects’ parents to predict long term disease progression from cross-
sectional data (17). However, such methods to estimate time of AD onset is not 
suitable for sporadic AD subjects as their parents might not have had AD. Given 
the need to reduce intra-group variability and compare subjects of different 
disease severity more effectively, there is a strong motivation to investigate 
methods that could describe the natural progression of the disease by placing 
subjects onto a common timescale. These would be addressed in Chapter 3 where 
disease time synchronization was carried out to construct a pathological timeline 
that allowed subjects to be positioned based on a series of disease markers. 
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Chapter 3 : Modeling the pathological timeline of ADNI subjects 
3.1 Introduction 
AD is a progressive neurodegenerative disease and characterizing the temporal 
pathological changes, from initial stages through fully developed disease, is 
important to the understanding and monitoring of disease progression. Even 
though AD data continues to accumulate from ongoing longitudinal studies, most 
of these studies remained “cross-sectional” with respect to the full disease 
duration. In addition, it has been reported that time from start of study might not 
be a suitable metric to measure disease progression due to the difference in onset 
and rate of disease progression between individuals (168; 170; 175).  
The concept that disease onset and progression rate could vary over a wide 
range between subjects, even those grouped under the same broad clinical 
categories, was supported by the consistent emergence of cognitive performances 
at study entry as a significant covariate that affected the rate of disease 
progression in earlier models (111; 135; 156). Nevertheless, it should be obvious 
that poor cognitive performance itself did not cause disease worsening. Rather, it 
acted as an indicator of the underlying biological mechanisms that led to disease 
progression. In contrast, it is thought that by disregarding symptomatic staging 
and aligning individuals in a continuous timeline, based on their longitudinal 
biomarker/s profiles relative to the entire population, a more accurate and refined 
picture of disease progression could be obtained (168). This was achieved by 
employing data-driven models to reconstruct longitudinal trends of disease 
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progression using cross-sectional or short-term data, as done by several research 
groups.  
Many previous approaches used a single neuropsychological assessment 
or biomarker as a surrogate to characterized disease progression and predict the 
disease course (147; 166; 168; 169; 231). For example, Yang et al. employed a 
synchronization method using ADAS-cog to estimate the position of each subject 
along the calculated timeline of disease progression and synchronized biomarker 
profiles based on changes in ADAS-cog (168). Using a similar method, Delor et 
al. devised a disease progression mixture model using CDR-SB which allowed 
separation of MCI subjects into fast and slow progressing subpopulations (147). 
Instead of utilizing psychometric tests, Lorenzi et al. “disentangled” normal aging 
from AD by estimating the brain’s anatomical age relative to the MRI model of 
healthy aging and came up with a morphological age shift for each individual, 
whereas Schiratti et al. accounted for individual differences in age at disease onset 
and speed of disease progression via subject-specific time reparamertization 
estimated from cortical thickness measurements (169; 231). However, the use of a 
single disease marker to delineate the long-term trends of AD-related measures 
carry the assumption that disease progression could be reflected by a single 
marker, thereby potentially limiting the characterization of disease evolution. 
It has been less common to combine data from multiple disease markers to 
estimate biomarker trajectories on a single time scale, possibly due to the lack of 
data or the complexity of such models. Jedynak et al. proposed a sophisticated 
method of using several cognitive measurements, hippocampal volume and CSF 
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biomarkers to estimate a continuous disease progression score that could act as a 
time proxy (175). Most recently, Donohue et al. attempted to synchronize the 
temporal ordering of biomarkers with respect to disease pathology using self-
modeling regression (SEMOR) (170). The model was able to estimate the 
pathological time of individual study subject and long-term disease progression 
curves simultaneously, using short-term data that encompassed a comprehensive 
array of neuropsychological tests and biomarkers (170). Both methods allowed 
variations in individual progression rates, used a least-squares approach for 
parameter estimation and utilized data from the ADNI database. The ADNI 
database is an ideal resource for such methods to study disease progression trends 
as a wide variety of markers were collected from subjects across different 
symptomatic groups over a considerable period of time. Although data from long-
term studies such as the PAQUID cohort, made up of more than 3000 individuals 
in France studied from 1988 to present, have richer longitudinal information, they 
lacked the biomarker data that could help unfold the mechanistic details of the 
disease (180; 232).  
Several key differences exist between the two multivariate models. Firstly, 
Jedynak et al. assumed disease markers trajectories to be sigmoidal while 
Donohue et al. only assumed them to follow a smooth and monotone time course. 
Secondly, Jedynak et al. modeled disease progression using scores instead of time 
on the x-axis. Donohue et al., on the other hand, modeled disease progression 
using time to specific events, such as 80
th
 percentile on CDR-SB or estimated 
disease onset, by integrating CDR-SB and MMSE scores into the predicted 
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pathological timeline. Lastly, disease progression scores were computed for all 
ADNI subjects in the model by Jedynak et al. In contrast, Donohue et al. focused 
on two groups of subjects divided by Aβ pathology or APOE-e4 genotype, with 
the assumption that the two biomarkers were the key to AD pathology. The 
assumption is built on the fact that abnormal formation and accumulation of Aβ 
plaques in the brain is a hallmark of AD and APOE-e4 is one of the most well-
known risk factor of AD. 
Although the approach taken by Donohue et al. presents a novel way of 
linking various biomarkers to estimate disease progression, the results presented 
by the group could not be easily interpreted nor utilized to examine relationships 
between the various biomarkers. For example, examination of ADAS-cog 
trajectories between subjects with and without Aβ pathology exhibited minimum 
differences, except for CSF biomarkers, whereas trajectories of subjects without 
APOE-e4 alleles had unrealistic steep slopes as time approaches onset of 
dementia compared to APOE-e4 carriers (Figure A3.1). Moreover, post-
processing steps to transform time using CDR-SB or MMSE hinders the 
application of results for further modeling of relationships between disease 
markers. The objective of this chapter is to position each subject on a pathological 
timeline by applying the methodology proposed by Donohue et al. for mapping of 
temporal changes in disease markers and calibrating subject-specific time 
component to facilitate model development. Rather than splitting subjects by Aβ 
pathology or APOE-e4 genotype, all subjects were included in the model to study 
the general trend of disease progression in the ADNI population. In addition, no 
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post-processing steps were taken to transform time using CDR-SB or MMSE 
trajectory. Despite lacking a pathological event anchor, such as time to 80
th
 
percentile on CDR-SB or estimated disease onset, the resultant time scale from 
the estimated subject-specific time shifts should allow direct comparison and 
quantification of time between disease markers and populations. Ultimately, a 
disease progression model similar to the hypothetical model proposed by Jack et 
al. could be constructed and tested (167). Detailed modeling assumptions and 
algorithms were published previously and described briefly below (170). Codes 
adapted for the following analyses, as well as other helpful visuals, can be found 
online (http://mdonohue.bitbucket.org/grace). 
 
3.2 Material and Methods 
3.2.1 Dataset 
All ADNI subjects included in the previous analyses (Section 2.2.3), with the 
exception of SMC, were used for modeling the pathological timeline. Subjects 
were grouped accordingly to their baseline symptomatic stage. A set of disease 
markers, namely CSF Aβ, PIB, florbetapir, CSF tau, AHV, FDG, ADAS-cog, 
MMSE, CDR-SB and FAQ, was selected to represent the hypothetical disease 
progression curves put forward by Jack et al. (Figure 1.2). Each outcome was 
converted to a percentile scale by the weighted empirical cumulative distribution 
function for comparison and weighting was introduced according to the inverse 
proportion of observations from each baseline symptomatic group due to the 
imbalanced representation of data between the groups.  
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3.2.2 Pathological timeline modeling 
3.2.2.1 Model assumptions 
The disease time synchronization modeling methodology utilized the SEMOR 
approach which assumed all progression trajectories followed a common shape, 
i.e. the same number of extrema or inflection points were located relatively near 
some common region (233). Variability in timing and amplitude of measurements 
in the data were accounted for by shifting and scaling along the axes. The general 
SEMOR model described observation Yij at time t for individual i = 1, . . . , n and 
outcome j = 1, . . . , m  in the form of:  
Yij(t) = gj(t+γi) + α0ij + α1ijt + εij(t)    (Eq. 3.1) 
where gj is a continuously differentiable monotone function for each outcome. 
Time from study entry is represented by t and γi corresponds to the averaged 
subject-specific time shift information estimated from all outcomes, with mean 
zero and variance 𝜎𝛾
2. The random intercept and slope for each subject and 
outcome are represented by α0ij and α1ij respectively and assumed to have a 
bivariate normal distribution with mean zero and covariance matrix Σj. Lastly, 
εij(t) represents the independent normal residual error for each outcome, subject 
and timepoint, with a mean of zero and outcome-specific variance 𝜎𝑗
2. The 
assumption that gj is a continuously differentiable monotone function for each 
outcome and the distributional conditions imposed on the transformation 




3.2.2.2 Model algorithm 
An alternating conditional expectation algorithm was applied to fit both the time 
shift parameters and long-term curves simultaneously through conditional 
expectations and iterative minimization. The highly dimensional and complex 
problem was simplified by the algorithm that estimated model parameters in an 
iterative procedure, where values were reset after each iteration, until convergence 
of the residual sum of squares (RSS), set at a tolerance level of 0.001. Assuming 
that the model (Eq. 3.1) was correct, three sets of partial residuals (R(t)), each 
with an accompanying conditional expectation (E(X|Y)) equivalent to the 
parameter of interest, were applied to provide an unbiased estimate for 1) gj, 2) 
α0ij and α1ij, and 3) γi: 
1) 𝑅𝑖𝑗
𝑔
(t) = Yij(t) - α0ij - α1ijt   E(𝑅𝑖𝑗
𝑔
(t)| gj, t, γi) = gj(t+γi)  (Eq. 3.2) 
2) 𝑅𝑖𝑗
𝛼 (t) = Yij(t) - gj(t+γi)    E(𝑅𝑖𝑗





(Yij(t)) - t  E(𝑅𝑖𝑗
𝛾
(t)| γi) ≈ gj
-1
(gj(t+γi)) - t = γi (Eq. 3.4) 
where α0ij, α1ij, gj
-1
 and εij are expected to be small. 




𝛼 (t) respectively. Subsequently, subject-specific γi was estimated by averaging 
of 𝑅𝑖𝑗
𝛾
(t) over all outcomes and timepoints from each individual. Stepwise 
algorithm of the model is as follows: 
A. Set initial estimates for γi, α0ij and α1ij to be zero. 
B. Estimate gj and αij by a monotone B-spline smooth of 𝑅𝑖𝑗
𝑔
(t) and linear 
mixed effect model of 𝑅𝑖𝑗




RSSj = Σit[Yij(t) - gj(t+γi)]
2     
(Eq. 3.5) 
C. Estimate γi by averaging 𝑅𝑖𝑗
𝛾
(t) for all outcomes and t. Repeat A-C until 
convergence of the total RSS: 
RSS = Σijt[Yij(t) - gj(t+γi)]
2     
(Eq. 3.6) 
 
3.2.2.3 Model implementation 
The model was implemented in R Version 3.2.2 (R Core Team, Vienna, Austria) 
using RStudio Version 0.98.507 (RStudio, Boston, MA) (206; 207). The R 
package fda Version 2.4.4 was used to smooth the data with a monotone function 
in order to estimate gj while lme4 Version 1.1-10 provided the functions for fitting 
and analyzing linear mixed effect models to estimate α0ij and α1i (234; 235). 
 
3.2.2.4 Model evaluation 
Model-estimated time shifts were summarized using boxplots by 1) baseline 
symptomatic stages and 2) conversion status of LMCI subjects to evaluate the 
results and characterize trends in model output. In order to assess the impact of 
incorporating the estimated time shifts back into the dataset, two sets of plots 
displaying longitudinal data before and after disease time synchronization were 
created. Each set of plots contained selected disease markers of interest that 
represented different aspects of the disease pathology, namely ADAS-cog, AHV, 
FDG, CSF Aβ and CSF tau. In the first set, x-axis represented time from trial 
entry and in the subsequent set, x-axis represented the model-estimated 
pathological timeline (t+γi), i.e. summation of the time from trial entry and 
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model-estimated time shifts. Subjects were grouped based on their most recent 
clinical diagnostic status in order to better assess the results as some subjects 
progressed to a more severe stage during the course of the study. Median and 90% 
percentile intervals (PIs) were plotted for each disease marker, group and 
timepoint, with the pathological time rounded off to the nearest year. Of note, a 
sample size of ≥ 30 (ADAS-cog and AHV) and ≥ 10 (FDG, CSF Aβ and CSF tau) 
for each timepoint was chosen as a plotting requirement due to the differences in 
data availability between the disease markers (Table 2.1). 
In addition, graphical analyses were performed to assess the temporal 
sequence and trends of disease marker changes by comparing with the 
hypothetical model proposed by Jack et al. as shown in Figure 1.2. A locally 
weighted scatterplot smoothing (LOESS) function was applied to each set of 
disease marker values over the model-estimated pathological timeline to produce 
a smoothed curve that described the general progression characteristics of each 
disease marker. The y-coordinates from each LOESS curve was transformed into 
a percentile scale to give a value between 0 and 1. As results of MMSE, AHV, 
FDG and CSF Aβ were believed to decrease with disease progression, the values 
were multiplied by negative one (-1) to orientate their direction to be the same as 
the other remaining disease markers (ADAS-cog, CDR-SB, FAQ and CSF tau) , 





3.2.2.5 Aβ pathology and APOE genotype 
Lastly, to evaluate the groups selected by Donohue et al. in the original 
publication, subjects were segregated by Aβ pathology or APOE-e4 allele and the 
algorithm was applied to each of the four groups. Aβ pathology (Aβ+) was 
defined as at least one sample showing CSF Aβ ≤ 192 pg/mL, florbetapir ≥ 1.1 
SUVr or PIB ≥ 1.5 SUVr while the absence of Aβ pathology (Aβ-) was defined as 
having Aβ measures within the cutpoints for all samples collected from an 
individual. Subjects without any Aβ measures were excluded from the Aβ 
pathology analysis to prevent misclassification. Similarly, APOE+ subjects were 
those with at least one APOE-e4 allele while subjects with no APOE-e4 alleles 
were labelled as APOE-. Those without any APOE genetic information were 
excluded from the APOE-e4 analysis as well. For each segregating factor, the 
pathological time was derived and rounded off to the nearest year for each group 
and the median and 90% PIs of both groups were overlaid in a single plot. This 
was carried out for the list of disease markers mentioned earlier using the same 
sample size cutoff without further post-processing transformation. 
 
3.3 Results 
3.3.1 Model evaluation 
Figure 3.1 illustrates a series of boxplots summarizing model-estimated time 
shifts by baseline symptomatic stages in the left panel and conversion status of 




Note: The middle line in each box plot represents the median; the top and bottom margins of the 









lines outside the whiskers represent potential outliers. 
Figure 3.1 Summary boxplots of time shifts (γi) by baseline symptomatic 
stages (left panel) and comparison between LMCI non-converters and converters 
(right panel). 
 
generally aligned based on their disease severity, i.e. NL subjects, representing 
the normal population, had the smallest time shifts whereas AD subjects had the 
largest time shifts which also indicated the presence of the disease. When LMCI 
subjects were divided based on their conversion status, majority of the converters 
were estimated to have positive time shifts with median similar to the AD group 
while the median time shifts for non-converters was close to zero. 






























































 percentile of the observations respectively. 
Figure 3.2 Median and 90% PIs of selected disease markers against (A) time 
from trial entry and (B) model-estimated pathological timeline. 
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Median and 90% PIs time course profiles of disease markers before and 
after disease time synchronization are plotted in Figure 3.2(A) and Figure 3.2(B) 
respectively. Non-converters NL, LMCI and AD subjects were selected as 
representative populations in order to reduce clutter while plots illustrating all 
symptomatic stages are available in Figure A3.2. Results from unsynchronized 
data displayed higher degree of overlapping between groups with no clear 
separation or obvious disease progression trends. Comparatively, a more coherent 
view of long-term disease progression trends on an extended x-axis that signified 
the model-estimated pathological timeline was obtained after disease time 
synchronization. Groups were aligned based on their disease severity on the 
pathological timeline, i.e. NL>LMCI>AD, as observed in Figure 3.2(B), with 
certain degree of overlapping between the polygons of each group.  
Figure 3.3 illustrates a series of disease progression curves plotted on a 
normalized vertical scale against the model-estimated pathological timeline, 
similar to the hypothetical model proposed by Jack et al. (Figure 1.2). Curves 
were adjusted so that each of them moved in the same direction as the disease 
progressed. Apart from CSF Aβ which was the first to become abnormal, disease 
markers progressed with relatively close succession in the following order: 
AHV>CSF tau> FDG>ADAS-cog>CDR-SB>MMSE>FAQ. Figure 3.3 also 
allows quantitative comparison of disease severity and time, for example, CSF Aβ 
was expected to reach 50% of its maximum severity approximately 10 years 
before ADAS-cog attained the same threshold. A closer examination of disease 




Figure 3.3 Plot of disease severity against model-estimated pathological 
timeline. 
 
Aβ and the remaining disease markers. CSF Aβ had an initial steep progression 
which was replaced by a gentler slope with time. On the contrary, worsening in 
the remaining disease markers started off slow and accelerated only after changes 
in CSF Aβ started to plateau. Unexpectedly, slope of AHV followed a relatively 
linear trajectory compared to the rest of the disease markers. 
Comparing with the hypothetical model proposed by Jack et al., the shape 
of the curves in Figure 3.3 was more variable and non-sigmoidal. The temporal 
sequence of the curves was fairly similar between the two figures except for AHV 
which was closer to CSF tau than curves representing cognitive impairment such 






































3.3.2 Aβ pathology and APOE genotype 
 





 percentile of the observations respectively. 
Figure 3.4 Median and 90% PIs of selected disease markers from subjects 
with and without Aβ pathology on the model-estimated pathological timeline. 
 
 Figure 3.4 depicts the estimated disease marker trajectories of 1242 
subjects with quantifiable evidence of amyloid burden in the brain. In general, the 
plots showed that disease markers of Aβ+ subjects progressed at a faster rate than 
Aβ- subjects. Results also demonstrated that CSF Aβ trajectories belonging to 
Aβ+ and Aβ- subjects started off at significantly different concentrations. 
Furthermore, CSF Aβ concentrations of Aβ+ subjects were predicted to 
experience a steep decline initially before plateauing with time whereas minimal 
changes in CSF Aβ concentrations were shown in the Aβ- curve. In contrast, 
starting point of the remaining disease markers was relatively close between Aβ+ 
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and Aβ- subjects. Also, most of them followed a linear progression except for 
ADAS-cog and FDG progression of Aβ+ subjects which seemed to adopt a 
nonlinear change. It was noted that the minimal change in CSF tau was predicted 
in the Aβ- group, similar to what was observed in CSF Aβ. 
APOE genotype information was available for a total of 1457 subjects. 
Compared with Aβ pathology, similar results were obtained when subjects were 
segregated by APOE status (Figure A3.3). Although substantial amount of CSF 
biomarker progression in APOE- subjects was predicted, disease progression was 
expected to be faster in APOE+ subjects.  
 
3.4 Discussion 
To understand the progression of AD and the temporal relationships between 
disease markers, complete profiles of each disease marker on the same time scale 
is necessary, especially when relationships are nonlinear and time sensitive. 
Ideally, to map out the full disease marker trajectories, one would track many 
individuals to collect samples at multiple time points over the entire span of the 
disease. However this is not feasible as data collection would last for decades. For 
reasons of practicality, disease time synchronization was utilized to piece together 
multiple short-term disease marker data from ADNI subjects at different stages of 
the disease to predict long-term trajectories by formation of a pathological 
timeline.  
Generally, the results from disease time synchronization showed that by 
discarding the use of discrete categories such as “NL”, “MCI” and “AD” and 
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treating disease markers as measures of continual progression, reasonable time 
shifts and progression curves could be predicted simultaneously from multivariate 
short-term observations. By virtually extending the x-axis from the maximum 
follow-up period of eight years to more than two decades for disease progression 
characterization, the disease time synchronization model was able to position each 
subject within the context of disease severity with improved resolution, allowing 
more confident and precise data interpretation. It has been suggested that time 
from start of study might not be a suitable metric to measure disease progression 
due inter-individual variability in disease onset time and rate of disease 
progression, even in those from the same symptomatic group. Disease time 
synchronization might ameliorate or solve the problems caused by broad clinical 
staging and allow more accurate comparison of data from all subjects on a 
common pathological timeframe. Results generally supported the hypothetical 
sequence of AD pathology put forward by Jack et al. and that disease marker 
trajectories changed nonlinearly over time, suggesting that disease progression of 
AD is time dependent. 
 
3.4.1 Model evaluation 
Based upon the pathological timeline after disease time synchronization in Figure 
3.2, the results suggested that disease progression, starting from the prodromal 
stage to early AD, could extend over a span of two decades, which is in general 
agreement with published data (236; 237). At the same time, it was reassuring that 
the model was able to align subjects based on their disease severity, from NL to 
 111 
 
AD, despite being blinded to the diagnostic categorizations. No clear separation 
between symptomatic groups was observed (Figure 3.1 and Figure 3.2(B)) but 
this was anticipated as the disease is in continual progression and diagnosis often 
lagged behind onset of symptoms by years (238). However, it would have little 
impact on the positioning of subjects on the pathological timeline which was 
based on values from a battery of disease markers independent of diagnostic 
status. 
 Figure 3.3 displayed results that generally concurred with the hypothetical 
model from Jack et al. (Figure 1.2) (167). The plot of adjacent slopes supported a 
sequence that CSF Aβ changes is an early event that precedes brain glucose 
hypometabolism or hippocampal atrophy such that when CSF Aβ started to 
plateau, changes in other disease markers were still continuing (239; 240). It also 
suggested that changes in CSF tau were more directly linked to changes in late-
stage biomarkers and cognitive function compared to CSF Aβ, supporting the 
presence of a temporal delay in CSF biomarker changes (168; 167). FDG was 
predicted to be the last biomarker in the series to become abnormal, backing its 
role as a late-stage biomarker that could aid in monitoring disease progression 
(18). It was reported in literature that CSF Aβ showed greater associations with 
cognitive decline in normal participants but as brain glucose hypometabolism 
became more pronounced in the course of the disease, it was also more closely 
linked to changes in cognitive symptoms (241). Similar relationships were 
presented in Table 2.11 where stronger correlations between FDG and 
neuropsychological tests were observed as the disease progressed. Abnormality in 
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function, represented by FAQ changes, was detected last, implying prominent loss 
of function as the last to surface after changes in ADAS-cog, CDR-SB and 
MMSE. This is aligned with the widely accepted symptomatic staging of AD 
where functional disabilities come after cognitive decline (7; 242).  
However, it was noted that the shapes of the long-term curves deviated 
from the hypothetical model and adopted non-sigmoidal trajectories. This was 
also the experience of several other groups working on the ADNI dataset which 
concluded that the general biomarker trends might be linear or exponential (166; 
243; 244). A plausible explanation to this observation is the absence of early and 
late stage data that characterize the floor and ceiling effects due to the study 
design of ADNI which did not include middle-aged individuals and end-stage AD 
subjects. Consequently, by truncating the subject population, the full dynamic 
range of disease marker trajectories could not be reconstructed and what was 
observed in Figure 3.3 is actually a series of truncated sigmoidal curves. Contrary 
to the hypothetical model which positioned hippocampal atrophy as a biomarker 
that tracked closely with cognitive impairment, results after disease time 
synchronization indicated that changes in AHV were more aligned to changes in 
CSF tau. This is not surprising as hippocampal atrophy was shown to be a strong 
measure of CSF tau changes and related neurodegeneration (15; 166; 245; 246). 
Furthermore, it had been suggested that changes in hippocampal volume might 
even precedes changes in CSF tau (165; 168; 170; 175). 
 Results from disease time synchronization modeling provided some 
insights on treatment strategies, patient population and endpoint selection for 
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clinical trials of AD. The results in Figure 3.3 implied that amyloid plaque 
accumulation occurred at approximately 10 years or more prior to the appearance 
of clinical signs and symptoms, represented by steepening of the ADAS-cog 
curve. This interval is when buildup of amyloid in the brain was believed to be the 
most rapid and thus critical, particularly if it is assumed that irreversible neuronal 
damage follows. Therefore, it might represent a therapeutic window where drugs 
that altered amyloid burden could be administered to patients at risk of AD for 
preventive intervention. The follow-up period for such interventions should be at 
least several years to allow disease progression to take place before any clinically 
significant differences between subjects taking placebo and drugs could be 
observed, more so if the primary endpoint involved cognitive or functional 
changes measured by psychometric tests. However, pharmacological reduction of 
amyloid burden in asymptomatic subjects might not be feasible, especially if the 
risk/benefit ratio was unfavorable as not all who had high amyloid burden would 
eventually develop AD. Unlike interventions lowering amyloid burden, 
interventions that aimed to modify CSF tau or FDG levels would require a shorter 
follow-up period and could be administered at a later stage, for instance once 
signs and symptoms of LMCI were noticed, to give the largest clinical response. 
Lastly, disease time synchronization could be useful for examining new AD 
biomarkers or composite scores in order to position them in the disease 
progression pathway with respect to other variables of interest and study their 
utility and validity as instruments of diagnosing or monitoring AD. As the field 
moves in the direction of earlier AD diagnosis to conduct tests on timely 
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treatments and preventive studies, more reliable and sensitive disease markers are 
required for the selection of potential AD subjects and detection of changes in 
cognition early in the disease process. This approach could be easily applied to 
predict the long-term trajectories of newly introduced disease markers with 
respect to the current ones for the study of temporal sequences and possible 
relationships. 
 
3.4.2 Aβ pathology and APOE genotype 
In the original publication by Donohue et al., time was shifted so that time zero 
represent CDR-SB at its 80
th
 percentile for both Aβ+ and Aβ- groups whereas for 
APOE+ and APOE- groups, time zero represent PAQUID-adjusted years to onset 
of dementia by MMSE trajectories (Figure A3.1) (170). Colored lines and shaded 
area in the diagram represent the mean and 95% confidence interval calculated 
from bootstrap analysis respectively. Results from Donohue et al. illustrated no 
major differences between subjects segregated by Aβ pathology except for 
distinctively different progression patterns in CSF biomarkers while APOE- 
subjects were predicted to experience a steep progression just before the onset of 
dementia, converging towards the severity levels of APOE+ subjects. Aβ- 
trajectories were interpreted as representation of non-AD pathology by Donohue 
et al. whereas the phenomenon in APOE- subjects was thought to be 
“concatenation of subjects without AD pathology antecedent to those with AD 
pathology” (170).    
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 The last section of the result in this chapter offered a different perspective 
to compare specific groups chosen by Donohue et al. Figure 3.4 suggested the 
presence of a mixed population that followed rather distinct disease courses: 1) a 
fast progressing type mediated by Aβ that led to changes in CSF tau and other 
downstream disease markers observed in the Aβ+ subjects and 2) a slow 
progressing version with minimal changes in CSF biomarkers observed in the Aβ- 
subjects. Analysis using APOE-e4 allele as a segregation factor produced similar 
results (Figure A3.3) which was not surprising as APOE is often linked to Aβ 
trafficking and groups with higher prevalence rates of APOE-e4 genotype had 
lower concentrations of CSF Aβ (Table 2.6 and Table 2.8).  
 Nevertheless, CSF Aβ changes could be due to other factors which 
explained the substantial amount of CSF biomarker progression predicted in 
APOE- subjects. Furthermore, it was predicted that Aβ- and APOE- subjects 
could eventually still get AD, as observed in the ADNI dataset, albeit in smaller 
numbers and at a slower progression rate, suggesting that the disease is 
multifactorial and could possibly be modulated by other factors such as age and 
comorbidities. At the same time, it cannot be ruled out that Aβ- and APOE- 
subjects who had signs and symptoms of AD were actually misdiagnosed with 
some other forms of dementia such as frontotemporal dementia and dementia with 
Lewy bodies. Notably, there was a vastly unequal distribution of subjects among 
the two groups where only 18 out of 237 AD patients (<10%) with known 
amyloid status were classified as Aβ-. Also, the use of short-term values and point 
estimates threatened reliability of the categorization, particularly if changes were 
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nonlinear. Lastly, while amyloid aggregation was assumed to be the precursor of 
the AD cascade, the actual cause of AD could well be the loss of neurons which 
occurred over a longer period of time than amyloid alterations and long-term 
patterns of brain and cognitive function were in fact not dependent on amyloid 
burden levels.  
 
3.4.3 Limitations 
Despite the numerous advantages of this approach to estimate subject-specific 
short-term time shifts and long-term disease marker trajectories, there were some 
limitations that should be considered. Firstly, the data was modeled with several 
assumptions. An important caveat of the disease time synchronization model is 
the assumption that MCI and AD subjects were simply a more progressed version 
of the NL and MCI population respectively and everyone in the trial would 
progress to AD eventually. However, the nature of the study is such that subjects 
at various disease stages were specifically selected and followed for a period of 
time. Although cognitive performance declines with age and approximately half 
of non-AD subjects over 90 were reported to have high levels of AD pathology at 
death, many MCI and especially NL subjects might never get AD in their lifetime 
(247). Even though a subset of NL and MCI subjects did progress to AD during 
the course of the study, this assumption would have an impact on the initial phase 
of the prediction, particularly if a NL or MCI subject was destined never to get 
AD and chose to remain in the trial for continual follow-up, resulting in a 
deliberate extension of the pathological AD timeline.   
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Another inherent limitation of SEMOR is the assumption that all curves in 
the series followed a common shape as observed in Figure 3.3. In the current 
disease time synchronization model, the nonparametric monotone smoothing 
allowed certain flexibility in the gradient without prespecifying shapes of disease 
trajectory, giving each curve a distinct shape. Over-parameterization is a common 
problem seen in previous modeling work where trajectories of disease markers 
were often prespecified since there was no way of determining the shapes of 
progression without long-term data (164; 168; 175). To counter this problem, the 
number of unknowns in the model was kept to a minimum while assumptions and 
constrictions on the parameters were made to help ensure identifiability. Yet, 
individuals might experience different disease marker trajectories that were not 
accounted for by the model which assumed disease progression to follow a 
smooth and monotone time course as seen between Aβ+ and Aβ- subjects in 
Figure 3.4. 
Since the disease time synchronization model was primarily data-driven, 
results would be affected by the data available. As mentioned, the lack of early- 
and late- stage data from middle-aged individuals and moderate to severe AD 
subjects prevented the full dynamic range of biomarker abnormalities to be 
reconstructed and therefore extrapolation of the results beyond the characteristics 
of ADNI population should be taken with caution. Even though ADNI is an 
ongoing study and larger quantity of observations would be made available with 
longer follow-up intervals, they could only be used to validate or strengthen the 
current model but unable to provide the crucial information at both extreme of the 
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disease spectrum due to the study design. Subjects enrolled into ADNI were at 
least 55 years old and the onset of biomarker abnormalities might have been 
missed for those who have started to show signs and symptoms of AD. On the 
other hand, patients with moderate to severe AD were not recruited in ADNI to 
fill the knowledge gaps of AD-related pathological changes at the final stages of 
the disease. Furthermore, the data remained susceptible to measurement errors, 
misdiagnoses and other sources of variability. 
Lastly, the analyses showed that the shape of the progression curves could 
differ depending on covariates introduced, such as Aβ pathology and APOE 
genotype (Figure 3.4 and Figure A3.3). However, these segregating factors were 
selected based on current knowledge of AD and presented graphically with no 
means of quantification or tests for statistical significance. Moreover, certain 
covariates proven to influence the rate of AD progression in previous longitudinal 
ADAS-cog models, for example age and gender, were not evaluated in the current 
disease time synchronization model (123; 128; 156). Covariates related to 
cognitive reserve, such as lifestyle and education which could account for some of 
the heterogeneity, were also not included. Incorporating significant covariates into 
the model could further reduce inter-individual variability, improve disease time 
synchronization accuracy and provide a better mechanistic understanding of the 





Despite the lack of long-term data, disease time synchronization modeling 
positioned ADNI subjects on a pathological timeline based on disease severity 
and estimated long-term trajectory characteristics of multiple disease markers 
from short-term observations with reasonable results and confidence. Instead of 
dividing subjects by Aβ pathology or APOE-e4 genotype, all subjects were 
included in the model to study the general trend of disease progression in the 
ADNI population. In addition, results were analyzed without any post-processing 
steps to transform time on the x-axis using CDR-SB or MMSE trajectory. Overall, 
long-term disease trends derived from the analyses demonstrated that disease 
markers generally change in a temporal sequence according to the hypothetical 
pathological cascade model proposed by Jack et al. and in agreement with 
prevailing theories of AD (167).  
CSF Aβ was estimated to exhibit the greatest change during the initial 
phase of the pathological timeline which could be a decade or more prior to the 
emergence of any clinical signs and symptoms of AD. Changes in CSF tau 
tracked closely with increasing hippocampal atrophy while glucose metabolism 
was the last biomarker to become abnormal, followed by cognitive and functional 
changes. On the other hand, results suggested that shapes of disease trajectory in 
the test population might not be sigmoidal. Hippocampal changes might have 
occurred earlier than expected and tracked more closely to changes in CSF tau 
and less to FDG and cognitive changes. Lastly, CSF tau changes might be 
 120 
 
dependent on CSF Aβ changes and disease progression without CSF biomarker 
abnormalities might take place at a slower rate. 
Although this approach allowed the estimation of subject-specific time 
shifts and deduction of temporal sequence of disease markers, some unanswered 
questions still persist. Quantification of the change in clinical outcomes over time 
and the influence exerted by key covariates such as FDG and AHV were two 
major interests that would be particularly useful for researchers and drug 
development. Even though the analyses suggested amyloid burden in the brain as 
a possible covariate on the rate of disease progression, it is only one of the many 
potential covariates tested and no explicit associations was derived. Nevertheless, 
the disease time synchronization model provided a continuous pathological 
timeline over the course of AD that could be used to validate hypotheses, provide 
insights for clinical trials and evaluate the effects of novel instruments at multiple 




Chapter 4 : Modeling Alzheimer’s disease progression on a pathological 
timeline 
4.1 Introduction 
Conventional longitudinal models of AD typically focus on a single population, 
usually AD subjects, which restricts the understanding of disease evolution to a 
certain symptomatic stage. It is likely that at earlier stages of the disease, the 
trajectories of various disease markers might be different from what is observed in 
AD patients, reflecting nonlinearity across the course of the disease. The use of 
symptomatic stages, such as MCI and AD, poses a further problem as it does not 
account for individual differences in disease start time and progression rate and is 
dependent on clinicians’ judgment and the availability of reliable information 
from caregivers. Application of the disease time synchronization method 
introduced by Donohue et al. enables the positioning of individual study subject 
in a single disease pathological time scale (170). This allows for the direct 
comparison of subjects, regardless of their symptomatic groups, and could 
account for the inter-group heterogeneity in disease start time and rate of 
progression. However, disease progression and covariate effects were not 
explored extensively or quantitatively by Donohue et al. to uncover the 
relationships between disease markers (170). 
 As data accumulate from clinical AD studies, an effective tool is required 
to efficiently integrate and summarize available information in a quantitative 
manner. Furthermore, given the number of risk factors and biomarkers associated 
with the progression of AD reported in literature, it is likely that relationships 
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between them are multivariate and nonlinear. Population modeling is a common 
approach for such situations as it allows pooling of sparse data from multiple 
individuals simultaneously to estimate population values while quantifying inter-
individual variability and covariate effects using nonlinear mixed effect (NLME) 
models (248). In brief, NLME is a nonlinear regression method to quantify 
population fixed and random effects simultaneously. Fixed effects refer to the 
estimated typical population values and random effects help describe the 
variability of the fixed effects within the population group. Although several 
software packages are able to perform NLME modeling (for instance, S+, 
Phoenix and R), NONMEM (NONlinear Mixed Effects Modeling) is by far one 
of the most frequently used tool by modelers in the pharmaceutical industry (205; 
206; 249; 250). First introduced by Sheiner and Beal in the early 1980s, 
NONMEM is a flexible and powerful tool that specialized in nonlinear systems, 
enabling the estimation of population parameters and random variability through 
modeling (251; 252; 253). 
The use of population modeling to understand disease progression of AD 
is not new. One of the earliest disease progression models of AD was conducted 
by Holford and Peace in 1992, using a simple linear model to describe changes in 
ADAS-cog of AD subjects (99). Despite the continuous emergence of new 
cognitive scales, ADAS-cog remained one of the most widely collected, used, and 
validated measures of cognitive deterioration in AD clinical trials, making it a 
popular endpoint for disease progression modeling. Due to advances in modeling 
and a better understanding of the ADAS-cog scale, more recent disease 
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progression models chose asymptotic curves to better describe the clinical 
observations and inherent boundaries of ADAS-cog (123; 135; 156).  
Ito et al. modeled ADAS-cog with a linear base structure while 
incorporating power (polynomial) functions to describe the curvilinear 
relationships between ADAS-cog and significant covariates. In addition to 
ADAS-cog at study entry, age, APOE-e4 genotype and gender were found to 
influence the rate of disease progression (111). These relationships were also 
observed in a beta regression meta-analysis model of ADAS-cog using both 
summary-level and patient-level data conducted by Rogers et al. (128). Gomeni et 
al. developed an indirect response model to describe ADAS-cog changes and 
predicted that MMSE score at study entry, education, age and APOE-e4 genotype 
to have significant influences on the rate of disease progression (119). Samtani et 
al. constructed a semi-mechanistic logistic mixture model describing disease 
progression by longitudinal changes in ADAS-cog. Disease progression rates 
were shown to be mainly influenced by Trail B-test at study entry and CSF 
biomarker pathology (123). In 2013, William-Faltaos et al. published a 
longitudinal log-linear ADAS-cog model built from placebo arms of clinical trials 
conducted in mild to moderate AD subjects, with ADAS-cog and MMSE at study 
entry being significant covariates of progression rate (135). One of the most 
recent longitudinal ADAS-cog models, published by Conrado et al., used an 
asymmetrical logistic structure with beta-distributed residuals and incorporated 
inter-study, inter-individual, and residual variability (156). Younger age, higher 
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number of APOE-e4 alleles and stable usage of AD medications were significant 
covariates predicting shorter times to disease worsening in AD subjects (156). 
 Even though these analyses significantly advanced the quantitative 
understanding of AD progression and the impact of covariates, certain limitations 
continue to persist. As mentioned earlier, most models were developed using a 
single population, usually the AD subjects. Additionally, relationships between 
disease markers are hard to interpret despite being statistically significant due to 
possible confounding factors. For example, the physiological meaning of gender 
as a covariate of ADAS-cog progression is poorly understood as gender 
represents a broad category that is linked to numerous sources of influence, from 
hormonal to smoking (225; 254; 255). More importantly, crucial biomarkers that 
are known to represent elements of the AD pathological cascade such as AHV, 
FDG and amyloid PET tracers were often not included in earlier models, as they 
were only made available recently due to technological advances. This adds 
another layer of confounding in the covariate analyses of those models.   
 The main objective of this chapter is to expand the understanding of the 
natural progression of AD quantitatively by developing a pathophysiological AD 
progression model using the ADNI dataset. Change in ADAS-cog was selected as 
the clinical outcome representing disease progression. Data on a pathological 
timeline after disease time synchronization from Chapter 3 was fit using NLME 
modeling in NONMEM. The influence of key CSF and imaging biomarkers, as 
well as relevant demographic factors on the rate of disease progression was 
investigated by means of covariate testing. In addition, a population disease 
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progression model of FDG was developed to study the long-term influence of 
FDG changes on changes in ADAS-cog.    
 
4.2 Material and Methods 
4.2.1 Dataset 
The model-estimated pathological timeline, i.e. sum of time from trial entry and 
model-estimated time shifts, discussed in Chapter 3 ranged from (-12.6) years to 
16.4 years. In order to meet requirements of the modeling software (NONMEM), 
the model-estimated pathological time values were all increased by 12.6 years 
(the minimum model-estimated pathological time), assuring that all time values 
were greater than or equal to 0. Natural log transformation was performed on 
ADAS-cog observations before modeling to reduce the inherent right skewness. 
ADAS-cog included values between zero to one that would give negative and 
undefined results upon natural log transformation, hence one point was added to 
all ADAS-cog observations (ADAS-cogobs) prior to the natural log transformation 
to calculate the modified ADAS-cog score (ADAS-cogmod) : 
ADAS-cogmod = ln(ADAS-cogobs + 1)   (Eq. 4.1) 
Data manipulation was completed using TIBCO Spotfire S+
®
 8.2 for Windows 
(TIBCO, Boston, MA) (205). The modified ADAS-cog was then input in 
NONMEM as the dependent variable and used for plotting the goodness-of-fit 
plots. Results were back-transformed to the original ADAS-cog scale in the 




4.2.2 Modeling building process 
 
 
Abbreviations: VPC = Visual predictive check 
Figure 4.1 General process for model development adapted from Byon et al. 
(256). 
 
The dataset was analyzed using NONMEM Version 7.3.0 (ICON Development 
Solutions, Hanover, MD) where the variable-time data was fit to provide 
estimates of the population parameters and error terms (NONMEM User’s Guide, 
Part VII) (257). NONMEM uses the extended-least-squares fitting routine, which 
continues iteratively until a minimal objective function value (OFV) is reached. 
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Change in OFV, a statistic which measures goodness-of-fit of the model and 
equals minus twice the log-likelihood of the data, was the main criterion for 
comparing models. First order conditional estimation with interaction was used as 
the estimation method throughout the NLME analysis (NONMEM User’s Guide, 
Part VII) (257). Model performance evaluation was carried out by bootstrapping 
utilizing Perl-speaks-NONMEM Version 4.2.0 (Department of Pharmaceutical 
Biosciences Uppsala University, Sweden) (258). Graphical analyses were 
conducted using Xpose Version 4.0 (Department of Pharmaceutical Biosciences 
Uppsala University, Sweden) and TIBCO Spotfire S+® 8.2 for Windows (205; 
259). The entire process required multiple steps that are detailed below and 
outlined in Figure 4.1 (256).  
 
4.2.2.1 Structural base model selection 
In order to select the best structural base model, a series of previously published 
base models were tested in NONMEM, including linear, exponential and logistic 
models and the results compared. The inter-individual variability of ADAS-cog 
scores at the arbitrary start time was assumed to be log-normally distributed as the 
parameter had to be constrained to a non-negative value due to the inherent 
characteristic of the scale. As for the rate of progression parameter, a proportional 
term was used to capture inter-individual variability as disease progression could 
either be positive or negative. Correlation between parameters was assessed 
within the model building process. An additive error model structure was used to 
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describe the residual variability for the log-transformed data and expressed as a 
standard deviation.  
Selection of the most appropriate structural base model was based upon 
agreement between predicted and observed ADAS-cog scores, lack of pattern 
(that is, randomness) in the weighted residuals versus the predicted values, and 
significant decrease in the OFV. Precision of model-predicted parameters was 
evaluated to confirm that all parameters were well estimated. A visual predictive 
check was also performed on the final base model to investigate the agreement 
between the observed and predicted values. More details on model evaluation are 
presented in section 4.2.2.3. 
 
4.2.2.2 Covariate evaluation 
Once an appropriate structural base model was established, the effects of subject 
factors were assessed for their clinical relevance and biological plausibility on the 
progression of ADAS-cog. Continuous covariates such as AHV, FDG, CSF Aβ, 
CSF tau, age at study entry and years of education, as well as categorical 
covariates such as Aβ pathology, gender and APOE-e4 genotype were selected for 
covariate testing. Aβ pathology (Aβ+) was defined as at least one sample showing 
CSF Aβ ≤ 192 pg/mL, florbetapir ≥ 1.1 SUVr or PIB ≥ 1.5 SUVr while the 
absence of Aβ pathology was defined as having Aβ measures within the cutpoints 
for all samples collected from an individual. Subjects without any Aβ measures 
had their Aβ pathology status left as missing to prevent misclassification. 
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Similarly, APOE+ subjects referred to those with at least one APOE-e4 allele 
while subjects without any APOE genetic information were not labeled.  
Covariate selection was carried out sequentially, as each marker was 
tested to assess their individual effect on the rate of progression in univariate 
analyses (forward inclusion) before combining all significant covariates in a 
multivariate analysis (backward deletion). As data available for each disease 
marker was unequal and numbers could differ widely, missing information was 
not included in the data analysis by any kind of substitution and ADAS-cog 
observations without corresponding covariate measures were excluded. 
Continuous covariates were tested using linear, power or exponential models as 
shown in Equation 4.2 through Equation 4.4.  Categorical covariates were tested 
using a categorical model, as shown in Equation 4.5. 
Linear Model              Pi = PTV (1+ Ecov(Covi- Covmed)) (Eq. 4.2) 
Power Model              Pi = PTV (Covi / Covmed)
Ecov (Eq. 4.3) 
Exponential Model Pi = PTV (EXP(Ecov(Covi - Covmed)))  (Eq. 4.4) 
Categorical Model Pi = PTV (1+ Ecov(IND))  (Eq. 4.5) 
where Pi is the i
th
 individual’s rate of progression, PTV  represents the population 
rate of progression, Ecov represents the effect of the covariate, Covi is the 
individual value of the covariate and Covmed is the population median of the 
covariate. For the categorical model, IND is an indicator variable with a value of 
either 0 or 1 assigned for a dichotomous categorical covariate (for example, 
female or male). 
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Covariates were added to the base model individually during the forward 
inclusion step with difference in OFV tested for significance at p-value no greater 
than 0.01 (a decrease in OFV ≥ 6.635 based on chi-square distribution with one 
degree of freedom). If the drop in OFV was <6.635, the covariate was then 
omitted from the model and the process repeated for the remaining covariates. 
Once the full model was achieved, backward deletion was carried out at a more 
stringent criterion of p-value no greater than 0.001 (an increase in OFV ≥10.828 
based on chi-square distribution with one degree of freedom). Starting with the 
least significant, covariates were removed from the model individually and 
difference in OFV calculated. If the increase in OFV was <10.828, the least 
significant covariate was then omitted from the model and the process repeated 
for the remaining covariates.  
Further investigation of the effects of significant covariates on the 
progression parameter was carried out graphically, for example using box plots 
and scatter plots for categorical and continuous covariates respectively. For 
continuous variables whose values change across time, also known as time-
varying covariates, their influences on the rate of change of ADAS-cog could not 
be fully explored using short-term observations or point estimates due to the time-
varying nature. As time-varying FDG was tested to have a significant influence 
on ADAS-cog progression, a secondary disease progression model was developed 





4.2.2.3 Model evaluation 
Other than statistical significance based on OFV, the final model was developed 
by taking into account the following criteria: 1) Convergence of the estimation 
and covariance routines, 2) Reasonable parameter and error estimates, 3) Good 
precision of the parameter and error estimates, 4) Agreement between predicted 
and observed values and 5) Clinical relevance of the change in parameter 
estimates caused by the addition of the covariate in the model.  
In cases where a substantial number of subjects did not have the covariate 
of interest, it was necessary to re-run the structural model using only subjects who 
had the covariate of interest. In such cases where the same structural model was 
ran twice, once using a reduced dataset and once with a larger dataset, parameters 
estimates from the two runs were reviewed. Results from the larger dataset were 
used for subsequent analyses, provided the estimates from both runs were 
comparable. 
Bootstrap analyses were conducted with Perl-speaks-NONMEM to assess 
the precision of the parameter estimates (258). The bootstrap was carried out by 
sampling from the analysis dataset with replacement to produce 1000 resampled 
datasets with the same number of patients and the model was fit to each one. The 





 percentile values from the distribution of bootstrap parameter values. 
The following goodness-of-fit (GOF) plots were routinely investigated 
using the Xpose package implemented in R to check for random, uniform and 
narrow spread of data around the line of identity/reference - 1) Measured 
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observation versus individual (IPRED) and population (PRED) predictions, 2) 
Individual weighted residuals (IWRES) versus IPRED and 3) Conditional 
weighted residuals (CWRES) versus TIME (206; 259). In addition, ε-shrinkage (a 
measure of informativeness of IPRED) was calculated as:  
ε-shrinkage = 100 × (1 − 𝜎𝐼𝑊𝑅𝐸𝑆)    (Eq. 4.5) 
where σIWRES represents the standard deviation of IWRES (260). It was reported 
that GOF plots of IPRED had little value at high shrinkage of more than 20%-
30% (260). 
Visual predictive check (VPC) was performed for model comparison, to 
evaluate model appropriateness and to ensure that the model maintained fidelity 
with the data used to develop it. The VPC approach entailed 200 simulations of 
variable data with the model of interest and the analysis dataset, taking into 
account variability in all parameters as given by the inter-individual variability 
and residual error term. Simulated and observed distributions were compared by 




 percentiles for each. Ideally, the median 
simulated measurements should be in concordance with the observed 
measurements and less than 10% of the observed data should fall outside the 90% 
prediction intervals (PI). Simulated ADAS-cog values beyond the boundaries of 
the scale (0-70) were excluded from the calculation. Similarly, in the VPC for the 
FDG model, a cutoff of 0.6 units was set based on the minimum observed FDG 
value in the dataset. 
In addition, model predictions were compared with results from Coalition 
Against Major Diseases (CAMD) database as well as ADNI database for 
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additional validity (261). Data from CAMD trials was obtained from the recent 
published paper by Conrado et al. using Graph Digitizer Version 2.0 
(http://www.chat.ru/~nick_gd/) and only trials with a sample size of more than 
100 and follow-up period of more than 30 weeks were included for assessment 
(156). Since FDG was singled out as the only significant covariate of ADAS-cog 
progression in the covariate evaluation and this piece of information was not 
readily available for the CAMD trials, the final base model was used for the 
graphical analysis. The median model-simulated ADAS-cog progression curve 
with 95% CI (of the median) was obtained from 1000 simulated subjects. The 
95% CI of the median were calculated using the following equations: 
j = nq ± 1.96√(𝑛𝑞(1 − 𝑞))     (Eq. 4.7.1) 
k = nq ± 1.96√(𝑛𝑞(1 − 𝑞))     (Eq. 4.7.2) 
where n is the number of observations at each timepoint, q is the quantile (0.5 in 
this case), j and k are values, rounded up to the nearest integer, and the resultant 
95% CI is between the j
th
 and the k
th
 observations (262). 
  Two steps were taken to superimpose the lines representing trial-level 
data from ADNI and CAMD onto the model-simulated disease progression curve 
to ensure comparison was made at the same starting ADAS-cog score for both 
predicted and observed data. For each trial, a back-calculation was carried out to 
establish the time when the median baseline ADAS-cog value for each study was 
attained based on the final base model. Time from study entry was then added to 
the baseline time to overlay the longitudinal median ADAS-cog values from each 
trial onto the model-simulated ADAS-cog progression curve. As the follow-up 
 134 
 
time of each trial is relatively short compared to the disease duration, the plot was 
truncated to magnify the region where the model-simulated curve and lines 
representing trial-level ADAS-cog overlay one another. 
Lastly, annual change in ADAS-cog in the AD population was calculated 
using the final model and results from descriptive analyses in Chapter 2. Median 
baseline ADAS-cog score was 19.0 (Table 2.7), while baseline and annual decline 
in FDG was 1.08 units (Table 2.8) and 0.0574 units (Table 2.10) respectively. 
Firstly, a back-calculation was carried out to establish the time when the baseline 
ADAS-cog value was attained based on the final ADAS-cog model. ADAS-cog 
value in the subsequent year was then determined using the observed median 
annual change in FDG. The difference between the two ADAS-cog values would 
be the annual disease progression rate. The same steps were repeated, using FDG 
results from the descriptive analyses, for a typical AD subject in the CAMD 
database with baseline ADAS-cog of 22.2 as reported by Conrado et al. (156).  
 
4.2.3 Effect of FDG on ADAS-cog 
Additional analyses were conducted to evaluate changes in model-predicted FDG 
and corresponding ADAS-cog values over time. The approach involved 200 
simulations of the FDG analysis dataset, taking into account variability in all 
parameters as given by the inter-individual variability and residual error term. 





 percentiles of simulated FDG values at each time interval into the 







 percentiles of simulated FDG values and corresponding 
ADAS-cog scores were then overlaid with observations. Model-predicted trends 
were expected to be in accordance with observed trends observed between 
ADAS-cog and FDG. In order to understand the pattern of change and study the 
relationship between ADAS-cog and FDG over the duration of the disease, 
simulated results were plotted as a function of time. 
 
4.2.4 Clinical trial simulations 
Given the relationship between ADAS-cog and FDG, clinical trial simulations 
were conducted to explore the potential utility of FDG as a candidate for 
predicting clinical success of potential therapeutic agents. Simulation of FDG 
progression was conducted for 10000 virtual subjects, taking into account 
variability in all parameters as given by the inter-individual variability and 
residual error term. Results were fit to the final ADAS-cog model, taking into 
account variability in all parameters as given by the inter-individual variability 
and residual error term, to obtain ADAS-cog scores at each timepoint for the 
virtual subjects. ADAS-cog score of 24 was chosen as a screening cutoff to select 
the appropriate mild to moderate AD subjects and the subsequent timepoint (0.25 
years from screening visit) was taken as the baseline. Hypothetical drug effect 
with 20%, 50% and 80% reduction in FDG progression was introduced into the 
post-baseline simulated FDG values. Due to the nonlinear change in FDG with 
respect to time, the first derivative of the FDG model was calculated at each 
timepoint using the simulated individual parameters. The hypothetical drug 
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effects were applied to the derivative to give three different change values and the 
cumulative change in FDG was summed and subtracted from the baseline. 
Corresponding ADAS-cog scores were re-simulated with the new FDG values to 
mimic the disease-modifying effect on cognition.  
Study sizes of 100-1000 subjects at 9-month, 12-month, 15-month and 18-
month post-baseline were investigated and used to compare the power to detect a 
significant difference in FDG and ADAS-cog between the control (placebo) group 
and treatment group. At each timepoint, 100 simulated trials were carried out for 
each sample size, drug effect and disease endpoint. Each simulated trial consisted 
of two sets of randomized subjects selected from the pool of 10000 virtual 
subjects to represent the control and treatment group and differences between the 
two groups were compared using t-test, with the criterion for statistical 
significance set at p < 0.05. The eventual power to detect a drug effect was 
calculated as the total number of trials out of the 100 simulated trials where a 
significant difference between the control and treatment group was detected. 
 
4.3 Result 
4.3.1 Structural base model selection 
In total, 6878 log-normalized ADAS-cog observations from 1501 subjects were 
available for modeling and Figure 4.2 demonstrates how log transformation 
helped to induce normality in the data. Several base models with the same number 
of parameters were tested and model forms, characteristics and OFV were 





Figure 4.2 Spread of ADAS-cog observations before (left panel) and after 
(right panel) natural log transformation. 
 
tested and gave the worst model fit with the highest OFV. Verhulst’s logistic 
model, a simplified logistic model, was also tested. The best model fit based on 
OFV monitoring came from the exponential and generalized logistic model, also 
known as Richard’s logistic model. The shape factor that controls the inflection 
point in the generalized logistic model was not estimated but fixed to a literature 
value of 6.91, which translated into an inflection point at ADAS-cog score of 52 
(263). To further demonstrate the characteristics of the structural models tested, 
progression curve of each model is displayed in Figure A4.1. The generalized 
logistic model characterized AD progression most appropriately and was selected 
as the final structural base model. The NONMEM control stream and summarized 
results are in Figure A4.2 while the original NONMEM output is available 
electronically as “adas_final_base_001.op001.pdf”. GOF plots and VPC for the 















































Table 4.1 Selection of structural base model for ADAS-cog. 





 Linear -7292.954 2 
Exponential model 
ADAScog(t) = 
  Nonlinear -8038.009 2 
Verhulst's logistic model  
ADAScog(t) = 
  Nonlinear -7886.279 2 
Generalized (Richard’s) logistic model [final] 
ADAScog(t) = 
 Nonlinear -8037.541 2 
Abbreviations: α = annual progression rate parameter; β = shape factor that controls inflection point; fixed to literature value of 6.91 which approximates to 
ADAS-cog of 52; ADAScogbase = Alzheimer’s Disease Assessment Scale–Cognitive Subscale score at arbitrary start time; ADAScog(t) = Alzheimer’s Disease 





4.3.2 Covariate evaluation 
A total of nine covariates of interest were tested on the progression rate of ADAS-
cog and results are summarized in Table 4.2. Four covariates - education, AHV, 
Aβ pathology and FDG - were found to be significant on the disease progression 
term during the forward inclusion step and included in the full model. On the 
other hand, covariates such as age, APOE genotype and education, did not meet 
the criteria for retention. The backward deletion step was carried out using a 
reduced dataset with 1162 subjects and 2545 observations with complete 
covariate information (education, AHV, Aβ pathology and FDG) present. The 
reduced dataset contained 37.0% of the observations compared to the full dataset.  
The resultant model, Run 12.1 in Table 4.2, consisted of the structural 
ADAS-cog base model with time-varying FDG as the only significant covariate 
on disease progression, described by a power function, after several rounds of 
backward deletion. Although Run 12.1 was the model derived from the backward 
deletion process, both Run 7 and Run 12.1 had the same model structure and 
similar parameter estimates (Figure A4.5 and Figure A4.6). The original 
NONMEM output for Run 7 and Run 12.1 are available electronically as 
“adas_final_model_001.op001.pdf” and “adas_back_del_001.op001.pdf” 
respectively. Additionally, Run 7 had 42 subjects and 230 observations more than 








Table 4.2 Selection of covariate model for ADAS-cog model. 
Run Forward inclusion Type n/N Base model OFV OFV with Covariates ∆ in OFV 
1 Age Continuous (Power) 1501/6878 -8037.541 -8037.997 -0.456 
2 Education Continuous (Power) 1501/6879 -8037.541 -8044.989 -7.448 
3 Gender (Female) Categorical 1501/6879 -8037.541 -8037.619 -0.078 
4 AHV 
Time varying continuous 
(Exponential) 1492/5784 -6809.880 -6819.926 -10.046 
5 APOE genotype (APOE+) Categorical 1457/6779 -7958.993 -7958.993 0 
6 Aβ pathology (Aβ+) Categorical 1242/5588 -6330.565 -6347.568 -17.003 
7 FDG 
Time varying continuous 
(Power) 1204/2775 -3170.673 -3292.119 -121.446 
8 CSF Aβ 
Time varying continuous 
(Exponential) 712/1263 -1360.795 -1362.525 -1.73 
9 CSF tau 
Time varying continuous 
(Power) 690/1229 -1325.093 -1326.107 -1.014 
Full model Covariates excluded n/N Base model OFV OFV with Covariates ∆ in OFV 
10 Education, AHV, Aβ+, FDG Not applicable 1162/2545 -2939.231 -3047.552 -108.321 
Backward deletion Covariates excluded n/N Full model OFV OFV with Covariates ∆ in OFV 
10.1 AHV, Aβ+, FDG Education 1162/2545 -3047.552 -3044.918 -2.634 
10.2 Education, Aβ+, FDG AHV 1162/2545 -3047.552 -3043.689 -3.863 
10.3 Education, AHV, FDG Aβ+ 1162/2545 -3047.552 -3047.552 0 
10.4 Education, AHV, Aβ+ FDG 1162/2545 -3047.552 -2948.331 -99.221 
Full model Covariates excluded n/N Base model OFV OFV with Covariates ∆ in OFV 
11 Education, AHV, FDG Aβ+ 1162/2545 -2939.231 -3047.552 -108.321 
 









Table 4.2    Continued 
Backward deletion Covariates excluded n/N Full model OFV OFV with Covariates ∆ in OFV 
11.1 AHV, FDG Education 1162/2545 -3047.552 -3044.91 -2.642 
11.2 Education, FDG AHV 1162/2545 -3047.552 -3043.576 -3.976 
11.3 Education, AHV FDG 1162/2545 -3047.552 -2948.322 -99.23 
Full model Covariates excluded n/N Base model OFV OFV with Covariates ∆ in OFV 
12 AHV, FDG Education 1162/2545 -2939.231 -3044.91 -105.679 
Backward deletion Covariates excluded n/N Full model OFV OFV with Covariates ∆ in OFV 
12.1 FDG AHV 1162/2545 -3044.91 -3040.568 -4.342 
12.2 AHV FDG 1162/2545 -3044.91 -2946.944 -97.966 
Final model Covariates excluded n/N Final model OFV 
  7 FDG AHV 1204/2775 -3292.119 




4.3.3 FDG model 
A secondary model was developed for FDG to describe the temporal changes with 
disease progression in order to investigate the long-term relationship between 
ADAS-cog and FDG. In total, 2789 FDG observations from 1206 subjects were 
available for model development. Several model types – linear, exponential, 
hockey-stick and empirical models – were tested and the final structural base 
model that most appropriately described the longitudinal FDG data, based on 
OFV and model fit, was the empirical model. Briefly, the empirical model 
assumed a baseline FDG at the arbitrary start time which decline nonlinearly with 
time, shaped by two scaling parameters γ1 and γ2. Model forms, characteristics 
and OFV of models considered for FDG base model are summarized in Table 
A4.1. GOF diagnostic plots and VPC for the final base model are presented in the 
appendices Figure A4.9 and Figure A4.10 respectively. 
 A total of eight covariates of interest were tested on the scaling parameter 
γ1 and results are presented in Table A4.2. Two covariates – age and AHV - were 
found to be significant on γ1 during the forward inclusion step and included in the 
full model. The backward deletion step was carried out using a reduced dataset 
with 1164 subjects and 2554 observations with all covariates information (age and 
AHV) present. The resultant model consisted of the structural base FDG model 
with age as the only significant covariate retained on γ1, described by a power 
function. The final FDG model selected was run using the original FDG dataset 
with age as a covariate on γ1. The NONMEM control stream and summarized 
results for the FDG final base model, model from backward deletion step and 
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final model are available in the appendices (Figure A4.8, Figure A4.11 and Figure 
4.12) and the original NONMEM output as “fdg_final_base_001.op001.pdf”, 
fdg_back_del_001.op001.pdf” and “fdg_final_model_001.op001.pdf” in the CD-
ROM provided. 
 
4.3.4 Model evaluation 
ADAS-cog population parameters from the final structural base model and final 
model, together with results from the bootstrap analysis, are presented in Table 
4.3. The final base model was developed using the original dataset while the final 
model with FDG as a covariate on disease progression was ran on a smaller subset 
of data (40.3% of the original datatset) that contained both ADAS-cog and FDG 
observations. In order to bridge the comparison between the final base model and 
final model, the final base model was rerun using the reduced dataset (3
rd
 column 
in Table 4.3). Results showed that all parameters were reasonably well estimated, 
with percentage standard error of the estimate (%SEE) at or below 10%, for the 
fixed effect parameters and 42% for random effects. When the base model was 
reran using a smaller subset of data with both ADAS-cog and corresponding FDG 
values, similar parameter estimates were obtained but with higher %SEE. 
NONMEM control stream and summarized results for the three models in Table 
4.3 are included in the appendices (Figure A4.2, Figure A4.5 and Figure A4.7). In 
addition, the original NONMEM output for Figure A4.7 is also available 
electronically as “adas_final_base_red_001.op001.pdf”. 
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Table 4.3 ADAS-cog population parameters and precision of parameters 








Final base model 







n/N 1501/6878 1204/2775 1204/2775 - 
OFV -8037.541 -3170.673 -3292.119 - 
ADAScogbase 2.70 (2.54) 2.94 (3.07) 
3.41 
(3.17) 3.41 (3.23,3.59) 
α 
0.0911  










β 6.91 FIX 6.91 FIX 6.91 FIX - 
Correlation 
between 
ADAScogbase and α 
 -88.9%  



































Abbreviations: α = annual progression rate parameter; β = shape factor that controls inflection 
point; fixed at literature value of 6.91; ADAScogbase = Alzheimer’s Disease Assessment Scale–
Cognitive Subscale Score at arbitrary start time; %CV = coefficient of variance; SEE = standard 
error of the estimate.  
a
 FDG effect on the progression parameter was described as = ((FDG/1.21)**EFFECTFDG) where 
1.21 is the calculated median FDG in the dataset 
b
 %CV = 100*SQRT(EXP(OMEGA(N))-1) where OMEGA(N) is the variance of the relevant 
parameter. 
c








Note: The observed data versus the population and individual predictions are displayed on the top 
left and right panels respectively. The bottom left panel shows the absolute values of the 
individually weighted residuals, and the bottom right panel shows the population conditional 
weighted residuals. Individual data points are indicated by black circles. The red lines are LOESS 
fit lines, smoothed values given by a weighted linear least squares regression over the span of 
observations. The black diagonal lines in the top panels represent the lines of identity and the 
black horizontal line in the bottom right panel indicates the ordinate value of 0. ε-shrinkage was 
14.0%. 
Abbreviations: iWRES = individual weighted residuals; LOESS = locally weighted scatterplot 
smoothing function. 












 percentiles of observed data respectively. The blue shaded areas represent simulated 






 percentiles of the simulations based on the model. 
Simulated ADAS-cog values beyond the boundaries of the scale (0-70) were excluded.  
Figure 4.4 Visual predictive check for final ADAS-cog model. 
 
Incorporating the nonlinear influence of FDG on the progression 
parameter using a power function resulted in an OFV reduction of 122 points, 
accompanied by a 4.9% reduction in inter-individual variability of ADAS-cog at 
the arbitrary start time and 5.0% reduction in inter-individual variability of the 
disease progression parameter. The final model, together with results from 
descriptive analyses in Chapter 2, predicted that the typical AD subject who 
entered ADNI with an ADAS-cog of 19.0, FDG of 1.08 units and annual decline 
in FDG of 0.0574 units, would experience an annual increase in ADAS-cog of 
2.81. Similarly, a typical AD subject with an ADAS-cog of 22.2 from the CAMD 





























VPC - ADAScog final model
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Bootstrap analysis was performed to assess the precision of the parameter 
estimates from the final model (Table 4.3, last column). Results indicated model 
stability as the median values from the bootstrap technique was similar to the final 
NONMEM parameter estimates and all estimates were well contained within 90% 
CI of the bootstrap percentiles.   
GOF diagnostic plots for the final ADAS-cog model were reviewed 
graphically (Figure 4.3) by the agreement between predicted values (PRED and 
IPRED) and observed scores, as well as the randomness of the weighted residuals 
(IWRES, CWRES). In general, random and uniform distribution of residual 
values was observed, suggesting no consistent bias or model misspecification in 
the predicted ADAS-cog scores. However, a slight mismatch at the boundaries 
was detected by the locally weighted scatterplot smoothing function lines in red. 
A VPC, shown in Figure 4.4, was conducted to assess the general 
predictability of the model. Visual examination of the observed versus predicted 
profiles was utilized to ensure general concordance of the predictions with the 
observed data. Validity of the model to describe ADAS-cog scores in the study 
population adequately was supported by the VPC, with the population median 
fitting into 90% CI of the simulated median in most bins and a relatively small 





Table 4.4 FDG population parameters and precision of parameters using 
nonparametric bootstrap. 
 
Estimates (%SEE) Median(90% CI) 
Parameter 
Final base 
model Final model 
Bootstrap replicates 
(n=1000) 
n/N 1206/2789 1206/2789 - 
OFV -11360.649 -11385.884 - 
FDGbase 1.38 (0.906) 1.37 (0.920) 1.37 (1.35,1.40) 
γ1 0.891 (0.864) 0.890 (0.855) 0.890 (0.878,0.902) 
γ2 34.8 (21.7) 35.4 (21.7) 35.8 (25.2,50.9) 
Age effect on γ1
a
 - 0.0424 (20.5) 0.0424 (0.0269,0.0571) 
Correlation between 








 7.40% (7.67) 7.43% (7.71) 7.41% (6.93%,7.89%) 
γ1
c
 1.66% (19.7) 1.55% (24.4) 1.53% (1.16%,1.82%) 
Residual variability    
Additive 0.00229 (6.51) 0.00230 (6.57) 0.00229 (0.00206,0.00256) 
Abbreviations: γ = scaling parameter; %CV = coefficient of variance; FDGbase = 18F-
fluorodeoxyglucose uptake at arbitrary start time  
a
 Age effect on γ1 was described as = ((Age/74)**EFFECTAge) where 74 is the calculated median 
age  of the subjects at the start of the trial.   
b
 %CV = 100*SQRT(EXP(OMEGA(N))-1) where OMEGA(N) is the variance of the relevant 
parameter. 
c
 %CV = 100*SQRT(OMEGA(N)) where OMEGA(N) is the variance of the relevant parameter.  
 
FDG population parameters from the final structural base model and final model, 
together with results from the bootstrap analysis, are presented in Table 4.4. 
Results suggested that the parameters were estimated with good precision as 
%SEE were below 22% for the fixed effect parameters and below 34% for 
random effects. Incorporating the influence of age on the scaling parameter γ1 
using a power function resulted in an OFV reduction of 25.2 points, accompanied 
by a modest reduction in inter-individual variability of γ1. Bootstrap analysis 







Note: The observed data versus the population and individual predictions are displayed on the top 
left and right panels respectively. The bottom left panel shows the absolute values of the 
individually weighted residuals, and the bottom right panel shows the population conditional 
weighted residuals. Individual data points are indicated by black circles. The red lines are LOESS 
fit lines, smoothed values given by a weighted linear least squares regression over the span of 
observations. The black diagonal lines in the top panels represent the lines of identity and the 
black horizontal line in the bottom right panel indicates the ordinate value of 0. ε-shrinkage was 
22.7%. 
Abbreviations: iWRES = individual weighted residuals; LOESS = locally weighted scatterplot 
smoothing function. 













percentiles of observed data respectively. The blue shaded areas represent simulated 






 percentiles of the simulations based on the 
model. Simulated FDG values below 0.6 units were excluded. 
Figure 4.6 Visual predictive check for final FDG model. 
 
similar to the parameter estimates and all estimates were well contained within 
90% CI of the bootstrap percentiles. 
GOF diagnostic plots for the final FDG model in Figure 4.5 were 
reviewed based on the agreement between predicted values (PRED and IPRED) 
and observed scores, as well as the randomness of the weighted residuals 
(IWRES, CWRES). In general, random and uniform distribution of residual 
values was observed, suggesting no consistent bias or model misspecification in 
the predicted FDG values. The VPC conducted to assess the general predictability 
of the final model, shown in Figure 4.6, supported its validity to describe long-
term changes in FDG values as the population median fit into 90% CI of the 




























Note: Solid black line denotes the 50
th
 percentile ADAS-cog scores from 1000 simulated subjects 




 percentiles of the predicted 
median. Solid colored lines superimposed represent observed median from each trial. 
Figure 4.7 Comparison between model-predicted and observed ADAS-cog 
scores from longitudinal studies. 
 
Figure 4.7 illustrates the model-predicted ADAS-cog progression curve 
with 95% CI of the median, overlaid with observed medians obtained from the 
placebo arms of eight independent trials conducted on mild to moderate AD 
subjects. As displayed in the figure, most of the observed data fell within the 
model-predicted median progression curve and its 95% CI, suggesting that the 
model was overall adequate in predicting the rate of change in patients with mild 
to moderate AD. Interestingly, mild AD subjects from ADNI seemed to progress 
faster than expected.  
 











































Note: The green lines represent model-predicted FDG values from 200 simulations and the 
corresponding ADAS-cog scores predicted by the final ADAS-cog model. Simulated FDG values 
below 0.6 units were excluded. The solid lines denote the 50
th
 percentile of the predicted values 




 percentiles of the predicted values 
respectively. Black dots are observations. 
Figure 4.8 Model-predicted effects of FDG on ADAS-cog superimposed with 
observations from ADNI subjects.  
 
 
Note: The blue lines represent model-predicted trajectory of FDG values from 200 simulations and 
the orange lines represent the corresponding ADAS-cog scores derived from the final ADAS-cog 
model. Simulated FDG values below 0.6 units were excluded. 
























































































The plot of model-predicted FDG and corresponding ADAS-cog values overlaid 
with observations demonstrated that most of the observations were within the 
90% PI of the simulated values (Figure 4.8). It shows that for the data available, 
the model adequately predicted the rate of change relationship between the two 
measures, further strengthening the validity of utilizing both models to study the 
longitudinal relationship between ADAS-cog and FDG. 
The long-term model-predicted dynamics of FDG and ADAS-cog can be 
seen in Figure 4.9 which displays the different degree of change and influence at 
various stages of the disease progression timeline. For a typical subject in the 
study population, changes in ADAS-cog started with a slight but steady increase 
regardless of FDG values as observed from the undifferentiated 5
th
, median and 
95
th
 percentile line of ADAS-cog at the initial phase of the figure. However, as 
FDG experienced a steeper rate of decline with time, ADAS-cog scores increased 
in a nonlinear manner, with the 5
th
, median and 95
th
 percentile line of ADAS-cog 
progressing at different rates.  
 
4.3.6 Clinical trial simulations 
Figure 4.10 shows the natural and hypothetical drug effect of 20%, 50% and 80% 
reduction in FDG progression and the corresponding ADAS-cog scores from the 
final FDG and ADAS-cog models. Although slowing FDG progression could lead 
to a decrease in ADAS-cog progression, any disease-modifying effect on FDG 
progression was expected to translate into a partial effect on ADAS-cog 




Note: Lines are medians calculated from a pool of 10000 virtual subjects. Solid lines represent the 
natural progression of the disease. Dotted lines represent different hypothetical drug effects on 
FDG, where short, medium and long dotted lines stand for 20%, 50% and 80% reduction in FDG 
progression respectively, and the corresponding ADAS-cog scores. 
Figure 4.10 Plot of natural and hypothetical drug effects on FDG progression 
(blue) and the corresponding ADAS-cog scores (orange) against time after 
intervention. 
 
an 80% reduction in FDG progression (long dotted lines) was estimated to give a 
35% reduction in ADAS-cog progression. 
Results from clinical trial simulations performed are presented in Figure 
4.11. In general, FDG had higher power to detect a significant difference from 
placebo and required lower number of subjects compared to ADAS-cog. For a 
disease-modifying therapy that could reduce FDG progression by 80%, a sample 
size of 600 subjects per arm would be required to detect a significant difference in 
FDG from the control group in a 9-month clinical trial with a power of 80%. 
Comparatively, in order to detect a significant difference in ADAS-cog with a 





























































Note: Each point represents the sum of trials out of 100 simulated trials where a significant difference was detected between the treatment and control (placebo) 
group. 
Figure 4.11 Power to detect a 20% (blue), 50% (orange) and 80% (green) reduction in FDG progression and corresponding effect 












































































































































































































































































The model-based analyses combined accumulated knowledge from longitudinal 
models of ADAS-cog available in the literature with model-estimated 
pathological timeline from Chapter 3 to construct a disease progression model 
based on changes in ADAS-cog. As AD is a continuously progressing disease, the 
model for one specific disease stage might not be applicable for describing 
disease progression of other stages. Rather than focusing on a single disease stage, 
NL, EMCI, LMCI and AD subjects were pooled to map out long-term changes 
and examine the whole spectrum of disease progression. In addition, covariates 
that were seldom tested in earlier models, such as Aβ pathology and time-varying 
biomarkers, were evaluated. The main findings were that ADAS-cog changes in a 
nonlinear manner and lower FDG could lead to faster progression in ADAS-cog, 
best described by a power function. Further investigation showed that age could 
exert an indirect effect on cognition through changes in FDG as younger subjects 
experienced faster decline in FDG. Validation conducted demonstrated that the 
models were well characterized and in agreement with observed data and 
published models. 
 
4.4.1 Structural base model selection 
Linear, exponential and logistic models were tested and compared to select a 
structural base model for ADAS-cog. Both the linear model and exponential 
model had the potential to predict ADAS-cog scores beyond 70. The Verhulst’s 
logistic model helped to overcome this limitation of exceeding the scale boundary 
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by assuming symmetrical nonlinear progression with inflection point at half-
maximal score of 35. The generalized logistic model, a variation of the Verhulst’s 
logistic model, curbed the progression rate with an inflection point controlled by a 
shape factor, after which changes in ADAS-cog would start to plateau, producing 
an asymmetric, inverted, concave trajectory (Figure A4.1).  
The final structural base model selected was the generalized logistic model 
which is in line with what was expected and observed clinically (92). Similar 
model structure was also considered or chosen in recent published works due to 
its ability to describe changes based on the current understanding of cognitive 
decline in AD (123; 153; 156). However, the shape factor that controls the 
inflection point in the generalized logistic model was not estimated but fixed to a 
literature value of 6.91, which translated into an inflection point at ADAS-cog 
score of 52 (263). This value was published by Conrado et al. who modeled 
ADAS-cog progression in mild to moderate AD patients whereas the current data 
used for modeling did not have sufficient late stage patients to describe the full 
profile of ADAS-cog changes, with 1.28% of the data at ADAS-cog scores 
greater than 40 (Figure 4.2) (156).  
 
4.4.2 Covariate evaluation 
The forward inclusion step shown that higher education, FDG, AHV and the lack 
of Aβ pathology were related to slower disease progression when tested 
individually on the progression parameter. However, FDG was the only covariate 
retained after the backward elimination step. The influence of FDG on the 
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progression parameter was best described by a power function, which translated 
into an asymmetrical, slow increment in ADAS-cog at high FDG to a steep, 
nonlinear increase as FDG decreased. Quantitatively, a subject with FDG of 1.75 
units was expected to have an ADAS-cog progression rate 19.1% slower than the 
median subject whereas a subject with FDG of 0.65 units was expected to 
progress 44.7% faster compared to the median subject. This is coherent with the 
recommendation that FDG is an important “late-stage” biomarker that could be 
useful in predicting disease progression (18). Results were aligned with linear 
mixed effect modeling in Chapter 2 (Table 2.12) and publications which 
suggested FDG to be more predictive of ADAS-cog changes compared to AHV 
(214; 264; 265). 
It was of no surprise that AHV was detected as a significant covariate of 
disease progression during the univariate search as brain atrophy, a measure of 
dendritic and neuronal loss, has been widely recognized as an important AD 
biomarker that correlates well with cognitive decline (85; 266). Similarly, 
education and CSF biomarkers have been reported to influence the rate of disease 
progression in previous ADAS-cog disease progression models (119; 123). While 
Gomeni et al. reported faster ADAS-cog progression in those with higher 
education, the current model suggested otherwise which is more aligned with 
theories of cognitive reserve (119; 208). Nevertheless, the lack of influence from 
other disease markers with the introduction of FDG could imply that their impact 
on the progression parameter might be exerted indirectly via FDG but is more 
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likely due to the loss of ability to detect significant changes as the dataset shrank 
to 40.3% of the original size (Table 4.3).  
The lack of data might explain why certain biomarkers such as FDG were 
not included in previous longitudinal models despite having correlation with 
changes in cognition. “Structured missingness” was introduced deliberately by the 
ADNI study design, resulting in partial data availability for certain measures such 
as CSF biomarkers and PET imaging results. In ADNI1, subsets of subjects 
undergo lumbar puncture and PET imaging whereas in ADNI2, data collection 
interval varied for different disease markers. A variety of approaches had been 
used for missing data, including replacement using a single value such as the 
median or multiple imputations with a model which could account for the 
uncertainty about the missing data (128; 150; 267). However, as some of the 
covariates were time-varying and substantial amount of them were not available, 
particularly for FDG and CSF biomarkers, complete cases analysis was chosen to 
prevent the introduction of artificial bias from imputation. Furthermore, results 
showed that model parameters estimated using a subset of the data were 
reasonably close compared to those from the original dataset (Table 4.3).  
Other covariates, such as APOE genotype, gender and age, did not meet 
the criteria for retention during the forward inclusion step even though they were 
reported to have significant influences on rate of disease progression in earlier 
models (111; 119; 128). This is in alignment with what Yang et al. had 
hypothesized that most of these covariates were artifacts of the unaccounted 
disease time function that was created when subjects of different disease severity 
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were grouped and assumed to be relatively homogenous (168). However, several 
differences were noted when compared with earlier disease progression models of 
AD (103; 111; 119; 128; 135; 156). Firstly, the selected list of covariates in the 
search is much shorter compared to previous modeling efforts. Covariates were 
not tested on “baseline” ADAS-cog score at the arbitrary start time as the aim was 
to identify those that had an impact on the rate of disease progression. ADAS-cog 
scores at trial entry was not included as a covariate given the confidence in the 
model to estimate the pathological time of each subject reasonably well and the 
fact that point estimates of time varying information at study entry would not be 
meaningful for interpretation. In addition, other forms of cognitive tests such as 
MMSE, Trail Making Test and CDR-SB were excluded from covariate testing as 
they were expected to correlate well with ADAS-cog changes. Lastly, covariates 
such as usage of AD medications were left out because they were taken by almost 
all AD subjects and a subset of mostly LMCI converters and did not apply to the 
general population of the dataset (268). 
 
4.4.3 FDG model 
Although an obvious relationship was present when observed ADAS-cog scores 
were plotted against FDG values, the influence of FDG on the rate of change of 
ADAS-cog could not be fully explored using short-term observations or point 
estimates present in the data due to the time-varying nature of FDG. FDG 
progression was best described by an empirical model with baseline FDG at the 
arbitrary start time declining nonlinearly with time, shaped by two scaling 
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parameters (γ1 and γ2). Although the hockey-stick model had better OFV (Table 
A4.1), it assumed FDG progress linearly up to a specific FDG value, followed by 
a second linear slope progression whereas the chosen model described a smooth 
nonlinear decline over time. Unlike the ADAS-cog model that included an 
inflection point to account for the scale boundary, the selected FDG model has the 
ability to go beyond zero into the negative region which is physiologically 
implausible. However, there was insufficient data to fully characterize the shape 
of the FDG curve, particularly in those with moderate to severe AD, and no 
boundary was provided on the possible FDG values attained. Thus interpretation 
of the model, particularly if values fall outside the range of the observed FDG 
results, should be done with caution. 
Age and AHV were significant covariates on γ1 during the forward 
inclusion step but only age was retained as a significant covariate after the 
backward deletion process. The influence of age on γ1 was best described by a 
power function where FDG decline became increasingly faster in younger 
subjects with time, representing a more rapid disease progression in the younger 
population. In general, a negative relationship existed between age and FDG (269; 
270; 271). Interestingly, Dukart et al. presented results of differential age-related 
glucose hypometabolism between symptomatic groups in which younger MCI 
and AD subjects showed a stronger reduction in glucose utilization (190). This is 
aligned with the findings of covariate testing in the FDG model. For studies in 
MCI and AD individuals that reported pronounced reduction in rates of clinical 
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decline with age, it is possible that these observations were due to the effect of 
age on FDG changes which in turn affected cognition (122; 130). 
 
4.4.4 Model evaluation 
Validation of the models generally suggested no model misspecification with an 
overall adequacy in predicting the rate of change in disease markers for the 
population. Since the reduced dataset only contained 40.3% of the records 
compared to the original dataset, higher uncertainty in the parameter estimate, as 
reflected by the higher %SEE, was anticipated (Table 4.3). Mismatch between the 
predicted and observed values in the GOF plots were likely due to the lack of data 
near the boundaries (Figure 4.3 and Figure 4.5). Results from the CAMD database 
(which was not included for model development) fit well with the model-
simulated disease progression curve, providing additional validity for the model 
(Figure 4.7). It should be noted that unlike trials that segregated subjects by broad 
clinical stages using a list of criteria, the model described the natural disease 
progression based on changes in ADAS-cog scores. Individuals with ADAS-cog 
of 19 would consist mostly of mild AD patients but also a significant proportion 
of LMCI and LMCI converters as suggested by Yang et al. (Figure A4.13) (168). 
The general consensus is that MCI subjects are expected to have a slower rate of 
progression compared to AD patients, thus lowering the model-predicted median 
and leading to the disparity between the observed and predicted rate of 
progression in ADNI subjects seen in Figure 4.7. One way to differentiate 
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individual rate of disease progression in the model would be through the use of 
covariates such as FDG. 
Results from the final model were also compared with recently published 
AD progression models which used ADAS-cog as an outcome measure (135; 
156). William-Faltaos et al. reported a typical AD patient with baseline ADAS-
cog score of 24 having a progression rate of approximately three points per year 
(135). Similarly, Conrado et al. reported an average patient with mild to moderate 
AD in the CAMD database was expected to have an ADAS-cog score of 22.2 at 
study entry and an annual increase of 3.40 points (156). Results from descriptive 
analyses showed that the typical AD subject entered ADNI with an ADAS-cog of 
19.0 and worsened at a median rate of 3.33 points per year (Table 2.7 and Table 
2.9). The final model predicted that the typical AD subject who entered ADNI 
would experience an annual increase in ADAS-cog of 2.81 whereas a typical AD 
subject from the CAMD database was estimated to have a yearly increment in 
ADAS-cog of 3.42. This is consistent with the literature findings, despite using 
disease time synchronized data and a different set of covariates, hence providing 
validation that the method was able to yield an accurate prediction of disease 
progression. It also provided confidence in using the same approach to explore 
long-term relationships between other disease markers to advance the knowledge 




4.4.5 Clinical implications 
Results reflected nonlinear changes with time and identified multiple factors that 
could affect disease progression. More importantly, findings provided 
implications for design of clinical trials of potential disease-modifying therapies. 
For a typical subject in the study, changes in ADAS-cog scores started with a 
slight but steady increase regardless of FDG values but as FDG experienced a 
steeper rate of decline, ADAS-cog scores increased in a nonlinear manner (Figure 
4.9). This relationship implied that ADAS-cog might not provide a sensitive 
enough signal that could demonstrate intervention efficacy for a therapeutic agent 
that target FDG in NL or LMCI subjects but could be an optimal endpoint when 
the trials were conducted in AD subjects.  
 Phase II and Phase III clinical trials of AD typically last for 18 month in 
mild to moderate AD subjects with ADAS-cog as one of the primary cognitive 
outcome (272). However, detecting an effective drug could be challenging due to 
the high heterogeneity of the clinical course and variability of the ADAS-cog 
scale, especially when drug effects are modest. Assuming that the relationship 
between ADAS-cog and FDG is accurate, results from clinical trial simulations in 
Figure 4.11 demonstrated that FDG could be used to predict clinical utility of 
potential therapeutic agents in Phase II settings, allowing pharmaceutical 
companies to set dose levels before entering into larger, confirmatory Phase III 
trials. If this approach proved to be successful, FDG could then be considered to 
be a surrogate biomarker for efficacy in AD clinical trials and thus reducing the 
number of subjects and shortening the study duration of Phase III clinical trials. 
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Although the effect size tested in the simulation was larger for FDG, the higher 
signal strength and study power were likely due to the fact that FDG provides a 
more objective measure with lower measurement variability compared to ADAS-
cog. 
 Similarly, power to detect a significant change in cognition could be 
affected by the age of the study population. The FDG model suggested younger 
age is associated with faster progression in FDG which could in turn exert an 
indirect effect on change in ADAS-cog. Therefore, a small but significant disease-
modifying effect is more likely to be detected in a younger cohort as they progress 
at a faster rate. Without understanding the complete trajectory of change in 
clinical measures and the demographic-biomarker-clinical relationships between 
subjects, research groups that chose to focus on a particular category of subjects 
might miss out the full picture, leading to inconsistent or even contradictory 
conclusions on important disease markers and potential treatments of AD. 
 
4.4.6 Limitations of the model 
There were several notable limitations in the model and those listed here are 
pertaining to the context of this chapter. One key limitation of the current model 
is the use of ADAS-cog as the clinical endpoint. Although ADAS-cog is a well-
known neuropsychological scale and a “gold standard” for clinical trials, it is not 
without its limitation. As with all neuropsychological tests, ADAS-cog is 
subjected to floor and ceiling effects. Also, it is widely acknowledged that ADAS-
cog was developed to assess cognitive performance in mild to moderate AD 
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patients and might not be suitable for subjects at other clinical stages or with 
different sets of clinical symptoms (273; 274). 
Some covariates that were expected to influence AD progression, such as 
APOE and Aβ pathology, were not retained in the current model. Ideally, this 
could be explained by the unaccounted disease time covariate that was resolved 
through the application of disease time synchronization but other possible reasons 
might exist. Firstly, sample size could be too small to detect any significant effect, 
as in the case of time-varying CSF biomarkers where concentrations were 
available for only 20% of the ADAS-cog observations. Related to this is the small 
magnitude of effect that might be lost due to data variability and thus require a 
larger dataset for detection. As the trial is still ongoing, these effects should be 
reassessed when the completed dataset is available. Covariates with a limited or 
narrow distribution among the study population might also hamper the detection 
of their influence on the rate of disease progression. For example, ADNI was 
carried out in North American and hence geographical location would not be a 
reasonable covariate to include. The use of AD medication is a commonly tested 
covariate in traditional AD progression models but was not included in the 
covariate list since it did not apply to most of the non-AD subjects in the dataset. 
Another limitation of the current approach compared to conventional 
models is the use of sparse samples. Each subject in the dataset contributed an 
average of 2.3 observations in the final ADAS-cog and FDG models which was 
less than the number of random effects. Furthermore, the data contributed by each 
subject could only be considered a snapshot on the pathological timeline that 
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extended for more than two decades. The lack of actual baseline ADAS-cog 
values together with the high variability of the scale might account for the 
negative correlation between ADAS-cog at the arbitrary start time and slope of 
disease progression observed in the model. Modeling sparse data can also lead to 
elevated shrinkage, a phenomenon that occurs when a model is over-
parameterized for the amount of information contained in the data (260). High 
shrinkage can cause misleading diagnostic plots, therefore, interpretation of 
model-based diagnostic plots such as GOF plots should be done with caution and 
more emphasis should be placed on comparison using OFV, simulation-based 
diagnostics and conditional weighted residuals (260).  
The model was developed using current available data together with 
knowledge of the disease. Advances in the field of AD are rapid and it may well 
be that what were used or collected are not optimal for describing and predicting 
AD. While the exact interplay between disease markers have yet to be identified, 
they were assumed to be independent of one another at any given time but it is 
more often than not that disease markers co-vary and failure to recognize this 
relationship tends to cause an underestimation of the covariance of progression 
patterns across the population. On the other hand, correlation does not imply 
causality and may reflect two ongoing processes that are parallel yet independent. 
Furthermore, the question of which is the main neurotoxic entity in AD is still 
unanswered as soluble Aβ species, amyloid plaques and tau have all exhibited 
harmful effects on neurons and yet relationships could be indirect, synergistic or 
concurrent (10; 275). Contributory effects from nature and nurture, leading to 
 168 
 
concepts such as mixed pathology and cognitive reserve, could complicate 
matters as well. Thus, the underlying mechanisms of AD could be diverse and 
whether changes are pathogenic, compensatory, survival responses or incidental 
side-reactions remained largely unknown. Finally, it should be noted that this 
dataset does not represent the full disease time course due to knowledge gaps at 
the beginning and end of the disease progression phase which may impact the 
disease trajectory estimation. 
 
4.5 Conclusion 
This chapter demonstrated that by using disease time synchronized data and a 
unique set of covariates, longitudinal change in ADAS-cog over the course of AD 
could be followed and described with a model. Change in ADAS-cog was best 
characterized by a generalized logistic model which produced an asymmetrical 
nonlinear trajectory. Contrary to traditional longitudinal models of AD, only FDG 
was retained as a significant covariate on the rate of disease progression, with its 
influence best characterized by a power function. Further investigation on FDG 
suggested that younger age is associated with faster decline in FDG which could 
in turn exert an indirect effect on change in ADAS-cog. Various evaluation 
methods supported the suitability of the models in describing progression of AD. 
Clinical trials simulation conducted suggest that FDG could be used to shorten 
trial duration and number of subjects required in AD trials. 
The modeling approach improved the quantitative understanding of AD by 
providing a platform to integrate data from subjects regardless of their 
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symptomatic stages, allowing a more complete presentation and interpretation of 
disease progression over time and identification of corresponding factors that 
could influence the rate of disease progression at different stages. Results 
provided important implications for design of clinical trials in endpoint selection, 
patient population and trial duration to study potential disease-modifying 
therapies. Without understanding the complete trajectory of change in clinical 
measures, research groups could end up with inconsistent or even contradictory 
conclusions on the important disease markers and potential treatments of AD. 
Lastly, this approach act as a starting point for future modeling efforts to explore 
long-term relationships between other disease markers to advance the knowledge 




Chapter 5 : Conclusion 
5.1 Summary and perspectives 
Disease progression modeling is often used to study changes in the disease over 
time and has been implemented to describe changes in AD, most commonly by 
mixed effect models. One of the most important limitations of typical AD 
progression models is the use of symptomatic staging, such as “NL”, “MCI” and 
“mild AD” for classifying and representing subjects of different disease severity. 
Such classification of subjects do not account for inter-individual variability in 
disease start time and progression rate which could augment variability and 
obscure disease progression trends. This is further aggravated by studying 
subjects from a single symptomatic stage, usually AD subjects, thus limiting the 
temporal resolution and power to discriminate the disease and understand the 
changes between groups. Another potential limitation of earlier disease 
progression models is in covariate testing. Critical biomarkers that are known to 
represent elements of the AD pathological cascade such as AHV, FDG and 
amyloid PET tracers were often not tested and this could introduce confounding 
in the search for significant covariates. Lastly, some research groups modeled 
relatively obscure endpoints that were expected to be more sensitive to changes in 
the study population compared to conventional disease markers (107; 110; 127). 
However, such endpoints are not commonly used and require additional 
validation before being accepted in the field, thereby affecting the models’ ability 
to compare results and outcomes with clinical trials and published models.  
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It was hypothesized that disease markers collected in clinical studies could 
be used to differentiate the healthy from the diseased population and would 
exhibit characteristic changes at different stages of the disease according to the 
pathological cascade model proposed by Jack et al. (167). Together, the 
relationships between the disease markers could be used to build a model that 
described the pathophysiology of AD. The overall objective of the thesis is to 
contribute to the understanding and characterization of the disease progression of 
AD through the development of a pathophysiologically meaningful model of AD 
using commonly collected disease markers. Firstly, differences in demographic-
biomarker-clinical relationships in subjects of various symptomatic stages were 
investigated and assessed for trends of disease progression using descriptive 
statistics to support subsequent disease progression modeling. In order to position 
subjects from different symptomatic groups onto a single time scale and map the 
sequential temporal changes in disease markers, a pathological timeline was 
developed based on the disease time synchronization method from Donohue et al. 
(170). Finally, a disease progression model was constructed to describe 
longitudinal changes in ADAS-cog and the influence of key disease markers and 
demographic factors were investigated by means of covariate testing.  
ADNI is an ongoing study that provides a rich, multidimensional database, 
making it ideal to investigate the demographic-biomarker-clinical relationships 
between subjects. The entire ADNI study occurred in phases and subjects were 
classified into symptomatic stages representing different disease severities based 
on clinical examination and neuropsychological tests. In Chapter 2, the data from 
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the ADNI studies were evaluated to identify trends that might suggest a potential 
modeling approach. Prior to any inter-group comparison, hippocampal volume 
was adjusted by intracranial volume, gender and acquisition methods to reduce 
variability and confounding effects. Comparison between symptomatic groups 
from ADNI1 and ADNI2 showed no clinical significant differences between the 
groups, providing the justification for combining data from the different ADNI 
phases for further analyses in this thesis. Baseline and 12-month change from 
baseline values in disease markers were employed to better understand the general 
trends, trajectories and temporal changes of disease markers while linear mixed 
effect models helped to elucidate and quantify the complicated relationships 
between psychometric tests, biomarkers and demographic factors in the different 
groups. Although baseline and 12-month change in most disease markers showed 
significant differences between the cognitively normal and AD population, high 
variability observed for each measure limit their ability to diagnose and monitor 
AD. This could be partially due to the use of broad staging categories and treating 
every individual within a given group as being relatively homogeneous with 
respect to disease start time and progression, leading to high intra-group 
heterogeneity. Different associations between neuropsychological assessments, 
biomarkers and demographic factors were observed in subjects at each 
symptomatic stage, reflecting nonlinearity across the course of the disease and the 
importance of studying subjects of various stages together to understand the 
underlying disease progression.  
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Following the approach proposed by Donohue et al., a pathological 
timeline was constructed in Chapter 3, using an array of short-term 
neuropsychological assessments and biomarker observations from the ADNI 
subjects (170). This allowed subjects from different symptomatic groups to be 
positioned onto a single time scale and compared. Instead of focusing on subjects 
with high amyloid burden or APOE-e4 genotype, all eligible subjects were 
included to construct the pathological timeline. Another notable difference from 
the work by Donohue et al. is that exploratory analyses carried out to investigate 
disease trajectories was based on the model-estimated pathological timeline 
without further transformation. Overall, long-term disease trends derived from the 
analyses demonstrated that disease markers change in a temporal sequence that 
follow closely to the hypothetical pathological cascade model proposed by Jack et 
al. (167). CSF Aβ was estimated to exhibit the greatest change during the initial 
stages of the pathological timeline which could happen a decade or more prior to 
the emergence of any clinical signs and symptoms of AD. Changes in CSF tau 
tracked closely with increasing hippocampal atrophy while glucose metabolism 
was the final biomarker to become abnormal, followed by cognitive and 
functional changes. Although various AD models assumed the shape of disease 
trajectory to be sigmoidal, results suggested that disease progression in the test 
population might follow non-sigmoidal patterns (Figure 3.3) (167; 175). 
Nevertheless, they could also represent different segments of the disease 
progression curve that follows a sigmoidal shape. This would require additional 
long-term data from younger cognitively normal subjects and moderate to severe 
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AD subjects for confirmation. Also, hippocampal atrophy might have occurred 
earlier than expected and tracked more closely to changes in CSF tau and less to 
FDG and cognitive changes which came as a surprise based on results from linear 
mixed effect modeling in Chapter 2 (Table 2.12). Comparison of subjects with 
and without Aβ pathology showed that CSF tau changes might be dependent on 
CSF Aβ changes and disease progression without CSF biomarker abnormalities 
could take place, albeit at a slower rate, supporting the complex and multifactorial 
nature of AD.  
Using the model-estimated pathological timeline, a population disease 
progression model that included subjects from different symptomatic stages was 
developed in Chapter 4. Change in ADAS-cog, which is a common endpoint for 
AD trials, was chosen as the clinical outcome representing disease progression. 
Change in ADAS-cog was best described by a generalized logistic model which 
produced an asymmetrical nonlinear trajectory. Novel covariates, such as time-
varying AHV and FDG, were tested for significant influence on the rate of disease 
progression. As some of the covariates were time-varying and to prevent any 
misclassification, records without corresponding covariates were excluded during 
covariate testing. Lower FDG could lead to faster progression in ADAS-cog, with 
its influence best characterized by a power function, while covariates that were 
tested to have considerable influences in earlier AD models, such as age, gender, 
education and APOE-e4 status, did not appear to have significant influence on the 
model (111; 119; 128). In addition, a population disease progression model of 
FDG was constructed to study the long-term influence of FDG on ADAS-cog. 
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The FDG model suggested that younger age is associated with faster decline in 
FDG and this could in turn exert an indirect effect on the change in ADAS-cog. 
Therefore, a small but significant disease-modifying effect on FDG or cognition is 
more likely to be detected in a younger cohort as they progress at a faster rate. 
Results of simulated FDG and corresponding ADAS-cog over the disease 
duration implied that ADAS-cog might not provide a sensitive enough signal that 
could demonstrate intervention efficacy for a therapeutic agent that target FDG in 
the early stages but could be an optimal endpoint when the trials were conducted 
in AD subjects. Clinical trial simulations demonstrated that the use of FDG could 
reduce the number of subjects needed or shorten the study duration for evaluating 
potential disease-modifying therapies. 
Multiple sources of evidence from the thesis (Table 2.12, Figure 3.3 and 
Table 4.2) and literature point to FDG as an important biomarker when studying 
cognitive decline in AD (32; 78; 276). It is widely believed that AD subjects 
experienced a decline in brain glucose metabolism as a result of the loss of 
neuronal cells and some even suggested that abnormal neuronal insulin signal 
transduction could impair synaptic function and neuronal survival (277; 278). As 
with all hypothesized cascades of AD, the mechanisms of glucose 
hypometabolism in AD are still unclear and proposed causes include amyloid 
plaques, oxidative stress, toxins, faulty glucose transporters, insulin resistance and 
loss of insulin receptors (45; 279; 280; 281; 282). Another area of interest is the 
possible connections between “early stage” and “late stage” biomarkers that could 
lead to AD. Although results from current analyses were unable to establish any 
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concrete relationships between CSF biomarkers and FDG, baseline and 12-month 
data suggested that changes in diagnostic biomarkers (CSF Aβ and CSF tau) 
occurred prior to progressive biomarkers (FDG and AHV) (Table 2.8 and Table 
2.10) and some modest correlations were witnessed between CSF Aβ and FDG 
(Table 2.11 and Table 2.12). Temporal change of disease markers on a 
pathological timeline (Figure 3.3) further supported the hypothetical model 
proposed by Jack et al. (167).  
Despite the absence of strong direct links to the hallmarks of AD (amyloid 
plaque and neurofibrillary tangles), drugs that address or target the abnormal 
cerebral glucose metabolic rate may prove to be a feasible treatment approach. 
Several epidemiological studies documented an increased incidence of dementia 
among diabetic patients but results from Phase III clinical trials of rosiglitazone, 
an oral diabetes drug, did not demonstrate any significant improvement in 
cognitive function by controlling peripheral glucose levels of AD subjects (43; 
44; 283; 284). As expected, longitudinal FDG-PET results from a multi-center, 
randomized, proof-of-concept clinical trial applying extended-released 
rosiglitazone in mild to moderate AD subjects showed no significant difference 
from placebo (285). On the other hand, intranasal insulin had provided promising 
results in at least four Phase II clinical trials, with one study showing preserved 
glucose uptake, measured by FDG-PET, and improved memory and functional 
performance which lasted for months after cessation of treatment (45; 279). Since 
intranasal insulin is believed to exert a highly localized effect on the central 
nervous system, the risk of systemic hypoglycemia at a therapeutic dose for AD 
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would be lowered. Even though insulin resistance might be a common concern 
with long term usage, intranasal insulin remained a sign of hope for AD (286).  
 
5.2 Limitations of the study 
Although the current approach undertaken provided a more holistic view of the 
temporal changes in AD over the disease duration, it had some overall limitations. 
ADNI subjects were recruited according to a list of criteria that might not be a 
good representation of the general AD population. Furthermore, all the sites were 
in North America and subjects were overall better educated and less ethnically 
diverse, making results less applicable for generalization. The time-response 
profiles that extended over two decades in Chapter 3 and 4 were estimated from 
relatively short longitudinal disease maker observations that were believed to be 
important for describing disease progression of AD. Modeling sparse data can 
result in high variations and lead to imprecise parameters. Therefore, as more 
follow-up data becomes available, they should be used to reassess, revise and 
refine the current models. Taking all information into consideration, the current 
research is inadequate to provide a claim to the probable cause of AD as there are 
still numerous “unknowns” in the AD equation and more in-depth work and long-
term data are needed to fill the gaps. 
 
5.3 Future work 
Future work may involve appending the dataset by incorporating the completed 
ADNI2 dataset, or eventually together with ADNI3, to update the present models. 
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Richer data, particularly for FDG and CSF biomarkers, will allow higher 
statistical power to evaluate potential covariates and longitudinal characteristics 
as well as for model validation. More data will also be necessary to study the 
connections between “early stage” and “late stage” biomarkers and the impact of 
sociodemographic factors on the rate of biomarker changes. In addition, current 
data can be combined with other longitudinal studies such as worldwide-ADNI 
projects, which are underway in China, Europe, Japan, Korea, Taiwan, and 
Argentina to study covariate effects that are not possible with present data such as 
genetic differences, geographical location and race (287). On the other hand, 
CAMD database is readily available and can be integrated to the dataset, 
providing information of change in mild to moderate AD patients.  
Additional development and modifications can be carried out to streamline 
and improve the models. Continual research in the field might bring about new 
information on the disease or more sensitive endpoints which could be used to 
update the existing models. A subset of data that includes only stable AD subjects 
and those who converted to AD, subjected to data availability to ensure 
satisfactory representation from cognitively normal subjects and MCI converters, 
can be analyzed to fulfill the assumption that all included subjects will eventually 
get AD. Alternatively, a subset of subjects with Aβ pathology can be tested as this 
group of subjects made up the majority of AD patients and may possess a distinct 
disease course compared to those with low amyloid burden. A dropout model, 
similar to the one developed by Samtani et al. for longitudinal CDR-SB scores, 
can be implemented to the models to better understand missing data mechanisms 
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in order to aid design of clinical trials by setting more realistic endpoints and 
inclusion/exclusion criteria (153). Since ADAS-cog is a bounded outcome, the 
error distribution is expected to be heteroscedastic where the variance decreases 
and approaches zero as scores reach the boundary of the scale. Most models 
assumed residual error to be normally distributed without accounting for the 
underlying heteroscedastic distribution and this can be overcome by the use of 
beta residuals to better characterize the data (128; 288). 
 
5.4 Significance of the project 
In addition to the provision of some directions for future research, the study has 
contributed to the understanding of AD in several ways. Comparing demographic-
biomarker-clinical relationships between subjects from different symptomatic 
stages showed high variability within and between groups and nonlinear changes 
in measures over the course of the disease. The disease time synchronization 
method proposed by Donohue et al. was modified to position subjects from 
different symptomatic stages onto a single time scale based on their disease 
severity and provide a more accessible approach to interpret and utilize the results 
(170). Using results from the disease time synchronization, longitudinal changes 
in ADAS-cog was modeled with nonlinear mixed effect modeling. This improved 
the quantitative characterization of AD by providing a platform to integrate data 
from subjects regardless of their symptomatic groups to allow a more complete 
presentation and interpretation of disease progression over time. The use of 
ADAS-cog as an endpoint allowed easy comparison with clinical data and other 
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published models. Biomarkers that represent elements of the hypothetical model 
proposed by Jack et al. but often overlooked or unavailable in previous models 
were included to test for sensitive covariates that could predict disease 
progression (167). FDG was found to be most predictive of ADAS-cog changes 
while age might exert an indirect effect on ADAS-cog via its influence on FDG. 
Covariates that were tested to have considerable influences in earlier AD models 
did not appear to be significant when the effect of FDG was taken into account. 
The identification and understanding of how covariates affect the rate of disease 
progression helped to elucidate the demographic-biomarker-clinical relationships 
between subjects and provided important insights for clinical trial 
implementation. Based on the relationship between FDG and ADAS-cog, FDG 
could be used as a less variable, more objective measurement of disease 
progression to evaluate the potential success of therapeutic agents or as an early 
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Chapter 2 : Quantifying the characteristics of ADNI subjects 
 
A2.1 ADNI1 vs ADNI2 
 
 
Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. Only pairs with significant differences 
tested using Wilcoxon rank-sum test set at p < 0.05 were plotted. 














































































































Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. Only pairs with significant differences 
tested using Wilcoxon rank-sum test set at p < 0.05 were plotted. 
Figure A2.2 Comparison of ADNI1 and ADNI2 – Baseline neuropsychological 















































































Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. Only pairs with significant differences 
tested using Wilcoxon rank-sum test set at p < 0.05 were plotted. 
 











































































Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. 
Figure A2.4 Descriptive baseline characteristics of non-converters segregated 




































































































































































































Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. 

























































































































































































































































A2.3 Non-converters: Longitudinal plots 
 
Figure A2.5 Longitudinal ADAS-cog scores of non-converters segregated by 
symptomatic stages.  
 

















































Figure A2.6 Longitudinal MMSE scores of non-converters segregated by 
symptomatic stages.  
 





































































Figure A2.7 Longitudinal CDR-SB scores of non-converters segregated by 
symptomatic stages.  
 














































Figure A2.8 Longitudinal FAQ scores of non-converters segregated by 
symptomatic stages.  
 




































































Figure A2.9 Longitudinal AHV of non-converters segregated by symptomatic 
stages.  
 









































Figure A2.10 Longitudinal FDG of non-converters segregated by symptomatic 
stages.  
 




































































Figure A2.11 Longitudinal CSF Aβ of non-converters segregated by 
symptomatic stages.  
 



























































































Figure A2.12 Longitudinal CSF tau of non-converters segregated by 
symptomatic stages. 
 
































































Figure A2.13 Longitudinal florbetapir of non-converters segregated by 
symptomatic stages. 
  















































































A2.4 Non-converters: Aβ pathology and cognitive reserve 
 
  
Note: The middle line in each box plot represents the median; the top and bottom margins of the 
box represent the 75th and 25th percentiles; the whiskers extend to the 90th and 10th percentiles; 
lines outside the whiskers represent potential outliers. 
Figure A2.14 Comparison of NL subjects with Aβ pathology and AD subjects 
without Aβ pathology. 
  



































































































































































Chapter 3 : Modeling the pathological timeline of ADNI subjects 
A3.1 Literature plots from Donohue et al. 
 
Figure A3.1 Comparison of (A) subjects with(+) and without(-) Aβ pathology and (B) APOE-e4 carriers(ε4+) and APOE-e4 non-














 percentile of the observations respectively. 
Figure A3.2 Median and 90% PIs of selected variables against (A) time from 
trial entry and (B) model-estimated pathological timeline. 
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A3.3 Disease time synchronization plots: APOE+ and APOE- 
 





 percentile of the observations respectively. 
Figure A3.3 Median and 90% PIs of selected variables from subjects with 






Chapter 4 : Modeling AD progression on a pathological timeline 
A4.1 Characteristics of base models tested for ADAS-cog  
 
  
Figure A4.1 Derived ADAS-cog progression curves from four structural base 
models in Table 4.1. 
 
A4.2 ADAS-cog model summary files and diagnostic plots 
 
========================================================================= 
Analysis: ADAScog_Final_Base_Model   Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
6878 Records    6878 Observations    1501 Patients 
Obj Func: -8037.541    # EVALS: 115    Sig. Digits: 4.3 
------------------------------------------------------------------------- 
Parameter                  Initial Estimate   Estimate    StdErr   %SEE 
---------                  ----------------   --------    ------   ---- 
THETA #1   BASE            (0,2.7,20)             2.70    0.0687   2.54 
THETA #2   SLOPE           (0,0.09,10)          0.0911   0.00152   1.67 
THETA #3   SHAPE           (6.91 FIX)             6.91     Fixed      - 
THETA #4   Additive        (0,0.2)               0.285   0.00491   1.72 
OMEGA #1   IIV_BASE_SLOPE  0.264 BLOCK (2)       0.264    0.0343   13.0 
INT 1-2    -               -0.136               -0.136    0.0225   16.5 



























; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population slope of disease progression  
TVSLOPE = THETA(2) 
; IIV for TVSLOPE 
SLOPE = TVSLOPE*(1+ETA(2))  
; Shape factor that controls inflection point 
TVSHAPE = THETA(3)   
; Generalized logistic model 
DEN1 = BASE**TVSHAPE 
DEN2 = (70**TVSHAPE)-(BASE**TVSHAPE) 
DEN3 = EXP(-TVSHAPE*SLOPE*TIME) 
DENN = DEN1+ DEN2*DEN3 
ADA = (70*BASE)/((DENN)**(1/TVSHAPE)) 
 
; Log transformed predictions and residual error 
IPRED = 0 
IF (ADA.GT.0) IPRED=LOG(ADA+1) 
IRES = DV-IPRED 
; Additive error (log scale) 
W = THETA(4)    
DEL=0.000001 
IWRES = IRES/(W+DEL) 
Y = IPRED+W*EPS(1) 
 
 MINIMIZATION SUCCESSFUL 
 
 ETABAR:         2.4055E-03 -9.2426E-04 
 SE:             8.4021E-03  3.9685E-03 
 N:                    1501        1501 
 P VAL.:         7.7465E-01  8.1584E-01 
 ETAshrink(%):   3.6611E+01  4.8351E+01 
 EBVshrink(%):   3.6488E+01  4.8293E+01 
 EPSshrink(%):   9.1386E+00 
 
CPU  Time: 0:00:8 
Real Time: 0:00:11 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 04:43:41 2016 on brainiac0942 
========================================================================= 






Note: The observed data versus the population and individual predictions are displayed on the top 
panels. The bottom left panel shows the absolute values of the individually weighted residuals, 
and the bottom right panel shows the population conditional weighted residuals. Individual data 
points are indicated by black circles, the red lines are LOESS fit lines, smoothed values given by a 
weighted linear least squares regression over the span of observations, the black diagonal lines in 
the top panels represent the lines of identity and the black horizontal line in the bottom right panel 
indicates the ordinate value of 0. ε-shrinkage was 9.14%. 
Abbreviations: iWRES = individual weighted residuals; LOESS = locally weighted scatterplot 
smoothing function. 












 percentiles of observed data respectively. The blue shaded areas represent simulated 






 percentiles of the simulations based on the 
model.  





Analysis: ADAScog_Final_Model        Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2775 Records    2775 Observations    1204 Patients 
Obj Func: -3292.119    # EVALS: 138    Sig. Digits: 3.1 
------------------------------------------------------------------------- 
Parameter                  Initial Estimate   Estimate    StdErr   %SEE 
---------                  ----------------   --------    ------   ---- 
THETA #1   BASE            (0,2.7,20)             3.41     0.108   3.17 
THETA #2   SLOPE           (0,0.09,10)          0.0733   0.00215   2.93 
THETA #3   SHAPE           (6.91 FIX)             6.91     Fixed      - 
THETA #4   ADD_ERR         (0,0.2)               0.270   0.00840   3.11 
THETA #5   FDG_SLOPE       (-0.09)              -0.587    0.0610   10.4 
OMEGA #1   IIV_BASE_SLOPE  0.264 BLOCK (2)       0.198    0.0318   16.1 
INT 1-2    -               -0.136              -0.0824    0.0240   29.1 
OMEGA #2   -               0.0887               0.0437    0.0184   42.1 
SIGMA #1   EPS             1                     1.000     Fixed      - 
 
$PRED 
; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population slope of disease progression, 1.21 is median FDG of pop 
TVSLOPE = THETA(2)*(FDG/1.21)**THETA(5)  
; IIV for TVSLOPE 
SLOPE = TVSLOPE*(1+ETA(2)) 
; Shape factor that controls inflection point 
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TVSHAPE = THETA(3)     
 
; Generalized logistic model 
DEN1 = BASE**TVSHAPE 
DEN2 = (70**TVSHAPE)-(BASE**TVSHAPE) 
DEN3 = EXP(-TVSHAPE*SLOPE*TIME) 
DENN = DEN1+ DEN2*DEN3 
ADA = (70*BASE)/((DENN)**(1/TVSHAPE)) 
 
; Log transformed predictions and residual error 
IPRED = 0 
IF (ADA.GT.0) IPRED=LOG(ADA+1) 
IRES = DV-IPRED 
; Additive error (log scale) 
W = THETA(4)       
DEL=0.000001 
IWRES = IRES/(W+DEL) 
Y = IPRED+W*EPS(1) 
 
 MINIMIZATION SUCCESSFUL 
 
 ETABAR:         3.3228E-03 -1.2320E-03 
 SE:             8.8660E-03  3.1247E-03 
 N:                    1204        1204 
 P VAL.:         7.0783E-01  6.9338E-01 
 ETAshrink(%):   3.0902E+01  4.8116E+01 
 EBVshrink(%):   3.0742E+01  4.7970E+01 
 EPSshrink(%):   1.3997E+01 
 
CPU  Time: 0:00:5 
Real Time: 0:00:08 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 10:05:43 2016 on brainiac0934 
========================================================================= 
Figure A4.5 Summary output of ADAS-cog model with FDG as covariate on 





Analysis: ADAScog_Back_Del        Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2545 Records    2545 Observations    1162 Patients 
Obj Func: -3040.568    # EVALS: 142    Sig. Digits: 3.0 
------------------------------------------------------------------------- 
Parameter                  Initial Estimate   Estimate    StdErr   %SEE 
---------                  ----------------   --------    ------   ---- 
THETA #1   BASE            (0,2.7,20)             3.39     0.107   3.16 
THETA #2   SLOPE           (0,0.09,10)          0.0743   0.00215   2.89 
THETA #3   SHAPE           (6.91 FIX)             6.91     Fixed      - 
THETA #4   ADD_ERR         (0,0.2)               0.269   0.00858   3.19 
THETA #5   FDG_SLOPE       (-0.5)               -0.570    0.0647   11.4 
OMEGA #1   IIV_BASE_SLOPE  0.264 BLOCK (2)       0.196    0.0308   15.7 
INT 1-2    -               -0.136              -0.0863    0.0246   28.5 
OMEGA #2   -               0.0887               0.0487    0.0197   40.5 
SIGMA #1   EPS             1                     1.000     Fixed      - 
 
$PRED 
; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
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BASE   = TVBASE*EXP(ETA(1)) 
; Population slope of disease progression, 1.21 is median FDG of pop 
TVSLOPE = THETA(2)*(FDG/1.21)**THETA(5)  
; IIV for TVSLOPE 
SLOPE = TVSLOPE*(1+ETA(2)) 
; Shape factor that controls inflection point   
TVSHAPE = THETA(3) 
; Generalized logistic model 
DEN1 = BASE**TVSHAPE 
DEN2 = (70**TVSHAPE)-(BASE**TVSHAPE) 
DEN3 = EXP(-TVSHAPE*SLOPE*TIME) 
DENN = DEN1+ DEN2*DEN3 
ADA = (70*BASE)/((DENN)**(1/TVSHAPE)) 
; Log transformed predictions and residual error 
IPRED = 0 
IF (ADA.GT.0) IPRED=LOG(ADA+1) 
IRES = DV-IPRED 
; Additive error (log scale) 
W = THETA(4)       
DEL=0.000001 
IWRES = IRES/(W+DEL) 
Y = IPRED+W*EPS(1) 
 
 MINIMIZATION SUCCESSFUL 
 
 ETABAR:         3.2722E-03 -1.2689E-03 
 SE:             8.6444E-03  3.2165E-03 
 N:                    1162        1162 
 P VAL.:         7.0503E-01  6.9321E-01 
 ETAshrink(%):   3.3350E+01  5.0311E+01 
 EBVshrink(%):   3.3197E+01  5.0171E+01 
 EPSshrink(%):   1.4304E+01 
 
CPU  Time: 0:00:5 
Real Time: 0:00:08 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 10:54:03 2016 on brainiac0952 
========================================================================= 




Analysis: ADAScog_Final_Base_Model_Reduced   Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2775 Records    2775 Observations    1204 Patients 
Obj Func: -3170.673    # EVALS: 143    Sig. Digits: 4.9 
------------------------------------------------------------------------ 
Parameter                  Initial Estimate   Estimate    StdErr   %SEE 
---------                  ----------------   --------    ------   ---- 
THETA #1   BASE            (0,2.7,20)             2.94    0.0903   3.07 
THETA #2   SLOPE           (0,0.09,10)          0.0866   0.00189   2.18 
THETA #3   SHAPE           (6.91 FIX)             6.91     Fixed      - 
THETA #4   Additive        (0,0.2)               0.277   0.00858   3.10 
OMEGA #1   IIV_BASE_SLOPE  0.264 BLOCK (2)       0.237    0.0398   16.8 
INT 1-2    -               -0.136               -0.111    0.0284   25.6 
OMEGA #2   -               0.0887               0.0669    0.0209   31.2 
SIGMA #1   EPS             1                     1.000     Fixed      - 
 
$PRED 
; Population arbitrary baseline at time 0 
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TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population slope of disease progression  
TVSLOPE = THETA(2) 
; IIV for TVSLOPE 
SLOPE = TVSLOPE*(1+ETA(2))  
; Shape factor that controls inflection point 
TVSHAPE = THETA(3)   
 
; Generalized logistic model 
DEN1 = BASE**TVSHAPE 
DEN2 = (70**TVSHAPE)-(BASE**TVSHAPE) 
DEN3 = EXP(-TVSHAPE*SLOPE*TIME) 
DENN = DEN1+ DEN2*DEN3 
ADA = (70*BASE)/((DENN)**(1/TVSHAPE)) 
  
; Log transformed predictions and residual error 
IPRED = 0 
IF (ADA.GT.0) IPRED=LOG(ADA+1) 
IRES = DV-IPRED 
; Additive error (log scale) 
W = THETA(4)      
DEL=0.000001 
IWRES = IRES/(W+DEL) 
Y = IPRED+W*EPS(1) 
 
 MINIMIZATION SUCCESSFUL 
 
 ETABAR:         3.4793E-03 -1.3372E-03 
 SE:             8.6348E-03  3.3585E-03 
 N:                    1204        1204 
 P VAL.:         6.8699E-01  6.9052E-01 
 ETAshrink(%):   3.8474E+01  5.4916E+01 
 EBVshrink(%):   3.8356E+01  5.4835E+01 
 EPSshrink(%):   1.3786E+01 
 
CPU  Time: 0:00:5 
Real Time: 0:00:08 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 11:19:53 2016 on brainiac0913 
========================================================================= 











A4.3 FDG model summary files and diagnostic plots 
 
Table A4.1 Selection of structural base model for FDG.  
Base models Disease 
progression rate 
OFV Numbers of  
parameters 
Linear model  
FDG(t) = FDGbase•(1-α•time) 
Linear -10696.578 2 
Exponential model  
FDG(t) = FDGbase•exp(α•time) 
Nonlinear -10668.618 2 
Empirical model [final] 





Nonlinear -11342.065 3 
Hockey-stick model  
FDG(t) = FDGbase-
FDGbase(α1•time) if FDG(t) ≥ β 
FDG(t) = FDGbase-
FDGbase(α2•time) if FDG(t) < β 
Nonlinear -11861.033 4 
Abbreviations: α = annual progression rate parameter; α1= α at or prior the cutpoint; α2 = α after 
the cutpoint; β = FDG cutpoint where “shaft” transit to the “blade” section; γ = scaling parameter; 
FDGbase = 18F-fluorodeoxyglucose value at arbitrary start time; FDG(t) = 18F-fluorodeoxyglucose 





Analysis: FDG_Final_Base_Model   Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2789 Records    2789 Observations    1206 Patients 
Obj Func: -11360.649    # EVALS: 452    Sig. Digits: 3.9 
------------------------------------------------------------------------- 
Parameter                Initial Estimate    Estimate      StdErr    %SEE 
---------                ----------------    --------      ------    ---- 
THETA #1   BASE          (0,1)                   1.38      0.0125   0.906 
THETA #2   SF1           (0,0.8,1)              0.891     0.00770   0.864 
THETA #3   SF2           (2,30,100)              34.8        7.55    21.7 
OMEGA #1   IIV_BASE_SF1  0.1 BLOCK (2)        0.00546    0.000419    7.67 
INT 1-2    -             0.05               -0.000482    0.000150    31.1 
OMEGA #2   -             0.1                 0.000276   0.0000543    19.7 
OMEGA #3   IIV_SF2       0                          0       Fixed       - 
SIGMA #1   ADD_ERR       0.09                 0.00229    0.000149    6.51 
 
$PRED 
; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population scaling factor 1   
 231 
 
TVSF1 = THETA(2)  
; IIV for TVSF1 
SF1 = TVSF1 * (1+ETA(2)) 
; Population scaling factor 2   
TVSF2 = THETA(3)   
; IIV for TVSF2   
SF2 = TVSF2 * (1+ETA(3))   
 
; Predictions and residual error 
IPRED = BASE - SF1**(-TIME)/SF2 
W = IPRED 
IRES=DV-IPRED 
IWRES = IRES/W 
; Additive residual error 
Y = IPRED + ERR(1)    
 
 MINIMIZATION SUCCESSFUL 
 HOWEVER, PROBLEMS OCCURRED WITH THE MINIMIZATION. 
 REGARD THE RESULTS OF THE ESTIMATION STEP CAREFULLY, AND ACCEPT THEM 
ONLY AFTER CHECKING THAT THE COVARIANCE STEP PRODUCES REASONABLE OUTPUT. 
 
 ETABAR:         3.6895E-03 -8.3816E-04  0.0000E+00 
 SE:             1.7362E-03  2.1249E-04  0.0000E+00 
 N:                    1206        1206        1206 
 P VAL.:         3.3583E-02  8.0029E-05  1.0000E+00 
 ETAshrink(%):   1.8386E+01  5.5562E+01  1.0000E+02 
 EBVshrink(%):   1.8360E+01  5.7246E+01  0.0000E+00 
 EPSshrink(%):   2.2869E+01 
 
CPU  Time: 0:00:11 
Real Time: 0:00:16 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 12:44:42 2016 on brainiac0968 
========================================================================= 







Note: The observed data versus the population and individual predictions are displayed on the top 
left and right panels respectively. The bottom left panel shows the absolute values of the 
individually weighted residuals, and the bottom right panel shows the population conditional 
weighted residuals. Individual data points are indicated by black circles. The red lines are LOESS 
fit lines, smoothed values given by a weighted linear least squares regression over the span of 
observations. The black diagonal lines in the top panels represent the lines of identity and the 
black horizontal line in the bottom right panel indicates the ordinate value of 0. ε-shrinkage was 
22.3%. 
Abbreviations: iWRES = individual weighted residuals; LOESS = locally weighted scatterplot 
smoothing function. 












 percentiles of observed data respectively. The blue shaded areas represent simulated 






 percentiles of the simulations based on the 
model.  

































Table A4.2 Selection of covariate model for FDG model. 
Run Forward inclusion Type n/N Base model OFV OFV with Covariates ∆ in OFV 
1 Age Continuous (Power) 1206/2789 -11360.649 -11385.885 -25.236 
2 Education Continuous (Power) 1206/2789 -11360.649 -11367.003 -6.354 
3 AHV 
Time varying continuous 
(Linear) 1164/2554 -10390.922 -10400.147 -9.225 
4 APOE (APOE+) Categorical 1163/2746 -11201.554 -11201.665 -0.111 
5 Ab pathology (Aβ+) Categorical 1095/2379 -9544.793 -9548.957 -4.164 
6 Gender (Female) Categorical 1206/2789 -11360.649 -11360.658 -0.009 
7 CSF Aβ 
Time varying continuous 
(Linear) 547/812 -3005.336 -3005.985 -0.649 
8 CSF tau 
Time varying continuous 
(Power) 525/780 -2876.778 -2880.418 -3.64 
Full model Covariates excluded n/N Base model OFV OFV with Covariates ∆ in OFV 
9 Age, AHV Not applicable 1164/2554 -10390.922 -10418.343 -27.421 
Backward deletion Covariates excluded n/N Full model OFV OFV with Covariates ∆ in OFV 
9.1 AHV Age  1164/2554 -10418.343 -10400.147 -18.196 
9.2 Age  AHV 1164/2554 -10418.343 -10414.291 -4.052 
Final model Covariates excluded n/N Final model OFV 
  10 Age AHV 1206/2789 -11385.885 




Analysis: FDG_Back_Del        Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2554 Records    2554 Observations    1164 Patients 
Obj Func: -10414.291    # EVALS: 566    Sig. Digits: 3.6 
------------------------------------------------------------------------- 
Parameter                Initial Estimate    Estimate      StdErr    %SEE 
---------                ----------------    --------      ------    ---- 
THETA #1   BASE          (0,1)                   1.38      0.0142    1.03 
THETA #2   SF1           (0,0.8,1)              0.893     0.00834   0.934 
THETA #3   SF2           (2,30,100)              32.6        7.70    23.6 
THETA #4   AGE_SF1       (0.09)                0.0415     0.00916    22.1 
OMEGA #1   IIV_BASE_SF1  0.1 BLOCK (2)        0.00543    0.000470    8.66 
INT 1-2    -             0.05               -0.000372    0.000206    55.4 
OMEGA #2   -             0.1                 0.000202   0.0000757    37.5 
OMEGA #3   IIV_SF2       0                          0       Fixed       - 
SIGMA #1   ADD_ERR       0.09                 0.00221    0.000157    7.10 
 
$PRED 
; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population scaling factor 1, 74 is median age of population 
TVSF1 = THETA(2)*(AGE/74)**THETA(4) 
;IIV for TVSF1 
SF1 = TVSF1 * (1+ETA(2))  
; Population scaling factor 2  
TVSF2 = THETA(3)   
;IIV for TVSF2   
SF2 = TVSF2 * (1+ETA(3))  
 
; Predictions and residual error  
IPRED = BASE - SF1**(-TIME)/SF2 
W = IPRED 
IRES=DV-IPRED 
IWRES = IRES/W 
; Additive residual error 
Y = IPRED + ERR(1)    
 
 MINIMIZATION SUCCESSFUL 
 HOWEVER, PROBLEMS OCCURRED WITH THE MINIMIZATION. 
 REGARD THE RESULTS OF THE ESTIMATION STEP CAREFULLY, AND ACCEPT THEM 
ONLY AFTER CHECKING THAT THE COVARIANCE STEP PRODUCES REASONABLE OUTPUT. 
 
 ETABAR:         2.8696E-03 -5.9844E-04  0.0000E+00 
 SE:             1.8013E-03  1.6336E-04  0.0000E+00 
 N:                    1164        1164        1164 
 P VAL.:         1.1114E-01  2.4910E-04  1.0000E+00 
 ETAshrink(%):   1.6538E+01  6.0800E+01  1.0000E+02 
 EBVshrink(%):   1.6469E+01  6.2356E+01  0.0000E+00 
 EPSshrink(%):   2.3735E+01 
 
CPU  Time: 0:00:14 
Real Time: 0:00:19 
------------------------------------------------------------------------- 
Report prepared Sun Jul 17 13:12:42 2016 on brainiac0972 
========================================================================= 






Analysis: FDG_Final_Model   Run: 1 
------------------------------------------------------------------------- 
Method:  First Order Conditional Estimation with Interaction 
2789 Records    2789 Observations    1206 Patients 
Obj Func: -11385.884    # EVALS: 494    Sig. Digits: 3.0 
------------------------------------------------------------------------- 
Parameter                Initial Estimate    Estimate      StdErr    %SEE 
---------                ----------------    --------      ------    ---- 
THETA #1   BASE          (0,1)                   1.37      0.0126   0.920 
THETA #2   SF1           (0,0.9)                0.890     0.00761   0.855 
THETA #3   SF2           (0,20)                  35.4        7.69    21.7 
THETA #4   AGE_SF1       (0.09)                0.0424     0.00871    20.5 
OMEGA #1   IIV_BASE_SF1  0.1 BLOCK (2)        0.00551    0.000425    7.71 
INT 1-2    -             0.05               -0.000456    0.000155    34.0 
OMEGA #2   -             0.1                 0.000238   0.0000580    24.4 
OMEGA #3   II_SF2        0                          0       Fixed       - 
SIGMA #1   ADD_ERR       0.09                 0.00230    0.000151    6.57 
 
$PRED 
; Population arbitrary baseline at time 0 
TVBASE = THETA(1) 
; IIV for TVBASE 
BASE   = TVBASE*EXP(ETA(1)) 
; Population scaling factor 1, 74 is median age of population 
TVSF1 = THETA(2)*(AGE/74)**THETA(4) 
;IIV for TVSF1 
SF1 = TVSF1 * (1+ETA(2))  
; Population scaling factor 2  
TVSF2 = THETA(3)   
;IIV for TVSF2   
SF2 = TVSF2 * (1+ETA(3)) 
 
; Predictions and residual error 
IPRED = BASE - SF1**(-TIME)/SF2 
W = IPRED 
IRES=DV-IPRED 
IWRES = IRES/W 
; Additive residual error 
Y = IPRED + ERR(1)    
 
 MINIMIZATION SUCCESSFUL 
 
 ETABAR:         3.2802E-03 -7.1030E-04  0.0000E+00 
 SE:             1.7629E-03  1.8953E-04  0.0000E+00 
 N:                    1206        1206        1206 
 P VAL.:         6.2797E-02  1.7857E-04  1.0000E+00 
 ETAshrink(%):   1.7467E+01  5.7336E+01  1.0000E+02 
 EBVshrink(%):   1.7394E+01  5.8948E+01  0.0000E+00 
 EPSshrink(%):   2.2679E+01 
 
CPU  Time: 0:00:11 
Real Time: 0:00:22 
------------------------------------------------------------------------- 
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Figure A4.12 Summary output of FDG model with age as covariate on scaling 





A4.4 Literature plots from Yang et al. 
 
Figure A4.13 Plot of progression rate of ADAS-cog versus ADAS-cog 
segregated by symptomatic stages from Yang et al. (168). 
 
 
 
 
 
 
 
 
 
